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Summary
The aim of this study was to determine the nucleotide and deduced 
amino acid sequences of the structural protein genes of strains of yellow fever 
(YF) virus of defined phenotype. Specifically, two wild-type/vaccine pairs 
were examined, namely passage of wild-type strain Asibi virus through chick 
tissue to develop the 17D live vaccine strain (studied as the 17DD substrain), 
and the French viscerotropic virus (FVV) through mouse brain to develop the 
French neurotropic vaccine (FNV) strain. The atypical African wild-type YF 
virus, Y5, was also analyzed.
In addition, the sequence of the envelope (E) protein genes of a 
neurovirulent revertant YF vaccine virus, and the vaccine batch from which 
it originated were also determined. In total, approximately 15 kilobases of 
nucleotide sequence data was generated in duplicate.
Despite different routes of attenuation, the two vaccine strains were 
found to share an amino acid substitution in the membrane protein (35), and 
also to exhibit a cluster of substitutions in the E protein. The neurovirulent 
revertant vaccine virus was shown to differ from the parent vaccine virus at 
just two amino acid positions in the E protein (155 and 303), suggesting that 
one or both may be important in the appearance of the neurovirulent 
phenotype in YF virus. Atypical wild-type strain Y5 proved to differ by nearly 
8% at the nucleotide level, but by less than 2% at the amino acid level from 
other African wild-type viruses. Three amino acid positions (325, 407 and 
416) were identified which may be important in the appearance of an E 
protein epitope associated with attenuation of YF virus.
Overall, the results obtained increase our knowledge of YF virus at the
11
molecular level and indicate particular amino acids are involved in attenuation 
of virulence. Future work could examine some of the hypotheses presented, 
with the hope of identifying amino acids within the structural proteins of YF 
virus which may be critical in attenuation, neurovirulence, and antigenic 
markers seen in YF virus.
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Chapter 1
General Introduction
1.1 Taxonomy and Classification
1.1.1 Arboviruses
The first virus which was recognised as being arthropod borne was 
yellow fever (YF) virus when, in 1902, pioneering work by Major Walter 
Reed and co-workers demonstrated that this disease was transmitted to man 
by mosquitoes.
The term arbovirus derives from arthropod-borne, and was first used 
in 1942 as an umbrella classification for those viruses which are maintained 
in a transmission cycle between susceptible vertebrate hosts and 
haematophagous arthropod vectors. Arthropods involved in the transmission 
of diseases in this way include mosquitoes, ticks, midges {Culicodes species) 
and sandflies (Phlebotomus species) (World Health Organisation Technical 
Report, 1967).
Other viruses, including Japanese encephalitis (JE), St. Louis 
Encephalitis (SLE), Murray Valley encephalitis (MVE) and Rift Valley fever, 
all of which were associated with large epidemics in man and/or in animals, 
were subsequently also shown to be arboviruses (World Health Organisation 
Technical Report, 1967). In 1953 thirty-five viruses were classified as 
arboviruses, and by 1978 this figure had risen to 389 (Berge, 1975). The
current edition of the International Catalogue of Arboviruses lists 503 
registered members, 32 of which are designated as "probably or not 
arboviruses" (Karabatsos, 1985). This dramatic increase in numbers is largely 
the result of field investigations connected with major epidemics of diseases 
such as YF, IE, dengue (Den) and tick-borne encephalitis (TBE) (Theiler and 
Downs, 1973).
The original classification of arboviruses was based on studies of their 
morphology and serological relationships, determined by the use of 
complement fixation (CF), haemagglutination inhibition (HAI) and 
neutralization (N) tests. Three groups were originally designated, members of 
which were recognised as antigenically distinct from one another; the groups 
were named A, B and C (Casals and Brown, 1954; Casals, 1957). By 1980 
the groupings had been more extensively studied, and were reclassified as four 
major taxonomic groups (Schlesinger, 1980):-
(1) The Togaviridae family (from the Latin for cloak or envelope),
containing genera Alphavirus and Flavivirus (equivalent to the A and
B groups described earlier by Casals).
(2) The Bunyaviridae (equivalent to Casals group C)
(3) The Rhabdoviridae
(4) The Reoviridae
Currently registered arboviruses are now separated into 63 serogroups 
(Karabatsos, 1985).
However, the classification of both alphaviruses and flaviviruses within 
the same family became increasingly unsatisfactory as the viruses were 
subjected to further study. Alphaviruses were shown to possess nucleocapsids 
of cubical symmetry (Horzinek and Mussgay, 1969), whilst the symmetry of 
flaviviruses remained unclear. More tangible differences between the genera 
were established by molecular analyses of their respective members. The 
alphavirus genome transcribes a subgenomic 26 S messenger RNA (mRNA) 
corresponding to the 3’ end of the genome containing genes coding for the 
structural proteins (Kaarianen and Soderlund, 1978). However, no subgenomic 
RNA could be demonstrated in flavivirus infected cells (Westaway, 1973; 
Westaway and Shew, 1977). In 1984, on the basis of these differences, the 
International Committee on Taxonomy of Viruses (ICTV) approved a 
recommendation by the ICTV Study Group to transfer the flaviviruses from 
the Togaviridae into a distinct family, which was named the Flaviviridae 
(Westaway et al., 1985a and b).
1.1.2 Flaviviridae
The family Flaviviridae contains two genera, the flaviviruses and 
pestiviruses. It is likely that hepatitis C will also be classified in this family. 
The flavivirus genus contains the prototype species, YF virus, from which the 
family name is derived (from the Latin for yellow, flavus). In addition, 
approximately 67 other viruses are classified in the Flaviviridae, which is 
divided into eight major antigenic complexes (Westaway et al., 1985b; 
Calisher et ah, 1989). Two other viruses were putatively described as 
flaviviruses; simian haemorrhagic fever virus (Leon et al, 1982) and ihtAedes 
albopticus cell fusing agent (Igarashi et ah, 1976). Both were placed outside 
the genus, but the recent publication of the entire nucleotide sequence of cell 
fusing agent suggests that it shares a degree of homology at the amino acid 
level, especially in the non-structural proteins, with other published flavivirus 
sequences that may lead to it’s re-inclusion in the genus (Camissa-Parks et al., 
1992). The presence of a type 1 cap at the 5’ end of simian haemorrhagic 
fever virus supports it’s classification within the Flaviviridae; however it has 
a polyadenylated genome which is unusual within the family (Porterfield, 
1989a).
1.2 Flaviviruses
1.2.1 Antigenic classification
Flaviviruses have been classified together within the family and genus 
due to their antigenic relatedness as determined by serological assays. The 
biological assays used are haemagglutination (HA), HA inhibition (HAI), 
plaque reduction neutralization tests (PRNTs), immunofluorescence (IF), and 
assays involving enzymes and radio-isotopes. These assays are based on the 
envelope protein antigens possessed by flaviviruses.
The original grouping of flaviviruses was established by their cross­
reactivities in HI tests performed using polyclonal antisera (Casals and Brown, 
1954). Cross-neutralization tests using polyclonal hyper-immune antisera 
refined these initial studies. In 1974, DeMadrid and Porterfield classified 
flaviviruses into seven antigenic complexes comprising 36 viruses, six of 
which did not fall within any of these groups. More recently, 68 members of 
the Flaviviridae were classified into eight antigenic complexes on the basis of 
cross-neutralization tests utilizing polyclonal antisera (Calisher et ah, 1989). 
Table 1.1 shows this classification structure, and also the vector with which 
the subgroups are associated. This antigenic classification conforms to major 
biological and epidemiological characterization of flaviviruses. Of the 68 
currently registered members 48% are mosquito borne, and responsible for 
epidemics of diseases such as YF, Den and JE. The remainder are either tick-
Table 1.1: Relationship between Flavivirus subgroup and mode of transmission
Tick-borneviruses 
Virus Subgroup
Non vector borne 
Virus Subgroup
Mosquito-borne viruses 
Virus Subgroup
Central European . Carey Island 1 Alfuy 3
tick-borne enc. Phnomh Penh bat 1 Japanese enc 3
Karashi 1 Kedougou 3
Kyasnur Forest 1 Apoi 2A Kokobera 3(5?)
Langat 1 Bukulasabat 2A Koutango 3
Louping 111 1 Dakar bat 2A Kunjin 3
Negishi 1 Entebbe bat 2A Murray Valley 3
Omsk 1 Rio Bravo 2A St. Louis enc. 3
Powassan 1 Saboya 2A Stratford 3
Royal Farm 1 Usutu 3
Russianspr/summ 1 West Nile 3
Yaounde (3)*
Sponweni 4
Zika 4
Meaban lA Cowbone Ridge 2B Bagaza 5
Saumarez Ridge lA Jutiapa 2B Israel Turkey 55
lyuleniy lA Modoc 2B NtayaTembusu 5
SalVieja 2B Yokose 5
SanPerlita 2B
Banzi 6
Bouboui 6
EdgeHill 6
Potiskum (6)*
Uganda S 6
Dengue 1 7
Dengue 2 7
Dengues 7
Dengue 4 7
Gadgets Gully U Aroa U Busuquara U
Kadam U Batu Cave (U)* Dheus U
Cacipacore U Jugra U
Naranjal UMontana M.L. U Rocio U
Sokuluk U Sepik U
TamanaBat U Wesselsbron U
Yellow fever u
Adapted from Calisher etal. , 1989. U = unrelated to any other virus
* Batu Cave, Potiskum and Yaounde viruses were not examined in the study, but are included 
for completeness ^
borne (27%) or have no known arthropod vector (25%) (Calisher et ah, 
1989).
1.2.2 Flavivinises of Medical Significance
Approximately half of the 68 currently registered flavivinises have 
been associated with human disease (Karabatsos, 1985). Indeed, many 
members have been isolated from humans during either sporadic or epidemic 
outbreaks of disease, and the flavivinises represent one of the most important 
groups of viruses from a medical point of view. Of those flavivinises which 
are associated with human disease, three cause epidemics which give rise to 
panregional and global concern (Monath, 1986). They are YF virus. Den and 
JE. All three of these viruses are mosquito borne.
a) Yellow fever YF has been recorded as a scourge of mankind for at 
least two centuries, and major epidemics still occur, despite the introduction 
of live attenuated vaccines in the 1930’s. The vaccine used today, "17D", is 
possibly the finest example of a live attenuated virus vaccine; however in an 
epidemic it’s effectiveness may be limited by the lack of availability of 
sufficient vaccine, the remoteness of some affected regions, and the failure to 
recognise early cases before an epidemic occurs.
bi Dengue There are four Den serotypes (Den 1-4), and all give rise
to ’classical’ dengue fever, a self-limiting febrile illness associated with a 
rash. As with YF, the virus is transmitted by the bite of an infected mosquito, 
and Den viruses cause the highest morbidity rates of any flavivirus (Halstead, 
1988). There are more severe forms of disease caused by Den viruses; these 
are known as dengue haemorrhagic fever (DHF), and dengue shock syndrome 
(DSS), and are believed to have an immunopathological basis (Halstead, 1980; 
1988). All four serotypes have been implicated with DHF/DSS, however 
infection with Den-1 virus followed subsequently by infection with Den-2 
virus carries the greatest risk (Sangkawibha et al. , 1984; Burke et al. , 1988). 
There continue to be severe epidemics of Den, and also worrying signs that 
the disease is re-appearing in regions from which it had been eradicated. For 
example, an outbreak was recorded at Rio de Janiero in 1986 (Shatzmayer et 
al. , 1986). Prior to this Den had been absent from Brazil for over 50 years.
c) Japanese encephalitis JE virus is associated with endemics and 
epidemics throughout much of Asia and causes the highest mortality rates of 
any flavivirus. Mortality rates are usually 10-20% in most epidemic outbreaks, 
but figures of greater than 30% have been recorded (Bu’Lock, 1986; Umenai 
et al. , 1985). In a significant proportion of those that survive the disease, 
permanent neurological impairment occurs as a sequelae. Massive vaccination 
programmes have been undertaken, yet large populations remain at risk from 
JE virus. It is possible that vaccination strategies are undermined by the high 
degree of antigenic variation exhibited by different sub-types of JE virus 
(Susilowati et ah, 1981).
In addition to the three major diseases described above, there are a 
number of other mosquito borne flavivinises of medical significance. St. Louis 
encephalitis (SLE) was first reported as a serious public health problem in the 
United States in the 1960’s, and continued sporadic outbreaks give cause for 
concern (Kokemot et ah, 1969). Murray Valley encephalitis (MVE) causes 
intermittent epidemics in Australia in regions that have experienced high 
rainfall levels (Forbes, 1975). Epidemics usually coincide with high population 
levels of the mosquito vector, and occur mainly between January and March 
(Shope, 1980). West Nile virus (WN), unlike the serologically related JE, 
SLE and MVE viruses, is not usually associated with encephalitis (except in 
elderly persons, but causes a generalised fever, rash and lymphadenopathy 
(Sprigland et ah, 1958). The virus is found in Africa, the Middle East, 
Europe and Asia. In hyperendemic ares, infection usually occurs during 
childhood as evinced by high numbers of sero-positive adolescents and adults 
(McIntosh et ah, 1976).
Several flavivinises which are transmitted by ticks cause encephalitic 
disease in humans. Tick-borne encephalitis (TBE) has long been recognised 
as a public health problem in Eastern Europe, and the virus caused high 
mortality in Russia in the 1930’s, prompting great efforts to isolate the 
causative agent and produce a vaccine (Silber and Soloviev, 1946). The term 
TBE encompasses a number of different viral sub-types found in different 
geographical areas. Eastern sub-types include Sofyn, the causative agent of 
Russian Spring-Summer encephalitis (RSSE) (Silber and Soloviev, 1946), and
10
Western subtypes include Neudorfl (Ackerman et al., 1986) and Hypr 
(Blaskovic et al., 1967).
Two further tick-borne flavivinises cause diseases which are largely 
haemorrhagic (rather than encephalitic) in nature. Kyasanur Forest disease 
(KFD) occurs annually in India, causing hundreds of infections in man, 
characterised by fever, mild meningoencephalitis and haemorrhagic fever. The 
mortality rate varies between 1 and 10% (Work 1958; Sreenivasen et al., 
1979). Omsk haemorrhagic fever (OHF) caused large outbreaks in 1944 and 
1946 in the Omsk region of the Soviet Union. As it’s name suggests, the 
disease causes fever with associated haemorrhage, but the case fatality rate is 
low (1-2%) (Shope, 1980).
1.2.3 Flavivinises of Veterinary Importance
Eight flavivinises have so far been reported to cause disease in 
domesticated and/or wild animals, and to be of major economic importance 
in the former group. The mosquito-bome IE virus is the most important in 
terms of economic impact, causing epizootic encephalitis in horses, and still­
birth/abortion in pigs in many parts of Asia (Umenai et al., 1985). The virus 
has also been shown to infect both wild and domesticated boars (Habu et al., 
1977). Pigs and birds have been established as the principal viraemic 
amplifying hosts of IE virus, with Culex species of mosquito responsible for
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the transmission of the virus to man (Beuscher and Scherer, 1959).
Louping ill (LI) virus is a member of the TBE complex which causes 
neurological disease in sheep, mainly in Scotland (Monath, 1989). It has also 
been responsible for economic losses due to infection of pigs, red grouse and 
deer (Reid et al. , 1982; Bannatyne et al. , 1980). Serologically related viruses 
have been isolated in Spain, Norway, Bulgaria, Portugal and Turkey.
Wesselsbron (WSL) virus, which is not classified within any antigenic 
complex (see Table 1.1) is found in South Africa, where it causes abortion 
and death of new-born lambs and pregnant ewes (Henderson et ah, 1970). It 
was also isolated from a cow which died during an epizootic Rift Valley fever 
attack in Zimbabwe in 1978 (Blackburn and Swanpoel, 1980). It has since 
been proposed that WSL infection occurs on a much greater scale than the 
number of recorded cases imply, and serological evidence suggests that 
detailed epidemiological study of livestock where virus infection is implicated 
is required (Swanpoel, 1988).
Between 1958 and 1959, turkey populations in Israel were dramatically 
affected by a flavivirus causing morbidity approaching 50% and case-fatality 
rates of between 10 and 12% (Komarov and Kalmar, 1960). The causative 
agent was Israel Turkey Meningo-encephalitis (ITME) virus, and the only 
other recorded outbreak of the disease occurred in South Africa (Barnard et 
al., 1980). A reservoir for the virus has never been found.
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Several other flavivinises cause diseases of veterinary importance to 
varying degrees. Horses have been infected by WN virus (Guillon et al., 
1968), and by Kunjin virus, which was isolated from the spinal cord of a 
horse with severe encephalomyelitis in Australia (Badman et ah, 1984).
1.2.4 Epidemiology
Flavivinises are generally transmitted to man via the bite of an 
arthropod vector, and, despite the fact that virus may be present in the blood 
and other bodily secretions during acute infection, spread directly from one 
human to another does not occur. It thus follows that prerequisites for the 
initiation of epidemics are that there is an available reservoir of infectious 
virus, and high levels of vector populations to maintain this transmission.
The natural epidemiology of YF is a cycling of the virus through 
transmission by forest mosquitoes to wild primates. However, there is 
evidence that transovarial transmission of YF can occur in mosquitoes (Beatty 
et al., 1980). The role of vertebrates other than forest primates in maintenance 
of the virus in nature remains uncertain (Porterfield, 1989b).
Transovarial transmission of virus in mosquitoes is important in the 
maintenance of YF virus, and has also been shown to be important in the 
natural history of other flavivinises (JE and SLE) (Rosen, 1986; 1987).
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1.3 Yellow fever virus
1.3.1 History of the disease
Evidence of YF epidemics can be traced back to the seventeenth 
century, but case definitions were difficult due to the clinical symptoms of the 
disease being confused with those of other infections (such as malaria, 
typhoid, typhus, leptospirosis and other bilious fevers (Monath, 1987)). It 
seems probable, however, that YF originated in Africa, and was only 
relatively recently imported to the Americas with the advent of sea-travel 
between the continents (Porterfield, 1989b). Between 1603 and 1968, major 
epidemics of the disease occurred in the Caribbean, Central and South 
America, and latterly in North America (Blake, 1968). Although YF has been 
limited in the main to Africa and the Americas, it has occurred sporadically 
in other continents, and was even recorded at Swansea in England, when 17 
deaths attributable to the disease followed the arrival in the port of a Cuban 
vessel (Smith and Gibson, 1986).
The nature of the disease and the basis of it’s epidemiology, including 
it’s transmission, remained an enigma until this century. As early as 1848 
Nott suggested that the mosquito was responsible for transmission of the 
disease; however his theory did not gain credence (Warren, 1951). Carlos 
Findlay in 1881 also subsequently proposed mosquito transmission, and again 
this hypothesis was largely disregarded (Warren, 1951). As epidemics of YF
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posed a major public health problem, the United States government established 
a commission to study the disease. The Yellow Fever Commission was formed 
in 1900, and was led by Major Walter Reed, whose contributions to our 
understanding of the disease were to prove paramount. The first significant 
breakthrough in YF research by the Commission was to prove that the agent 
of YF was filterable (and thus that it was a virus), and also experiments which 
showed that the virus was present in the blood of infected individuals during 
the first three days of infection (Reed and Carroll, 1902). This discovery was 
followed by confirmation of the theories of Nott and Findlay who had both 
suggested that the disease was transmitted by mosquitoes. Reed and Carroll 
(1902) demonstrated that infected Aedes aegypti mosquitoes were capable of 
transmitting YF when allowed to feed on non-immune volunteers.
Following these initial findings, there were also setbacks which 
stemmed to some extent from the failure to isolate the virus itself for a further 
quarter of a century. In the face of this lack of evidence, a Japanese scientist 
suggested in 1918 that the causative agent of YF was not viral in nature, but 
in fact a bacterium, Leptospira icteroides (Noguchi, 1919). This claim gained 
some support, and there was a very real price in human terms due to this 
misapprehension, as the mosquito abatement campaigns in Africa and the 
Americas, which had been instigated by the Yellow Fever Commission, 
suffered as a result (Porterfield, 1989).
In the 1920’s and 1930’s steps were taken towards producing live
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attenuated vaccine strains of YF virus, and this will be discussed in further 
detail in Section 1.4; however some aspects of this work included the 
successful passage of YF viruses from monkey to monkey, and mosquito 
transmission studies (Stokes et ah, 1928).
1.3.2 Medical Significance
Humans become infected with YF virus following the bite of an 
infected mosquito. Diagnosis in the field is complicated by the fact that the 
disease course can take many different forms. A single patient with severe 
disease is relatively easy to identify, as opposed to an abortive infection 
(Monath, 1989). YF virus gives rise to a viscerotropic disease in humans, 
which shares clinical features with other viral haemorrhagic fevers such as 
Den haemorrhagic fever. Lassa fever and Congo-Crimean haemorrhagic fever. 
However, with YF virus hepatic involvement is usually more prominent 
(Monath, 1987). The clinical symptoms of YF infection have been reviewed 
both classically and more recently (Kerr, 1951; Monath, 1987; Freestone,
1988).
The symptoms of abortive YF infection are mainly non-specific, and 
so make it difficult to confirm in the field. Fever, headache and constitutional 
problems are all presented. In such cases, patients recover in a few days and 
no sequelae ensue. Severe YF is much more delineated; onset is abrupt and
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the disease course is divided into three distinct phases. The first, the ’period 
of infection’ (during which the virus is present in the blood, and thus 
infectious for mosquitoes) lasts three days, and clinically is marked by chills, 
severe headache, lumbosacral pain, myalgia and Fagets signs (increasing 
temperature with decreasing pulse rate). Classically, a ’period of remission’ 
succeeds this initial stage lasting up to 24 hours, during which time the patient 
feels well. The final stage is the ’period of intoxication’ with frequent 
vomiting, epigastric pain, prostration, dehydration and jaundice. Antibodies 
can be detected at this stage, whilst viraemia is usually absent. Haemorrhage 
can occur, and is indicated by coffee-grounds haematemesis (black-vomit) and 
melena, ecchymoses and diffuse oozing from mucous membranes may also be 
present. Evidence suggests that between 20 and 50% of cases which enter this 
phase result in a fatal outcome (usually between the seventh and tenth days of 
illness). However, death sometimes occurs as early as three days after the 
onset of symptoms without significant hepatic or renal signs; these are atypical 
fulminant cases of YF (Sérié et al. , 1968). In those cases that prove not to be 
fatal, convalescence and complete recovery usually ensue and are rarely 
prolonged, although jaundice can sometimes persist for several months 
(Monath, 1984).
Pathological examination of fatal cases of YF confirms that liver 
damage has occurred. Macroscopic inspection of the liver reveals that it is 
either normal or slightly enlarged in size, reddish or yellow in colour, and 
when it is cut the lobular markings have been destroyed. Microscopic
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examination shows degradation of hepatocytes (Councilman bodies) and 
immunofluorescence detects the appearance of viral antigen in Kupffer cells 
(Monath, 1989). Also, the spleen and lymphatic tissue show that lymphocytes 
are depleted and large mononucleated cells have arisen (Klotz and Belt, 1930). 
The pathogenesis of the haemorrhagic diathesis in YF disease has been linked 
to the decreased synthesis of vitamin K dependant coagulation factors by the 
diseased liver (Monath, 1989). Cerebral involvement is a late development in 
YF infection, and is characterised by petechial and perivascular haemorrhage 
and oedema. Cerebral oedema may be an important factor in the 
encephalopathy observed during the terminal phase of infection (Monath, 
1987).
It should be noted that the disease caused by wild-type YF virus 
infection is largely viscerotropic in nature, with any neurological symptoms 
appearing rarely, and late in the infection process. However, it has been 
observed that when vaccine strains of YF virus revert to virulence, they tend 
to cause neurotropic disease, as opposed to viscerotropic. This will be 
discussed in more detail in Section 1.4.3.
1.3.3 Pathogenesis in other animals
al Monkeys: The Indian rhesus monkey (Macaca rhesus) was 
the first primate to be successfully infected with YF virus (Stokes et ah,
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1928). The virus has since been shown to infect other species (Burgher, 
1951). When inoculated peripherally, the disease is viscerotropic in nature, 
although more rapid than in humans, with death occurring five to six days 
post-infection. Viraemia is first detected on the second or third day after 
infection, and titres increase to the fifth day. Anti-YF virus antibodies are not 
observed, and hepatocellular degeneration and necrosis advance rapidly during 
the 24-36 hours preceding the animals death (Monath et ah, 1981). Central 
nervous system involvement is seen in the terminal phase, as in human 
infection. Monkeys inoculated intracerebrally with wild-type YF virus develop 
encephalitis, but die of viscerotropic YF (Monath et al., 1981).
hi) Mice: YF virus is neurotropic in mice; the brain and ganglia
are the major sites of replication. Theiler discovered in 1930 that adult white 
mice succumbed to YF virus when inoculated intracerebrally (i.e.), but were 
in most cases resistant to infection when inoculated intraperitoneally (i.p.). In 
comparison, newborn mice (up to the age of two weeks) are susceptible to i.p. 
challenge with YF virus. Considerable variation in neurovirulence for mice 
is seen between strains of YF virus (Barrett and Gould, 1986).
In addition, guinea pigs have been shown to be susceptible to i.e. 
challenge with YF virus (Theiler, 1933). The European hedgehog {Erinaceus 
europaeus) is the only non-primate animal in which infection of the liver 
following inoculation with YF virus is observed (Findlay and Clarke, 1934).
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1.3.4 Mosquito vectors and transmission
YF is a zoonotic disease, and human infection arises as the result of 
the bite of an infected mosquito, typically Aedes aegypti. This strain can 
transmit YF in urban outbreaks in both Africa and the Americas; however 
other mosquito species are vectors with non-urban (sylvatic) YF in Africa 
(Haddow et ah, 1967; Germain et al., 1979) and the Americas (Downs,
1989). In the sylvatic forms of the disease, primary transmission cycles 
involve wild non-human primates and various sylvatic (tree-hole breeding) 
aedine mosquitoes. Humans become infected when they enter jungle regions, 
and for this reason this form of the disease is also known as "jungle" yellow 
fever. Epidemic spread can then continue from human to human by means of 
the sylvatic vector. The process is outlined in Figure 1.1.
a) Africa Outbreaks of YF occurred in Africa, where the disease is 
thought to have originated, much earlier than in the Americas; however the 
first well documented epidemic was recorded in 1778 (Freestone, 1988). In 
1971, the World Health Organisation suggested that YF virus was either 
endemic or epidemic in 29 countries between the latitudes of 15°C North and 
10° South (WHO 1971). Many species of monkey have been found to be 
effective hosts, with infection only occasionally resulting in clinical illness, 
representing a balanced host-parasite relationship. Among the non-human 
primate population, Aedes africanus mosquitoes are usually responsible for 
transmission in African forest throughout the year. Aedes bromeliae is
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Figure 1.1: Representation of sylvatic and urban yellow fever transmission cycles
Sylvatic Urban
Monkey Mosquito
Mosquito Mosquito ' Man Man
Monkey Mosquito
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generally involved in the transmission to humans, and also in the intense inter­
human spread during epidemics in these regions.
Savannah vegetational regions which support considerable and 
concentrated populations of both monkeys and mosquito vectors have assumed 
great importance in the ecology of YF, and have been termed the "zone of 
emergence" (Germain et û/.,1982). In these regions, virus activity increases 
during the rainy season, and sylvatic transmission and also transmission of YF 
virus to man occurs; the vectors associated with this are Aedes jurcifer, Aedes 
africanus and Aedes luteocephalus. In areas subject to extremely arid 
conditions, such as Northern Sudan and the savanna regions of West Africa, 
domestic water storage is intensively practised and populations of Aedes 
aegypti are high. Under such conditions, the introduction of YF virus can 
result in explosive outbreaks of the disease (Monath, 1989). Transovarial 
transmission of the virus in Aedes aegypti has been demonstrated 
experimentally, and is believed to be important in the virus surviving extended 
dry periods and over winter (Aitkin et al., 1977; Beaty et al., 1980). YF virus 
has also been isolated from ticks in Africa, and both transovarial and 
transstadial transmission demonstrated (Saluzzo, 1980); however the 
importance of this in nature is unclear. Breeding populations of Aedes 
albopticus were recently recorded in continental Africa for the first time, 
giving cause for concern (Savage et al., 1992). Aedes albopticus is an 
aggressive colonizer, as demonstrated by it’s rapid spread and establishment 
in North America and Brazil (Hawley, 1988). It is therefore feared that, due
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to it’s utilization of a wide variety of oviposition sites, it’s aggressive biting 
habits, and it’s competence as a YF vector (Miller and Ballinger, 1988), 
Aedes albopticus may link the sylvatic and urban YF transmission cycles 
(Savage er aZ., 1992).
bl Americas YF was recorded earlier in the Americas than in Africa, 
when an outbreak occurred in the Yucaton in 1648 (Blake, 1968). Since the 
1940’s the majority of YF outbreaks have occurred exclusively in South 
America. In tropical America, the howler monkey (Alouatta spp.), spider 
monkey {Ateles spp.) and several other primates are effective viraemic hosts, 
which, unlike those in Africa, usually succumb to the disease. This unstable 
relationship between virus and host has been proposed as corroborative 
evidence for the theory of the relatively recent introduction of the virus to the 
Americas (Monath, 1989). In tropical areas mosquitoes of the genus 
Haemagogus are the principal vectors of "jungle" YF, with humans becoming 
infected when they enter habitats supporting enzootic/epizootic transmission 
(Monath, 1989). Transovarial transmission in a Haemagogus sp. has been 
demonstrated for YF (Duraty and Le Duc, 1981), but the mechanism of virus 
maintenance during the dry season remains unclear. The species Aedes 
albopticus has recently invaded Brazil, and this has led to concern about it’s 
potential to transmit YF. Although Aedes albopticus is a less efficient vector 
than Aedes aegypti, it is nonetheless a competent one (Whitman, 1951). 
Sporadic endemic cases of YF were recorded in South America in 1986 and 
1987, and the Brazilian Ministry of Health advised travellers to the country
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to be vaccinated against YF as the result of "jungle" YF in 1988 (Weekly 
Epidemiological Record, 1989a & b).
As stated previously, the historical view is that YF virus originated in 
Africa (Taylor, 1951) and was then disseminated to South America, possibly 
as a result of slave trading, some time during or after the 16th century. It has 
been noted that wild-type YF viruses from South America and Africa can be 
distinguished in a number of ways. South American, but not African, YF 
viruses are virulent for 8  day-old mice when inoculated by the i.p. route 
(Deubel et al. , 1987). Antigenic differences have also been observed (Clarke, 
1960; Deubel et ah, 1987). In addition the E protein of the two virus 
populations differs in electrophoretic mobility and carbohydrate content 
(Deubel et al., 1987; Cane and Gould, 1989). T, oligonucleotide mapping has 
demonstrated that South American and African YF viruses differ at the 
molecular level (Deubel et ah, 1986).
1.3.5 Control of vectors
The combination of high populations of Aedes aegypti and human 
habitation gives rise to the possibility of urban YF. This mosquito strain is 
often associated with human habitation, as it utilises potable water supplies as 
primary breeding sites (Monath, 1986). Low levels of insecticide in the water 
supplies can reduce vector levels to such an extent that the risk of outbreaks
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of YF can be considered low. A more environmentally friendly method of 
vector control is to place Gambusia minnows into the water. These fish prey 
on mosquito larvae, and in a controlled programme were shown to be most 
effective (Monath, 1989). However, larviciding and environmental measures 
provide only delayed control of adult populations, and, in the event of an 
outbreak in a human population, the application of ultra-low volume 
insecticide (ULV) is employed. ULV can be distributed by aerial, ground, 
vehicle mounted and hand-held equipment, and trials using the insecticide 
fenitrothion in Asia, South America and Africa have produced satisfactory 
results (Gratz, 1991). ULV is used for rapid and effective emergency control 
of vectors when outbreaks of YF occur in urban or semi-urban regions, but 
are not suitable as routine control measures (Gratz, 1991).
1.4 Yellow fever vaccines
YF has been prevented by the use of two types of live attenuated vaccines; 
namely 17D and the French neurotropic vaccine (FNV).
1.4.1 17D vaccines
The 17D substrains used as live YF vaccines today originate from 
studies performed by Max Theiler and colleagues, who in 1937 reported the
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live attenuated YF vaccine strain 17D (Theiler and Smith, 1937a & b). Today 
the 17D vaccines are considered probably the safest viral vaccines currently 
available.
In 1927, an atypical wild-type strain of YF virus was isolated from a 
mild case of the disease in a Ghanian named Asibi (Stokes et al., 1928). This 
strain was named Asibi, after its human host, and initially passaged in mice 
in an attempt to increase virus titre; however it was noted that an increase in 
monkey virulence following peripheral challenge accompanied the increased 
titre. Following 18 passages in mouse tissue, the virus was then passaged 
consecutively in whole chick embryos a further 50 times. An additional 108 
passages in chick embryo from which the head and spine (and thus the 
majority of the nervous tissue) had been removed ensued. At passage 176, a 
strain of the virus was isolated which had lost the ability to cause fatal 
encephalitis in rhesus monkeys following intracerebral challenge, and also was 
no longer mosquito competent. This candidate vaccine virus was designated 
17D and was unique among other isolates derived at the same time using a 
similar method (17A, 17B, 17C etc.), which were not sufficiently attenuated. 
Additionally, Theiler and co-workers were unable to generate such a strain 
again in subsequent experiments (Theiler and Smith, 1937a & b, Theiler, 
1951).
Strain 17D was further passaged in chick embryo, with nervous tissue 
removed, and at passage 204 (p204), a safe and effective vaccine strain was
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produced. The vaccines derived from this passage are known as 17D-204 
substrain vaccines.
Today, two substrains of the 17D vaccine are manufactured; 17D-204 
and 17DD. The 17D-204 vaccines are currently at p233-240 from the parent 
Asibi virus, whilst the 17DD substrain diverged from 17D at pl95, was 
passaged independently of the 17D-204 strain, and is currently between p286- 
288 from Asibi. The derivation of these substrains, together with the countries 
that are licensed by the World Health Organization (WHO) to produce them, 
is shown in Figure 1.2.
The 17D vaccine was initially evaluated in YF immune and non- 
immune volunteers without apparent side effects (Theiler and Smith, 1937b). 
It was then introduced into Brazil in 1937, and between that date and 1938 
approximately 59,000 doses administered; again no documented sequelae 
occurred (Barrett, 1987). Subsequently its’ use became more widespread. At 
this time a number of laboratories were responsible for YF vaccine 
production, all of which were independently maintained with vaccine ’lots’ 
produced as and when required. No quality control procedures were 
performed. In 1943, the first of a number of problems arose with YF vaccine 
production; these are described in Section 1.4.3.
At present the WHO controls the production of YF vaccine, and 
manufacturers must meet certain criteria. Twelve countries are currently
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Figure 1.2: Derivation of the yellow fever 17D vaccine viruses 
and their WHO approved manufacturers
Asibi
Original 17D(pl76)
17DD
17D-204(p204)
Low(pl95)
France
Colombia S. Africa U.K. India
Senegal
U.S.A
Australia
Holland
WHO ALV free 17DD
High(p243)
Australia Russia F.R.G 
(p238-239)
Brazil
Senegal
Colombia
(p286-288)
Adapted from Barrett, 1987
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licensed to produce YF vaccine, although two recently ceased production 
(Colombia and Holland). In contrast, Russia and Nigeria have recently 
commenced producing the vaccine (WHO, 1981; WHO 1988). Vaccine lots 
are tested in primates to safeguard against revertant viruses. The WHO 
(WHO, 1981) specifies that the test animal must be a rhesus monkey, or a 
primate of similar susceptibility. The dose administered should be between the 
thresholds of 5,000 mouse LD50 and 50,000 mouse LD5 0  in a 250 ^1 volume 
which is injected into the frontal lobe while the animal is under anaesthetic. 
The test subjects are then observed for up to 30 days for any signs of 
encephalitis, such as instability, paralysis or death, which should not occur in 
more than 1 0 % of the study group.
In humans, the 17D vaccines induce seroconversion in greater than 
96% of vaccinees, and neutralization indices are also high (>12.0) (Freestone 
el al.y 1977). The immunity generated is prolonged, and may be life-long 
following a single vaccination (Poland et aZ.,1981), although re-vaccination 
is recommended by the WHO at 10 year intervals. Contra-indications include 
pregnant women, infants under 6  months of age, and individuals who are 
allergic to eggs, as the vaccine is produced in embryonated eggs. Also, those 
who are immunocompromised, whether due to disease (including clinical 
AIDS) or treatment with immunosuppressive drugs should not receive 
vaccination (Monath, 1989).
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1.4.2 The French neurotropic vaccine (FNV)
The second attenuated strain of YF virus to be used as a vaccine was 
developed at the Institut Pasteur in Dakar, Senegal, in the 1930’s. The wild- 
type virus from which it derived, the French viscerotropic virus (FVV) was 
isolated in 1927, as was the Asibi strain; however, FVV was isolated from an 
individual named Françoise Mayali in Senegal (Mathis et al. , 1928), who, like 
Asibi, was a patient with a mild form of YF. The wild-type FVV was 
passaged intracerebrally in adult mice, until the virus exhibited loss of 
viscerotropism for monkeys following peripheral challenge and also loss of 
mosquito competence. The first such attenuated variant was obtained following 
128 passages in mouse brain, and the first vaccine viruses were established 
and used at passage 237 (see Figure 1.3). Although the attenuated strain thus 
produced, the French neurotropic vaccine (FNV), had lost it’s viscerotropic 
characteristics, it displayed an enhanced neurotropism for both mice and 
monkeys, particularly following intracerebral inoculation. This was probably 
as a result of its’ prolonged passage in brain tissue.
The FNV vaccine was manufactured in mouse brain and used 
extensively between 1939 and 1980, especially in French speaking regions of 
Africa, and was responsible for the virtual eradication of the disease YF from 
these areas between these dates. An estimated 80 million doses of the vaccine 
were administered during this time (Barrett, 1987) with the last doses 
administered in Malawi. The vaccine proved to have better heat stability than
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Figure 1.3: Derivation of the French neurotropic vaccine viruses
Mayali* (Senegal, 1927) 
(French viscerotropic virus [FVV])
Original FNV virus (pl28)
First FNV administered (p237)
Later vaccines (p260)
* Name of the patient, Franscois Mayali, from whom the 
virus was isolated by Mathis et. al., 1928
Figure adapted from Barrett, 1987
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17D, and could also be administered more easily (by scarification rather than 
intra-muscular injection). However, problems were observed with post­
vaccinal sequelae (discussed in Section 1.4.3), which resulted in the WHO 
proscribing it’s use in individuals younger than 14 years of age; consequently, 
use of the vaccine was discontinued in 1980 (Barrett, 1987).
1.4.3 Problems with YF vaccines
The FNV strain of YF vaccine was in some ways more efficacious and 
easier to administer than the 17D strain (as described above). However the 
main reason that it is no longer in use was an unacceptably high level of post­
vaccinal encephalitis. Whilst 17D has not been without it’s problems, this has 
not (in general) been one of them.
Very little data or statistical studies were amassed on the incidence of 
post-vaccinal encephalitic incidents observed with FNV; one of the few 
documented studies was performed by MacNamara (1953), who monitored the 
vaccine in Nigeria. Approximately 42,000 people were vaccinated, and 83 
cases of post-vaccinal encephalitis were recorded, of which 32 proved to be 
fatal. The virus was isolated from the brains of four fatalities. It is probable 
that the real number of cases and fatalities may have been higher, as recording 
of such cases was probably suspect, and some workers in the field are of the 
opinion that the actual incidence of both encephalitis and death were higher
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than the 0 .2 % and 0.08% respectively that the figures from this one study 
would suggest (Barrett, personal communication). The incidence among 
children was particularly high: following the Nigerian vaccination campaign 
it was 0.3-0.4%, and where encephalitis did develop there was a 40% chance 
of the outcome proving fatal. It is not surprising therefore, that the vaccine 
was banned for use in children under the age of 14. Since, in areas where YF 
is endemic, it is advisable that vaccine is administered at as early an age as 
possible (as infants are at greatest risk from YF), the vaccine lost popularity 
and was discontinued in 1980.
There have also been a number of documented problems that have 
arisen with the 17D vaccine strains. Some arose partly as a result of their 
being no satisfactory quality control mechanism during the early years of its' 
production. In 1943, some 17DD strains had been passaged between 300 and 
350 times from the parent Asibi. Some of these preparations became over 
attenuated and failed to provide a protective immune response in vaccinees. 
This was solved by the return to earlier passages of 17DD as vaccine (Theiler, 
1951). One batch of 17DD vaccine caused central nervous system disorders 
in Brazilian children vaccinated with it. Fox et al. (1942) discovered that the 
degree of encephalitis was related to the substrain of vaccine which was used. 
The stability of the 17D vaccines was not ideal in the field, and human serum 
was added to a number of preparations in an attempt improve this. However, 
serum hepatitis ensued in a number of vaccinated British, American and 
Brazilian army personnel (Strode, 1951). The problem of heat stability was
33
diminished by increasing the concentration of egg protein present in the 
lyophilized vaccine. An additional improvement in overall vaccine production 
came about with the introduction of the seed lot/batch system in 1945, which 
introduced standardization and quality control techniques to the vaccine 
production (Barrett, 1987). The 17D vaccine is still produced in embryonated 
eggs, some of which are contaminated with avian leucosis virus (ALV), 
depending on the manufacturer. In addition to the potential threat posed by 
any contaminating virus (although there have been no recorded problems 
resulting from ALV (Waters et al., 1972)), the presence of ALV in vaccine 
preparations reduces the heat stability of the vaccine batch. This can cause 
major problems when a reliable cold chain for the transport of vaccine, 
especially to tropical and sub-tropical areas, is not available (Lloyd, 1977). 
Thus stable ALV-free vaccine strains have been developed, which have been 
shown to confer solid protection and few side-effects in recipients (Moss- 
Blundell et al., 1981). Several attempts have been made to improve the 
thermal stability of the 17D vaccine since the abortive addition of human 
serum, including the addition of lactose, sorbitol, histidine and alanine to the 
lyophilised preparation (Barme and Bronnert, 1984). In field testing, the 
vaccine was found to have favourable stability, with the lyophilized material 
remaining effective after 5 months storage at 5°C (Georges et al., 1985).
In contrast to FNV, 17D vaccine strains have largely been free from 
post-vaccinal problems, including encephalitis. In fact the number of 
documented cases of encephalitis following vaccination with 17D strains is
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less than 20, and of these only one has proved fatal. This involved the 
inoculation of a 39 month old girl with batch 6145 of the 17D-204 vaccine 
produced in the USA by the National Drug Company. The girl developed 
encephalitis and died 1 2  days after the vaccination was administered. 
However, neither of her parents, who were vaccinated with the same batch at 
the same time, exhibited any signs of encephalitis. YF virus was subsequently 
isolated from her brain at post-mortem (Anonymous, 1966). This case remains 
unique in the history of the 17D vaccine strains.
1.4.4 Attenuated variants of YF virus
In addition to the vaccine strains of YF derived by conventional 
methods described above, YF has also been shown to become attenuated 
following passage in HeLa cells.
The HeLa cell line was isolated in February 1951, from a cervical 
carcinoma of a 31 year old woman (Henrietta Lacks), who subsequently died 
from the cancer (Gey et a l, 1952). HeLa cells were the first human tumour 
cells to be established as a continuous cell line. The original slides, when re­
examined, showed the tumour to be adenocarcinoma-like in nature (Jones et 
a l ,  1971).
The alphavirus Venezuelan equine encephalitis (VEE) was the first
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virus to be attenuated by passage through HeLa cells. After 23 consecutive 
passages it was found that there was a reduction in the virulence of the virus 
for mice when inoculated by the intraperitoneal (i.p.) route. Following 65 
passages the virus was found to be avirulent via the i.p. route (Murphy et al. , 
1955 a & b).
In 1963, Hardy cultivated the wild-type YF virus strain Asibi in HeLa 
cells (Hardy 1963a). Further studies examined the properties of Asibi 
following six consecutive passages in HeLa cells (Asibi HeLa-p6 ) (Hardy, 
1963b). The Hela passaged virus was found to be still virulent for mice, as 
was the parent, but exhibited a lower average survival time (AST), suggesting 
that the HeLa passaged virus was of enhanced virulence. However, unlike the 
parent non-HeLa passaged Asibi virus, Asibi HeLa-p6  virus did not cause a 
lethal infection in monkeys following subcutaneous inoculation. Thus, the 
passage of Asibi in HeLa cells resulted in the loss of viscerotropic disease for 
monkeys.
In 1965 Hearn et al. examined this phenomenon further. Asibi virus 
was characterised following either one or three passages in HeLa cells. This 
study demonstrated that biological changes occurred much earlier than passage 
six. After one passage the virus failed to exhibit cytopathic effect (cpe), 
although this returned following three passages. The virus was attenuated for 
monkeys after only three passages, as opposed to the much greater number of 
passages described in section 1.4.1 that were required to produce the 17D
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attenuated variant from the same parent virus. Another altered property of 
Asibi HeLa-p3 virus was a reduced incubation period for peak infectivity titre 
(3 days, as opposed to 5 for Asibi). However the HeLa-pl and p3 virus 
populations appeared genetically very unstable.
Further studies by Hearn et al. (1966) characterised Asibi virus that 
had been passaged 7 times through HeLa cells. It was found to be highly 
attenuated, requiring inoculation of over 700,000 mouse infectious doses to 
elicit the same virulent response in monkeys as 1 - 1 0  infectious doses of the 
parent non-HeLa passaged Asibi virus.
The attenuation of wild-type YF viruses by passage through HeLa cells 
was examined in more detail in studies performed by Dunster (1990), Barrett 
et ah, (1990) and Sil et al. (1992). This work not only repeated and 
confirmed the earlier results obtained for Asibi virus, but also showed that 
other wild-type YF viruses could also be attenuated in the same way (FVV 
and B4.1 viruses). In addition, studies with monoclonal antibodies (MAbs) 
showed that wild-type YF viruses attenuated in this manner exhibited E 
protein epitopes which were also found on YF vaccine viruses (17D and FNV) 
which had been attenuated conventionally, as described above in Sections
1.4.1 and 1.4.2 (Barrett et al., 1990; Sil et al., 1992). The implications of 
this work are discussed in more detail in Chapters 5 and 6 .
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1.5 Molecular biology of flaviviruses
Studies on the molecular biology and sequence analyses of flaviviruses 
have trailed behind those performed on other virus families. However, recent 
years have seen our understanding of the significance of the flavivirus- 
specified proteins increase. This has depended largely upon the determination 
of the complete sequences of a number of flaviviruses, the first being that of 
YF, the type species (Rice et al. , 1985), and the partial determination of those 
portions coding for specific genes, particularly the envelope protein gene, of 
many others.
1.5.1 Morphology
Flavivirus virions consist of an isometric core which is 30-35 
nanometres (nm) in diameter; this is encased by a lipid bilayer which gives the 
whole virion a total diameter of approximately 45nm. The outer surface is 
covered in projections which are 5-10 nm in length which terminate in a 2nm 
diameter knob (Murphy, 1980). The nucleocapsid core contains a single copy 
of single stranded RNA which is of positive polarity and complexed with a 
single species of capsid protein (Westaway, 1980).
SLE virus, when subjected to chemical analysis, revealed a
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composition of 6% RNA, 66% protein, 17% lipid and 9% carbohydrate 
(Trent and Neave, 1980). However both the lipid type and overall content 
varies depending upon the cell line in which the virus is propagated (Trent and 
Neave, 1980). Infectious particles have a sedimentation co-efficient in sucrose 
of between 175 and 218 S (Boulton and Westaway, 1972) and buoyant 
densities in caesium chloride and sucrose of 1.22 g/cm^ and 1.18-1.20 g/cm^ 
respectively (Smith et a l ,  1970). The majority of flavivirus virions exhibit 
maximal stability in the range pH 7-9 (Brinton, 1986); however tick-borne 
flaviviruses can tolerate much lower values (pH 3 for 24 hours) (Pogodina, 
1958). Virions have also been shown to be sensitive to ultraviolet light, both 
ionic and non-ionic detergents, trypsin digestion and temperature, with a 50% 
decrease in infectivity seen following 10 minutes at 50°C (Brinton, 1986; 
Porterfield et al. , 1978).
1.5.2 Genome organization
The flaviviral genome consists of a single-stranded positive sense RNA 
molecule which is approximately 11 kilobases in length, containing short 
untranslated 5’ and 3’ regions (Rice, 1990). The genomic RNA is infectious, 
and genome length RNAs are the only virus specific mRNA molecules that 
have been detected in flavivirus infected cells; the viral RNA thus appears to 
act directly as message (Chambers et al. , 1990). Flaviviral genomic RNA has 
a type 1 cap at it’s 5’ end (m^GpppAmpNJ, which probably aids in the
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binding of RNA to ribosomes (Mathukrishnan et ah, 1975, 1976; Wengler et 
ah, 1978; Cleaves and Dubin, 1979). The 5’ cap is followed by the conserved 
dinucleotide sequence AG. All mosquito-bome flaviviruses appear to lack a 
3’-terminal poly(A) tract (Brinton, 1986; Rice et ah, 1986), and instead 
terminate with the conserved dinucleotide uridylic acid (CUqh) (Wengler et 
ah, 1978; Wengler and Wengler, 1981; Deubel et ah, 1983). However the 
presence of a 3’ poly (A) tract has been detected in at least one TBE virus 
(Mandl et ah, 1991).
As stated, YF was the first flavivirus for which the nucleotide sequence 
was determined in entirety (Rice et ah, 1985). However, a number of other 
flaviviruses have also been sequenced in full. These include WN (Castle et 
ah, 1985 and 1986; Wengler et ah, 1985), JE (Hashimoto et ah, 1988; 
Sumiyoshi et ah, 1987), Central European (CE) TBE (Mandl et ah, 1989a), 
Far Eastern (FE) TBE (Pletnev et ah, 1990) and Den serotypes 2 , 3 and 4 
(Hahn et ah, 1988; Osatomi and Sumiyoshi, 1990; Mackow et ah, 1987). 
From the data thus determined it was found that flavivirus RNA contains a 
single uninterrupted long open reading frame, which is 10,233 nucleotides in 
length for YF virus. This is translated into a polyprotein of 3411 amino acids. 
In other flaviviruses the figures are similar (Chambers et ah, 1990). The 5’ 
non-coding region is shorter than the 3’ in mosquito-bome flaviviruses; in YF 
it is 118 nucleotides in length, whilst the 5’ non-coding region consists of 511 
nucleotides. The 3’ non-coding sequence of CE-TBE and FE-TBE virus 
appears to be much shorter than that of mosquito-bome flavivimses, and also
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appears to lack a number of RNA sequences and structures found in the latter 
group (Mandl et ah, 1989a).
The polyprotein coded for by flaviviruses consists of at least 10 virus- 
specific polypeptides which are produced by co-translational and post- 
translational processing (see Section 1.5.4). The order of proteins encoded 
is:-
5’-C-prM(M)-E-NSl-NS2a-NS2b-NS3-NS4a-NS4b-NS5-3’
The structural proteins, capsid (C), membrane (M and its’ precursor 
prM) and envelope (E) are encoded by the 5’ one quarter of the genome, 
while the sequence coding for the non-structural proteins (NSl, 2a, 2b, 3, 4a, 
4b and 5) is located in the remaining three quarters (Rice et al. , 1986) (see 
Figure 1.4).
Among flavivirus sequ&ces thus far determined, there are several 
regions in the genome which appear to be conserved. These include 90 
nucleotides at the 3’ terminus of most mosquito-bome vimses which may be 
organised into a stable hairpin loop stmcture (Brinton et al. , 1986; Grange et 
a l,  1985). No evidence yet exists that flavivimses undergo cyclization of 
RNA prior to replication; however two short conserved repeat features 
(named CSl and CS2) are found 5’ to the 3’ putative secondary stmcture 
sequence. It has been postulated that base-pairing of these terminal sequences
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Figure 1.4: Notes
NC - untranslated non-coding region. Boxes below the genome indicate precursors and 
mature proteins generated by combinations of host and virus encoded proteinases.
Structural proteins
I I Non-structural proteins
j j  Long stretches of uncharged amino acids
* Probable NH^linked glycosylation site for YF virus in pre-M and NSl
Proposed cleavage sites and their mechanisms
\ 7  Signalase, rapid lumen 
Dibasic, rapid lumen 
^  Dibasic, delayed?, cytoplasm
Dibasic, delayed, lumen 
I  Novel, slightly delayed, lumen
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could lead to cyclization of the viral genome which may be important for 
regulating genome translation, replication or packaging (Brinton and Dispoto, 
1988; Sumiyoshi et al., 1987). Evidence supports the cyclization of the 
genomes of alphaviruses (Frey et al., 1989; Hsu et al., 1973) and 
bunyaviruses (Hewlett et al., 1977), but in flaviviruses the possibility has not 
as yet been investigated (Chambers et a l ,  1990).
Some degree of sequence conservation can also be observed in the 5’ 
non-coding region of the flavivirus genome; hairpin loop structures have also 
been predicted in this region (Brinton and Dispoto, 1988).
1.5.3 RNA replication strategy
Following translation of infecting genomic mRNA, complementary 
minus-strands are synthesised that in their turn act as templates for the 
production of further genome-length positive sense RNA molecules. These 
may then either be translated to produce the viral proteins, encapsidated into 
virions, or used to produce more negative-sense RNA molecules (Brinton,
1986).
Synthesis of flaviviral RNA is detectable six hours after infection in 
vertebrate cells (Chu and Westaway, 1985). From studies on replicative 
intermediates, it appears that between 10 and 15 minutes are required for the
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synthesis of flavivirus genome-length products, which is about 1 0  times slower 
than poliovirus genome synthesis (Chu and Westaway, 1985; Cleaves et ah, 
1981).
Viral RNA synthesis appears to be located principally at the 
membranes of the perinuclear endoplasmic reticulum (Chu and Westaway, 
1985 & 1987; Grun and Brinton, 1986).
1.5.4 Processing of the flavivirus polypeptide
As stated earlier the flavivirus genome encodes a single long 
polyprotein which then undergoes co- and post-translational modification (Rice 
and Strauss, 1990). The mechanisms thought to be implicated with each 
cleavage are shown in Figure 1.4. There appear to be five distinct processes 
involved.
The N-termini of prM, E and NSl follow predicted signalase cleavage 
sites (von Heijne, 1984) contributed by the C-terminal hydrophobic regions 
of anchored-C, prM and E respectively (Chambers et al., 1990). In addition 
a similar sequence is also found to precede the N-terminus of NS4b. Although 
the N-terminus of NS2a follows a cleavage sites that fulfils the basic 
prerequisites for a signalase site, it lacks the required upstream hydrophobic 
region (Chambers et ah, 1990). However, Falgout et al. (1989) have shown
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that the cleavage between NSl and NS2a occurs in the absence of other viral 
proteins, suggesting that either a host-specified enzyme or a viral proteinase 
encoded within NSl-NS2a is responsible.
Cleavage sites generating the N-termini of NS2b, NS3, NS4a and NS5 
are highly conserved among flaviviruses, and occur after two basic amino acid 
residues (a combination of lysine and arginine), which are usually flanked by 
amino acids with short side-chains, such as glycine, serine or alanine 
(Chambers et ah, 1990). A virally specified protease was postulated for the 
cleavage at such sites, and recent studies suggest that a domain within NS3 is 
responsible for these cleavages (Chambers et ah, 1991), and that the serine 
residue at position 138 in NS3 is instrumental in this activity. It has also been 
demonstrated that NS2b in tram is also necessary for the cleavage at the N- 
termini of NS2b and NS3 (Falgout et ah, 1991). The cleavage of anchored-C 
to produce the C protein found in virions also follows a dibasic site, but 
appears to be delayed, but associated with the cytoplasm. (Chambers et ah, 
1990). In contrast, the dibasic cleavage of prM to produce the pr and M 
fragments appears to be delayed but associated with the lumen.
A detailed review of the processing of the flavivirus polyprotein, along 
with a discussion on the role of NS3 as the flavivirus specified proteinase can 
be found in Rice and Strauss (1990).
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1.5.5 Flavivirus structural proteins
Ï) The capsid (O  protein
The C protein forms a structural part of the virus nucleocapsid, and 
that present in virions is a small (predicted MW 12-14 kDa) highly positively 
charged protein (27% lysine and arginine for YF virus (Rice et a l ,  1986)) ( 
Chambers et a l ,  1990). The basic nature of C is believed to offset the 
charged RNA molecule with which it is associated (Rice et a l ,  1986). 
Although the amino acids that make up the C protein exhibit little homology 
amongst the flaviviruses so far sequenced, regions of hydrophobicity and 
hydrophilicity are conserved, including a C-terminal hydrophobic domain that 
is immediately preceded by a hydrophilic region, and also a central 
hydrophobic region (Mandl et a l ,  1988). The N-terminal portion contains a 
hydrophilic section which, in mosquito-bome flaviviruses is interrupted by a 
hydrophobic insert that is not found in tick-home flaviviruses.
The precursor to the virion C protein is known as anchored C, and 
contains a 20 amino acid C-terminal hydrophobic section (for YF virus) which 
is not found in mature virions (Nowak et al. , 1989). Purified C does not elicit 
neutralizing antibody when injected into mice (Brinton et al., 1986).
n) The pre-membrane (prMl protein
prM is a glycosylated precursor form of the stmctural protein, M. This 
precursor undergoes a delayed cleavage to form M and the N-terminal
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segment, "pr" (the fate of which is unknown) (Chambers et al., 1990). Since 
prM and M are found on intracellular and extracelluar virions respectively, 
this cleavage is thought to be linked to virus maturation and release.
The N-terminal pr segment is predominately hydrophilic, and contains 
six conserved cysteine residues, all of which are involved in di-sulphide 
bridging (Nowak and Wengler, 1987). Serologically related flaviviruses show 
conservation of potential N-linked glycosylation; in YF virus there are three 
potential sites within the pr region; data suggests that two are utilized, 
although which two is not known (Chambers et al., 1990).
The C-terminal M portion contains a shortened ectodomain (approx. 
41 residues) and retains the two potential membrane-spanning domains. M is 
associated with the envelope (E) protein, but in it’s mature form is not 
glycosylated. It is a minor component of the envelope (MW 7-9 kDa), and 
may play a role in virus/cell interactions, as Banzi virus is unable to attach to 
cells which have been pre-treated with purified Banzai M protein (Lee and 
Schloemer, 1981). Unlike C, purified M protein does elicit a neutralizing 
antibody response following inoculation into mice (Brinton, 1986). It may be 
a component of the viral spike, and have functions involved with the binding 
to and entry of cells.
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iiïl The envelope (E) protein
The E protein, with a predicted molecular weight of 53-59 kDa, is the 
major structural protein of the virus and the major component of the virion 
surface (Chambers et ah, 1990). As such, it possesses most of the sites 
concerned with biological activity including binding to cell receptors (tropism 
and haemagglutination), invoking immunological responses (neutralization, 
passive protection and antibody dependent enhancement), virion assembly and 
fusion activity at low pH (Monath, 1989).
The E protein is glycosylated in some, but not all flaviviruses, and 
appears to be a typical membrane protein consisting of a large N-terminal 
ectodomain, anchored in the bi-layer by means of a hydrophobic C-terminal 
domain (Chambers et ah, 1990).
As in prM, the cysteine residues within the E protein are strictly 
conserved within all flavivirus E proteins so far studied; there are 12, and all 
are involved in the formation of di-sulphide bridges (Nowak and Wengler, 
1987). Within the E proteins there are regions which exhibit high degrees of 
homology, particularly at the amino acid level, and others where both 
nucleotide and amino acid homology is low.
The E protein is the most studied flaviviral protein, and several 
workers have attempted to produce two-dimensional models of it’s structure. 
These have been based on:-
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a) the determination of the intra-molecular disulphide bridges for WN 
virus (Nowak and Wengler, 1987).
b) study of the biological and topological properties of E protein 
epitopes defined by MAbs (for a review see Heinz, 1986).
c) physical and immunological characterization of E protein fragments 
derived by protease or chemically induced cleavage (Guirakhoo et al. , 
1989b; Mandl gfaZ., 1989b).
d) localization of antibody binding sites to the deleted forms of the JE 
virus E protein expressed in bacteria (Mason et al., 1987; Mason,
1989).
e) nucleotide sequencing of neutralization escape mutants of YF and 
TBE (Lobigs et a l ,  1987; Mandl et a l ,  1989b).
f) reactivity of anti-peptide sera with native E protein from MVE and 
Den-2 viruses (Roehrig et a l ,  1989).
Originally three domains, stabilized by di-sulphide bonding, were 
defined by examination of the WN virus E protein (Nowak and Wengler, 
1987). These were: an N-terminal region containing five strongly hydrophilic
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segments, a central region and a C-terminal region where a hydrophobic 
anchor is found.
However, the most detailed studies of the E protein have been 
performed using the CE-TBE virus E protein as a model. Heinz and co­
workers in 1990 characterized the TBE E protein using a panel of monoclonal 
antibodies in competitive binding assays (CBAs). They determined three major 
epitope clusters, which were termed A, B and C (see Figure 1.5). The 
experimental approaches listed above have enabled these domains to be 
associated with specific regions of the E protein.
Domain A is proposed to be made up of amino acids  ^ in the di­
sulphide rich region from 50-125, and also residues 200-250. Whilst aU three 
domains contain epitopes that have been shown to be involved in 
haemagglutination inhibition and neutralization, only domain A contains 
flavivirus cross-reactive epitopes. It is therefore not surprising that the amino 
acids which form this domain contain some highly conserved regions, 
including one from positions 98-111 which is almost totally conserved 
amongst all flavivirus E proteins so far studied, and is postulated to be 
involved in acid-catalyzed fusion (Heinz et ah, 1990; Roehrig et ah, 1989). 
This domain does undergo a pH-dependant conformational change consistent 
with it’s possible role in endocytotic fusion events (Guirakhoo et ah, 1989a).
 ^ Numbers listed correspond to the TBE E protein.
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Figure 1.5: Notes
1) A, B and C correspond to antigenic protein domains recognised by 
MAbs.
2) Cysteine residues forming di-sulphide bridges are shown by connecting 
solid lines.
3) Thin lines indicate variable sequences; thick lines hypervariable 
sequences.
4) Diamonds indicate potential N-linked glycosylation sites for TBE and 
other viruses (as marked).
5) Filled circles denote conservative and partially conservative residues; 
empty circles denote non-conservative, variable residues.
6 ) Arrows together with names of neutralizing MAbs mark the locations 
of mutations identified in antigenic variants of TBE virus. Arrowheads 
indicate non-conservative substitutions in the 17D-204 YF vaccine 
strain (Y), the attenuated Den-2 SI strain (D), and an attenuated MVE 
variant (M).
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Figure 1.5: Structure of the TBE virus envelope
protein (adapted from Mandl et al. , 1989)
A
c
TBE-E
B
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However, some stretches of the amino acids which make up this domain 
also exhibit regions of variability. Neutralization escape mutants map to this 
domain for YF (Lobigs et ah, 1987) and CE-TBE (Mandl et al., 1989) 
viruses. Domain A epitopes of CE-TBE virus are sensitive to dénaturation 
with sodium dodecyl sulphate (SDS), reducing agents and trypsin (Guirakhoo 
e ta l ,  1989).
Domain B, consisting of residues 300-395 (see Figure 1.5), is trypsin 
resistant. Epitopes on this domain of CE-TBE virus E protein are resistant to 
SDS, acidic pH and trypsin, but sensitive to reducing agents (Guirakhoo et 
a l,  1989). Two studies suggest that this region may be involved in tissue 
tropism, and perhaps in virus-host cell interactions. A TBE MAb 
neutralization escape mutant which was attenuated in mice and conferred 
protection against lethal challenge mapped to position 384 (Heinz et al., 
1990). Secondly, following passage in SW-13 cells, an attenuated variant of 
MVE virus was selected that was attenuated for mice (Lobigs et ah, 1990). 
The substitution of one of four amino acids for an aspartic acid at position 390 
was found in the E protein.
Domain C is composed of a di-sulphide free loop, made up of amino 
acids 131-177 (Chambers et ah, 1990). Epitopes in this domain are not 
denatured by SDS, but are sensitive to protease treatment (Guirakhoo et ah,
1989). In several flaviviruses, N-linked glycosylation occurs within this 
region; in TBE this is at position 154 (see Figure 1.5).
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The role of N-linked glycosylation in the flaviviruses E protein remains 
unclear. Potential sites are not conserved throughout the Flaviviridae, but 
similarities can be observed amongst serogroups. In addition to the TBE virus 
site mentioned above, all four Den serotypes possess a site near amino acid 
150, as do several members of the JE subgroup (Chambers et al. , 1990) (see 
Figure 1.5). There is indirect evidence that the CE-TBE virus site is utilized 
(Heinz et al. , 1990) There is also a site at position 67 for the Den viruses. YF 
virus contains a potential site at 309, as does SLE virus (Chambers et ah, 
1990). Whether or not these sites are utilized or remains unclear. Although 
there are further potential sites located near the C-terminus of the E protein 
for YF, Den 3 and 4 and CE-TBE viruses, these are probably not utilized due 
to their location in the hydrophobic transmembrane region.
Evidence exists for both simple and complex glycans being 
incorporated into the E protein (Deubel et al., 1987; Smith and Wright, 
1985). Differences in glycosylation have been observed for South American 
and African isolates of YF virus (Deubel et al., 1987). It would appear from 
studies on the JE virus E protein that newly synthesized, cell-associated E 
protein contains a single mannose-rich glycan, but when released as virion 
associated E endo H-resistance suggests that glycans have been converted to 
complex forms prior to virus release (Mason, 1989). The release of E is 
impaired in the presence of tunicamycin, indicating that E glycosylation may 
be important for some flaviviruses. However, for TBE virus E protein,
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carbohydrate removal does not reduce infectivity for avian cells (Winkler et 
a l ,  1987).
Recently, the E protein of TBE virus has been isolated in a soluble 
form and crystallized (Heinz et a l ,  1991). It is to be hoped that X-ray 
crystallographic analysis will resolve the three-dimensional structure of the E 
protein, which will greatly assist in elucidating the functional activities and 
antigenic properties of this protein.
1.5.6 Flavivirus non-structural proteins
Compared to the structural proteins, the non-structural proteins of 
flaviviruses have been relatively poorly studied. However, recently they have 
been subjected to more intense scrutiny. There are a total of seven non- 
structural (NS) proteins encoded by the flavivirus genome (Rice, 1990) (see 
Figure 1.4).
i) NSl NSl is a large protein (MW 39-41 kDa) of biological 
importance, and is found in several forms; associated with the plasma 
membrane of infected cells, and in a released form as the soluble complement 
fixing antigen (Smith and Wright, 1985) which may be slowly or rapidly 
sedimenting (Lee et a l , 1989; Mason, 1989. The physical differences between 
the membrane-associated and secreted forms may be due to glycosylation, as
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discussed below. NSl has also been detected in monomeric, dimeric and 
trimeric forms (Chambers et ah, 1990).
NSl is unusual for a non-structural virus protein in that it is 
glycosylated, and also in that it elicits antibody-mediated protective immunity. 
(Westaway, 1975; Schlesinger et ah, 1983; Smith and Wright, 1985; Gibson 
et ah, 1988). As observed in E, NSl contains 12 cysteine residues which are 
conserved in all flaviviruses so far sequenced, except Den-4 virus (Mackow 
et ah, 1987). The N-linked glycosylation in flavivirus NSl proteins so far 
examined also exhibits a high degree of conservation dependant on the vector 
involved in transmitting the virus (Chambers et ah, 1990). All mosquito-bome 
flaviviruses contain two potential sites with an additional site between them 
seen in members of the JE complex, excepting JE virus itself. TBE viruses 
share one of these sites but have two additional unique sites (Chambers et ah ,
1990). There is direct evidence that NSl is glycosylated: cell-associated Den-2 
NSl contains N-linked oligosaccharide consisting of mannose-rich glycan 
(Smith and Wright, 1985). For YF virus it has been suggested that the 
observed differences between the different forms observed may be due to the 
nature of the glycosylation, with membrane associated forms containing 
mannose, and the secreted form containing complex-type sugar (Post et ah ,
1990).
The protein is largely hydrophilic except for the C-terminal region, 
which contains a hydrophobic region for anchoring NSl in the plasma
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membrane. Since NSI is expressed on the surface of flavivirus infected cells 
it is capable of eliciting an immune response from the host. Immunization with 
NSl has been shown to be protective (Schlesinger et û/.,1985, 1986, 1987), 
and antibodies raised against NSl to elicit passive protection in mice (Gibson 
et ah, 1988). Type specific, complex specific and group reactive epitopes 
have been detected on NSl by the use of MAbs (Henchal et ah, 1987). The 
function of NSl is not fully understood, but it may play a role in virus 
morphogenesis rather than replication (Russell et ah, 1980; Chambers and 
Rice, 1987).
in NS2a NS2a is the first of four small non-structural flavivirus 
proteins, the others being NS2b, NS4a and NS4b. All four exhibit regions of 
hydrophobicity which are conserved in position, although not in the amino 
acids which constitute them, suggesting that these proteins are membrane 
associated (Chambers et ah, 1990).
NS2a has been implicated in the processing of NSl (Falgout et ah,
1989). Two forms of NS2a in YF virus have been observed with molecular 
weights of 20 and 22 kDa respectively; the structural basis and significance 
of these forms is not clear (Chambers et ah, 1989).
iiil NS2b It has recently become apparent that NS2b, a protein of 
13kDa, is involved in the processing of regions of the flaviviral polyprotein 
which are cleaved by the proteinase domain encoded for by NS3 (see
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following section). Studies using vaccinia virus to express regions of both 
Den-4 virus (Falgout et ah, 1991) and YF virus (Chambers et ah, 1991) 
polyproteins have demonstrated that NS2b, in addition to the NS3 proteinase 
domain, is required for cleavage of all the dibasic sites in the flavivirus 
polyprotein (see Figure 1.4). NS2b also appears necessary in tram for a series 
of internal cleavages of NS3. However the precise nature of the role played 
by NS2b remains unclear, although it is possible that the active proteinase is 
formed of a complex of NS3 and NS2b, such that NS2b induces 
conformational changes necessary for cleavage in the catalytic domain 
(Chambers et ah, 1991).
ivl NS3 As stated in the previous section, at least part of NS3 
has been identified as being important in the processing of the flavivirus 
polyprotein at dibasic cleavage sites (either Arg-Arg or Lys-Arg), surrounded 
by short-side-chain amino acids.
Within the N-terminal one third of NS3 (residues 1-180), a region was 
identified by sequence comparisons and molecular modelling which exhibited 
homology to the trypsin family of serine proteases (Bazan and Fletterick, 
1989; Gorbalenya et ah , 1989a). Also residues were located in YF virus NS3 
(His-53, Asp-77 and Ser-138) that were spatially equivalent to those in the 
active site of this family of proteinases (Bazan and Fletterick, 1989). Deletion 
at Ser-138 inactivates the protease activity.
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NS3 also contains regions which exhibit homology with the D-E-A-D 
family of RNA helicases (Gorbalenya et ah, 1989b), specifically between 
residues 191-508 of YF NS3 protein. Although two functions are proposed for 
NS3, there is no evidence that supports cleavage of the protein into separate 
protease and helicase domains.
vl NS4a and NS4b The role of these proteins is poorly understood. 
Both may form membrane components of the viral replication complexes, a 
role suggested by the multiple hydrophobic, potential membrane spanning 
domains they both contain. They may be involved in membrane localisation 
of NS3 and NS5 via protein-protein interactions (Chambers et ah, 1990).
No post-translational modification of these proteins has been detected, 
although NS4b contains a potential N-linked glycosylation site (Lee et ah,
1990).
vil NS5 NS5 is both the largest (predicted MW 103-104 kDa) 
and the most highly conserved of the flavivirus proteins (Mandl et ah, 1989a). 
A cytoplasmic location is suggested by it’s basic nature, and the lack of any 
long hydrophobic stretches, although it has been found to be associated with 
membranes (Chambers et ah, 1990).
It has been suggested that NS5 is the viral RNA polymerase, as a 
highly conserved domain (in YF virus, residues 531-675) contains the
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sequence motif Gly-Asp-Asp (Rice et ah, 1985, 1986). This motif has been 
shown to be present in the nonstructural proteins from several positive 
stranded RNA viruses and is believed to play a role in RNA-dependant RNA 
synthesis (Kamer and Argos, 1984).
1.5.7 Nucleotide sequence analysis of YF virus
In 1985, the sequence of the entire genome of the 17D-204 strain of 
YF vaccine virus was published (Rice et al., 1985). This was the first full- 
length sequence of a flavivirus to be determined, and provided the opportunity 
to understand in greater detail the structure, organisation and processing of the 
genome. Two years later the entire sequence of the wild type YF virus, Asibi, 
from which the 17D-204 vaccine was derived was also determined (Hahn et 
ah, 1987). This allowed, for the first time, comparisons to be made at a 
molecular level between a flavivirus wild-type/vaccine pair.
Table 1.2 shows the changes seen at both the nucleotide and amino 
acid level between the two viruses. Over the genome of 10,862 nucleotides, 
there were 6 8  nucleotide changes, leading to 32 amino acid changes. 
Considering the fact that the two viruses are separated by some 240 passages 
the number of changes is relatively small. Despite the determination and 
comparison of the wild-type and vaccine, few conclusions could be drawn 
regarding the significance of those changes observed. However, it can be
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Table 1.2: Summary of the nucleotide and amino differences between 
Asibi virus and it’s vaccine derivative, 17D-204 (ATCC)
Region Total nt / AA
Change 
nt /  AA
% Change 
nt /  AA
5’ noncoding 118/- 0 /- 0 /-
C 363/121 2/0 0.55/0
prM 267/89 0/0 0 /0
M 225/75 2/1 0.89/1.89
E 1479/493 15/12 1.01/2.43
NSl 1227/409 5/2 0.41/0.49
NS2a 501/167 6/5 1.20/2.99
NS2b 390/130 4/2 1.03/2.31
NS3 1869/623 9/2 0.48/0.32
NS4a 861/287 6/3 0.70/0.78
NS4b 336/112 2/1 0.60/0.89
NS5 2715/905 11/4 0.40/0.44
3’ noncoding 511/- 6 /- 1.17/-
Total 10862/3411 6 8 /3 2 0.63/0.97
Adapted from Hahn etaJ. , 1987.
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noted that changes are found at a much greater frequency in some of the genes 
and proteins than in others (E and NS2a).
In the structural proteins, coding changes were only present in the M 
and E proteins, with only one in M compared to 12 in E (2.43% divergence 
in E). In the nonstructural proteins, a proportionately greater number of 
changes (as a percentage of the size of the proteins) were seen in NS2a and 
NS2b, with 2.99% and 2.3% divergence respectively.
It was also noted that 15 nucleotide changes in the E protein gene led 
to 12 amino acid substitutions in the E protein, compared to the rest of the 
coding region where 53 nucleotide changes gave rise to 20 amino acid 
substitutions. This suggested that in the E protein some of the amino acid 
substitutions may have been positively selected for during passage, rather than 
being simply neutral in effect (Hahn et ah, 1987). In addition, the E protein 
genes of a number of YF 17D-204 escape mutants selected for by treatment 
with a YF type specific neutralizing MAb have been sequenced (Lobigs et al. ,
1987). The E protein genes proved to differ from that of the 17D-204 strain 
sequenced by Rice et al. (1985) at one or two positions; these coded for 
amino acid substitutions at either amino acid 71, 72 or 125 in the E protein. 
At position 71, an asparagine was replaced with a lysine, a tyrosine or a 
histidine residue, and in one mutant a glycine replaced an aspartic acid at 
position 72. In one of the mutants sequenced, the change at amino acid 71 was 
accompanied by the substitution of an isoleucine for a methionine at amino
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acid 125.
The only other YF virus for which sequence data has been published 
is a plaque-pick (B4.1) of a wild-type South American isolate, 1899/81, from 
Peru. The nucleotide sequence of the genes encoding the structural proteins 
and also NSl of this strain were reported (Ballinger-Crabtree and Miller, 
1989). Comparison with Asibi and 17D-204 viruses showed that the South 
American wild-type strain was very different from both the wild-type African 
strain Asibi, and the vaccine strain 17D-204 derived from it, at both the 
nucleotide and amino acid level. Although the data presented was interesting 
in highlighting the difference between wild-type strains of YF virus from the 
two different continents at the molecular level, it did not help answer 
questions about the molecular basis of attenuation and virulence of YF virus.
1.6 Biological analysis of yellow fever viruses
Compared to molecular studies, there is a relatively large 
volume of data available examining YF virus biologically, with most of the 
recent publications involving the use of monoclonal antibodies (MAbs). In 
1983, MAbs were reported which distinguished between the wild-type Asibi 
strain and it’s vaccine derivative, sub strain 17D-204 (Schlesinger et ah). 
Gould et al. (1985) included the other vaccine strains, FNV and 17DD, and 
a number of wild-type strains of YF in a study which showed that 17D-204,
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17DD and FNV vaccine strains could be distinguished from each other and 
from wild-type viruses by MAbs. Each of the three vaccine substrains was 
shown to exhibit unique epitopes. In addition, MAbs were identified which 
recognised epitopes present on all fiaviviruses examined, including tick-borne 
viruses and those with no known arthropod vector. Barrett et al. (1989) 
demonstrated that 17D-204 vaccine viruses from different centres around the 
world could be distinguished by MAbs in neutralization tests.
In addition to those studies detailed above, work in the University of 
Surrey has examined MAbs raised against both vaccine and wild-type strains 
of YF virus (Ledger et ah, 1992; Sil et ah, 1992), and has identified, 
amongst others, the presence of an epitope (termed the "vaccine epitope") 
which is present on the E protein of all attenuated YF virus strains, but absent 
on wild-type viruses. This and other properties of YF virus will be discussed 
in more detail in the relevant Chapters (Chapters 4-8).
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Aims of the thesis
Despite the publication of the nucleotide sequences of the entire 
genomes of the wild-type strain Asibi and the 17D-204 vaccine substrain 
derived from it, the molecular basis of attenuation of YF virus remains 
unclear. The aim of this thesis was to use the RT-PCR to amplify regions of 
the genome of strains of YF virus, specifically those coding for the structural 
proteins, and to then clone and sequence these.
A number of YF strains were available which had previously been 
examined both biologically and antigenically with MAbs, and which presented 
interesting properties often associated with the E protein. These included a 
second wild-type vaccine pair (FVV and FNV viruses), a neurovirulent 17D- 
204 vaccine revertant (P-16165) and an atypical African wild-type isolate 
(Y5). The determination of the nucleotide sequence of the structural protein 
genes of these viruses, and their comparison with those published for Asibi, 
17D-204 and B4.1 viruses, in conjunction with antigenic and in vivo studies 
would be used to postulate changes at the molecular level in YF virus which 
may be involved in factors such as the neurovirulence of some vaccine strains, 
and the presence of E protein epitopes on viruses associated with attenuation 
of virulence.
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Chapter 2
Materials and Methods
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All reagents used were assessed by the COSSH procedure, and precautions were 
taken whilst carrying out work in accordance with the School of Biological Sciences 
Safety Procedures.
2.1 Cell culture
2.1.1 Cell Unes used
All cell lines employed in the study were stored in liquid nitrogen 
stocks in the Flavivirus Research Laboratory (FRL) at the University of 
Surrey. Three cell lines were used; LLC-MK2 cells were derived from rhesus 
monkey (Macaca rhesus) kidney cells (Evans et ah, 1964), whilst Vero cells 
(obtained from Epsom Public Health Laboratory, U.K.) were derived from 
African Green Monkey (Cercopithecus aethiops) kidney cells (Yasmura and 
Kawakita, 1963). SW-13 cells derived from a human adenocarcinoma 
(Leibowitz et ah, 1973).
2.1.2 Maintenance of cell lines
Cells were grown and maintained in Eagles minimal essential medium 
(EMEM, Flow Laboratories, UK), supplemented with L-glutamine [2mM]f 
(Flow Laboratories, UK) and non-essential amino acids [lmM]f (Flow 
Laboratories, UK). Media was also supplemented with sodium bicarbonate 
[20mM]f (Flow Laboratories, UK) and 100 units/ml of penicillin G (Sigma, 
UK) and 0.1 mg/ml streptomycin sulphate (Sigma, UK). The media contained 
either 1% (v/v) or 5% (v/v) foetal calf serum (FCS, Flow Laboratories, UK)
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for maintenance medium or growth medium respectively. Cells were incubated 
at 37®C in the presence of 5% carbon dioxide.
Sub-culturing of cells was performed by trypsinization of a confluent 
monolayer (using trypsin 2.5% w/v in Hanks salts (Flow Laboratories, UK)), 
triturating the cells in fresh medium and then seeding fresh tissue culture 
flasks (Falcon Laboratories, UK) as described by Lenette and Schmidt (1969). 
Cells were normally split at a 1:4 ratio.
2.1.3 Viruses
The origins and derivations of the YF virus strains employed in this 
study are shown in Table 2.1.
2.1.4 Virus propagation
Viruses were grown by infecting Vero, LLC-MK2 or SW-13 cell 
monolayers which were 80% confluent, following washing of the cell sheet 
with phosphate buffered saline (PBS). Inoculation of virus at a multiplicity of 
infection of 0 . 1 - 1 . 0  plaque forming units (pfu)/cell was then performed. 
Virus was allowed to absorb to the cell sheet by incubation at room 
temperature for 30 minutes prior to the addition of cell maintenance medium
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containing only 1% FCS. Cultures were incubated at 37°C, in a 5% carbon 
dioxide atmosphere, until cytopathic effect was evident in 90-100% of the 
cells (24 - 72 hours). The supernatants were then harvested, clarified by low- 
speed centrifugation (2000 rpm for 5 minutes), aliquoted, and stored at -70°C 
in cryotubes (Nunc).
2.2 Sterilisation of culture media and buffers.
All media and buffers were sterilised by autoclaving at 121 ®C (15 
pounds/square inch (psi)) for 15 minutes (mins) or by filtration through a 0.2 
/zM Flowpore D-filter (Millipore). Except where indicated. Mill! Q grade 
water was used in the preparation of all media and buffer solutions and is 
referred to as ’water’ throughout this thesis.
2.2.1 Diethyl pyrocarbonate (DEPC) treatment.
DEPC is a strong, but not absolute, inhibitor of RNAases (Fedorcsak 
and Ehrenberg, 1966). Several of the solutions used were employed in the 
isolation, extraction or treatment of RNA, and so glassware and plasticware 
that was to be used for this purpose was treated with DEPC by soaking 
overnight in a 0.1 % (v/v) solution of DEPC in water. The solution was then 
discarded, the containers rinsed with ethanol, which was also discarded, and
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then autoclaved before use.
2.3 Preparation of virions prior to RNA extraction
Four methodologies were employed to concentrate and/or purify virus 
prior to extraction of their RNA. Different methodologies were employed for 
different strains of YF virus for various reasons; for example some strains 
would not grow to high titre in tissue culture, and hence such strains were 
amplified in vivo in adult mouse brain (see Chapter 3 for further details). The 
publication of methodologies dealing with viral RNA extraction was also 
instrumental in the choice of small-scale preparations from tissue-culture fluid 
towards the end of this study.
2.3.1 Concentration of virus from large volumes of tissue
culture fluid
Cell culture monolayers, usually of Vero or LLC-MK2 cells, were 
inoculated with virus as described in Section 2.1.4. To achieve a relatively 
large volume of infected tissue culture fluid, usually 15-20 175 cm  ^ flasks 
(Nunc) of cells were infected for each strain to be purified. A control flask 
was mock-infected with PBS. Following the appearance of 90% cpe, the tissue 
culture supernatant was harvested into sterile 300 ml centrifuge buckets. The
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supernatants were then clarified by centrifugation at 2 0 , 0 0 0  xg for 30 
minutes at 4°C in an MSE HS-21 centrifuge.
The clarified supernatant was then decanted into centrifuge tubes 
(Beckman), and the virus pelleted by centrifugation at 120,000 xg f in an SW28 
rotor for 6  hours. The supernatant was then discarded, the tubes drained and 
the pellet resuspended in 100 /xl of TE buffer, pH 8  (lOmM Tris, ImM 
EDTA). The tubes were sealed with "Nescofilm", and the pellet allowed to 
swell at 4°C overnight. The tubes were vigorously vortexed prior to the 
removal of the virus suspension, which was then used for RNA extraction as 
described below in Section 2.4
2.3.2 Concentration and purification of virus by gradient
centrifugation
Large volumes of tissue culture fluid were also employed for this 
methodology, and the initial steps were as described above in Section 2.3.1. 
The supernatants of 10-15 175cm  ^ flasks of infected cells were clarified as 
described above.
Virus was then precipitated from the clarified medium by the addition 
of polyethylene glycol (PEG) 8000 to a concentration of 7g/100ml of fluid 
while slowly stirring at 4°C for three hours.
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The precipitated virus was then pelleted by centrifugation at 2 0 , 0 0 0  xg 
for 30 minutes at 4°C in the MSE HS-21 centrifuge. The supernatant was 
removed, and the pellet resuspended in 1ml of TE buffer, pH 8 .
A 14 ml potassium tartrate-glycerol gradient was employed (30% (w/v) 
potassium tartrate to 45% (v/v) glycerol, both in TE buffer, pH 8 ). The 
pelleted virus was layered onto the top of the gradient using a sterile pasteur 
pipette, and the gradient subjected to centrifugation at 300,000 xg for 3 hours 
in a Beckman SW40 Ti rotor. The virus band was visualized as a pale blue 
band, removed using a sterile pasteur pipette, and resuspended in a final 
volume of 1 ml TE buffer, pH 8 .
Finally, TE buffer was added to the virus which was then pelleted by 
centrifugation for 3 hours at 300,000 xg in a Beckman SW 40 Ti rotor, the 
supernatant removed, and the pellet allowed to swell overnight as described 
in Section 2.3.1.
Although the above methods were effective, both were time 
consuming, particularly the gradient purification method. This method 
produced purified concentrated virus; however a very pure preparation was 
not always necessary for the RT-PCR reaction, and more crude methodologies 
were also employed.
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2.3.3 In vivo preparation of virus
Strains of YF virus replicate efficiently in the brains of adult mice, and 
this fact enabled several strains to be amplified in vivo.
100fil (containing 1 0 0  pfu) of the chosen virus was inoculated 
intracerebrally (i.e.) into 3-4 week old female outbred TO mice. The animals 
were observed daily for signs of encephalitis, manifested by erratic activity, 
partial and total paralysis. When the animals exhibited advanced clinical signs 
of infection (days 5-9 post-infection, depending on the virus), they were 
sacrificed, and the brains removed and stored at -70°C.
Prior to extraction of viral RNA, the brains were homogenized to 
release virus. This was achieved by rapidly thawing the brains and then 
suspending each brain in 500 [xl of TE buffer, pH 8 . The brain suspensions 
were vortexed, and then passed through the barrel of a 2ml luer syringe. The 
brain suspensions were then forced through needles of decreasing bore size 
(19g and 21g) to produce a homogenate. This was then bulked to 1 ml with 
TE, pH 8 , and centrifuged at 12,000 ipm for 20 seconds to remove the 
majority of brain tissue before RNA extraction was performed on the 
supernatant as described below in Section 2.4..
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2.3.4 Extraction of virus RNA from small volumes of
tissue culture fluid.
Towards the end of these studies a methodology was published (Lewis 
et al. , 1992) which described extraction of flavivirus RNA for PCR directly 
from small volumes of tissue culture fluid, rather than following an 
amplification/purification step, as described for the previous three methods. 
This methodology employed RNA extraction, as described in the following 
section, on 1-5 ml volumes of tissue culture supernatants, and relied on the 
addition of 5/xg tRNA (Sigma) to act as carrier RNA and aid the extraction. 
In general, each RT-PCR required vRNA extracted from 500 {A o f tissue 
culture fluid.
2.4 Extraction of viral RNA
Whichever method was used for preparation of virus, the procedure for 
the extraction of RNA was basically the same, with only minor variations 
employed.
The purified virus was dispensed into aliquots and the total volume was 
made up to 500 jul with TNE buffer (lOOmM Tris-HCl, pH 8.5, 50mM 
sodium chloride, ImM disodium EDTA). Viral protein was digested with 0.1 
mg of autodigested (37°C for 15 mins) proteinase K for 30 mins at 37°C. 1%
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(w/v)f sodium dodecyl sulphate (SDS) was added, and the sample incubated 
for a further 15 mins at 37°C. For extraction directly from tissue culture 
fluid 5 fig of tRNA was added at this point.
Protein was removed by extraction with an equal volume of 
phenol/chloroform/isoamyl alcohol/8 -hydroxyquinoline (PCI) mixture (phenol: 
chloroform: isoamyl alcohol: 8 -hydroxyquinoline =  25:24:1:0.1 equilibrated 
with an equal volume of TE buffer, pH 8 , and kept at 4°C in the dark). For 
each PCI extraction, an equal volume of PCI was added to the nucleic acid 
sample, the sample was thoroughly vortexed to form an emulsion, which was 
then centrifuged at 14,000 rpm in an Eppendorf 5415C benchtop centrifuge 
(microfuge) for 2  mins at room temperature to separate the phenol and the 
aqueous nucleic acid-containing phase. The aqueous phase was transferred to 
a fresh microcentrifuge (MCC) tube taking care to avoid the interface.
For extraction from mouse brain, further PCI extractions were 
required, as these preparations contained a much higher level of protein than 
the other preparations described in Section 2.3. After this first PCI extraction 
only, the aqueous phase was stored whilst the phenolic phase was ’back 
extracted’ by the addition of an equal volume of TE, pH 8 , vortexing and 
centrifugation as described; this second aqueous phase was then combined 
with the first and the second PCI extraction was initiated. For some! mouse 
brain preparations with a high protein content , a third PCI extraction was performed.
Residual phenol was removed from the aqueous phase by ether extraction: an
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equal volume of di-ethyl ether was added, the preparation vortexed and then 
centrifuged at 14,000 rpm for 1 min at room temperature. The upper di-ethyl 
ether phase was removed and any residual di-ethyl ether was removed by 
incubating the preparation in the MCC tube, lid open, at 6 8 °C for 10 mins. 
Viral RNA (vRNA) precipitation and pelleting was effected by ethanol 
precipitation: 2.5 volumes of chilled ethanol (-20°C) and 300 mM sodium 
acetate pH 5.2 were added to the vRNA suspension, mixing by inversion was 
performed, and precipitation effected at -70°C for 30 mins. The vRNA was 
then pelleted by centrifugation at 14,000 rpm for 20 mins at 4°C in a 
microfuge. The pellet was washed with 200 fil of 70% chilled ethanol, a 
further centrifugation of 14,000 rpm for 5 mins at 4°C was performed and the 
pellet was dried in a cool oven (40°C).
Resuspension was effected in high performance liquid chromatography 
(HPLC) purified water (Aldrich). For direct extraction from tissue culture 
fluid 5.5 /Ltl of HPLC water for each ml extracted was used to resuspend the 
pellet, as this equated to the volume required for the initial RT reaction. RNA 
extracted using the other methods was resuspended in a total of 20-30 pi. 
Crude large-scale tissue culture fluid and gradient-purified vRNA was 
quantitated by the spectrophotometric method (section 2.5). The vRNA was 
aliquoted and stored at -70°C, in the presence of RNAsin (Boehringer- 
Mannheim (5U/10)Ltl)).
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2.5 Quantitation of nucleic acid bv spectrophotometric analysis
The principle of this method (Maniatis et al. , 1982) is based on the 
absorption of ultra violet (UV) light by the bases of nucleic acid. This method 
was routinely employed for nucleic acid samples greater than 500 ng, 
including vRNA and also oligonucleotides designed as primers following 
deprotection. The principle disadvantage of this method is its failure to 
distinguish between degraded and undegraded nucleic acid.
The DNA or vRNA suspension was diluted 1000 fold in sterile HPLC 
water in a quartz cuvette. The absorbance readings at 260 (A260) and 280 
(A280) nm wavelength were measured using a Pye Unicon model PU8820 
UV/VIS spectrophotometer. Purified vRNA was quantitated by absorbance at 
260 nm assuming that one A260 unit corresponds to 40 jug/ml of vRNA. 
Purified DNA was also quantitated by absorbance at 260 nm, although one 
A260 unit corresponds to 50 pglml of DNA. The purity of the nucleic acid 
was assessed by the ratio of the optical density (OD) readings at 260 nm and 
280 nm. Pure preparations of RNA and DNA have OD260/OD280 values of 
2 . 0  and 1 . 8  respectively.
2.6 Synthesis and purification of oligonucleotides
Oligonucleotide primers were synthesised on an Applied Biosystems
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381A synthesizer using phosphoramidite chemistry (Beaucage and Caruthers, 
1981). Primers were removed from their supports in the snap column by 
drawing 2 mis of 35% (v/v) ammonia (4°C) through, by syringe, at the rate 
of 200 ^1/20 mins. The suspension was placed in a screw capped MCC tube 
and incubated at 55°C for a minimum of 8  hours in order to deprotect the 
primers. The suspension was then cooled to room temperature and the primers 
precipitated overnight at -20 °C by the addition of three volumes of chilled 
ethanol and 300 mM sodium acetate, pH 5.2. The primers were pelleted by 
centrifugation, washed with 70% ethanol and dried in a cool oven. 
Resuspension was effected in 30 p\ of HPLC water and the primers were 
quantitated by absorbance at 260 nm assuming that one A260 unit corresponds 
to 33 /xg/ml of single stranded oligonucleotide primers. An aliquot of each of 
the primers was resuspended to a produce a working stock of 500 ng!p\ and 
storage was effected at -2 0 °C.
2.7 First strand synthesis of cDNA to the vRNA
In the early stages of this study, vRNA was subjected to dénaturation 
by both heat and methyl mercury hydroxide (MMH) prior to first strand 
synthesis of cDNA. MMH (Alfa products) was previously shown to have a 
denaturing effect on RNA secondary structure (Simpson, 1963; Grunwedel and 
Davidson, 1966). In addition the use of this chemical for the dénaturation of 
flavivirus RNA secondary structure has been optimized (Whitby, 1992). This
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method proved reliable (see Chapter 3); however when a protocol was 
published which employed dénaturation by boiling (Lewis et ah, 1992), this 
was adopted in place of heat and MMH, due to the toxic nature of this 
chemical.
2.7.1 Reverse transcription employing heat and MMH
500 ng of vRNA was employed for RT, unless RNA extracted from 
mouse brain was utilized, in which case 1 - 2  pg was used to take into account 
the presence of cellular RNA.
The vRNA was resuspended in a volume of 4.5 p\ of HPLC water, and 
heat denatured by placing it in a 94° C water bath for 5 mins. The sample was 
then quick-chilled on ice. At the same time sufficient anti-sense primer to 
allow 500 ng per reaction to be added was also subjected to heat dénaturation 
and then chilled.
MMH was then added to a final concentration of 0.63 mM, the 
reaction mixed thoroughly, and the tube incubated at room temperature for 1 0  
minutes. Following this, 500 ng of the heat-denatured antisense primer was 
added, and then B-mercaptoethanol added to a final concentration of 0.59 mM. 
The tube was thoroughly vortexed, and then incubated on ice for five mins. 
13-mercaptoethanol has the effect of reversing the binding of the MMH to the
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nucleic acids. The compound was added in slight excess to remove any excess 
mercury ions from the reaction mix, as these would otherwise interfere with 
the activity of reverse transcriptase. However, J3-mercaptoethanol also reacts 
with other divalent cations, such as magnesium. As reverse transcriptase has 
an absolute requirement for magnesium ions (Maniatis et ah, 1982), a 
calculated amount of magnesium ions, in the form of magnesium chloride was 
added to the reaction mixture (Whitby et ah, 1992).
Thus, magnesium chloride was added to a final concentration of 0.1 
mM, and the concentrations of these solutions were calculated such that the 
reaction mix now had a total volume o i l  ii\. The reaction mix was maintained 
on ice for all stages following the addition of the B-mercaptoethanol to 
maintain the RNA and primer in a denatured form.
1 III of xlO RT buffer (500mM Tris, 500mM KCl, lOOmM MgCl;, 
30mM DTT), 14 units of RNAse inhibitor (Boehringer), ImM of each 
deoxynucleoside triphosphate (dNTP (Pharmacia)), and 7.5 units of Rous- 
associated virus (RAV-2) reverse transcriptase (RT) (Amersham) were then 
added, to give a final volume of 10 jul. The reaction mix was then incubated 
at 42°C for 2 hours.
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2.7.2 Reverse transcription employing dénaturation by
boiling
This procedure was employed during the latter parts of these studies, 
especially with RNA extracted from small volumes of tissue culture fluid, as 
it avoided the use of the toxic mercury compounds, and proved to give 
satisfactory results (see Chapter 3).
The RNA was suspended in a volume of 5.5 fû (RNA extracted from 
tissue culture was not subjected to spectrophotometric analysis, and so the 
concentration of RNA was unknown) of HPLC water. 500 ng of the 
appropriate reverse primer was added, and the sealed tube then incubated in 
a boiling water bath for 5 minutes, and placed immediately onto ice. Addition 
of xlO RT buffer, dNTPs, RNAsin and RT was effected as described above 
in section 2.7.1. to give a final volume of 10 fû. The reaction mix was then 
incubated at 55°C for 1 hour.
2.8 Use of the polymerase chain reaction
Following reverse transcription by the method utilizing MMH and heat 
dénaturation, the PGR (Saiki et al. , 1985) reaction was performed as follows.
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Each reverse transcription mix was divided into two in order to provide 
two PCR reactions. The reaction was performed in a volume of 50 fxl, 
comprising 5 fû of the first strand synthesis, 5 fû of the lOx buffer supplied 
with the Tag DNA polymerase enzyme (Boehringer), 250 ng of antisense 
primer and 500 ng of sense primer. HPLC water was used to make the final 
volume up to 50 fû. The reaction mix was overlayed with 50 fû o f mineral oil 
(Sigma) to prevent evaporation.
Amplification was performed in a Techne PHC-2 programmable 
temperature cycler, or a Hybaid Thermal Reactor (3-15A). The reaction mix 
was heated to 94°C for 10 minutes to denature the vRNA/cDNA hybrid, and
2.5 units of Toq DNA polymerase (Boehringer) added below the surface of the 
mineral oil as the reaction mix cooled to the annealing temperature of 40°C, 
which was held for 2 mins. An extension step was then effected at 72°C for 
3 mins.
Following this initial sequence, the following cycle of incubations was 
then repeated 27 times:-
-dénaturation at 94°C for 1 min 
-primer annealing at 40°C for 2 mins 
-extension at 12°C for 2  mins
The final cycle was as above, except that the extension time was 10
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mins. After the final cycle the PHC-2 was programmed to hold the reactions 
at 4-6°C if the reactions were set up overnight; otherwise they were subjected 
to analysis by agarose gel electrophoresis immediately following completion.
Following the dénaturation of RNA by boiling as described in Section
2.7.2 the procedure for PCR was essentially as described above, with the 
following differences. 250 ng of antisense primer and 500 ng of sense primer 
were added to 5 jul of the first strand synthesis reaction mix, which was then 
placed into a boiling water bath for 5 mins. It was then rapidly chilled on ice, 
and 50 ( j l I  of mineral oil used to overlay it. An appropriate amount of a 
cocktail containing the lOx enzyme buffer, HPLC water and Taq DNA 
polymerase was then prepared and maintained on ice.
Following an initial dénaturation step for 4 mins at 94°C, 44 fû of this 
mixture was then added to each reaction to bring the total volume to 50 fzl. 
The temperature cycling used was as shown below:-
-dénaturation at 94°C for 3 mins
-primer annealing at the lower of the calculated annealing 
temperatures of the primers employed for 2  
mins
-extension at 72°C for 10 mins
This cycle was then repeated 27-30 times except that the dénaturation
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step was subsequently performed for 1 min, and in the final cycle only, the 
extension step was increased to 2 0  mins.
2.9 Gel electrophoresis of amplified PCR products
The mineral oil was removed by the addition of 100 /xl of chloroform, 
vortexing and removal of the organic solvent lower phase. 10 ^1 TBE gel 
loading dye (50% (v/v) glycerol, 0.05% (w/v) bromophenol blue, 100 mM 
Tris-HCl pH 8 , 90.6 mM boric acid, 52 mM disodium EDTA) was added to 
the amplified product mix which was then separated by electrophoresis at 1 0 0  
- 150 volts for 30 mins to 1 hour in a 2% agarose gel in TAE buffer in a 
horizontal electrophoresis apparatus. The gel was stained in a solution of 
ethidium bromide (0.5 jug/ml in TAE buffer), photographed on a UV 
transilluminator and the cDNA bands of correct size located by comparison 
with molecular weight markers.
2.10 Recovery of cPNA from agarose gels
As the PCR products produced were all of a length greater than 300 
base pairs, the Geneclean HR kit (Stratech) was employed to recover DNA 
from agarose gels. This system exploits the affinity of DNA molecules to 
silica matrices. The kit contains a specially formulated suspension of silica
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matrix called ’Glassmilk’ which binds both single and double stranded DNA, 
without binding contaminating material, and the system routinely recovers 
80-90% of DNA.
Gel slices containing the appropriate amplified cDNA fragments were 
excised and weighed and 3 volumes (w/v) of 6  M sodium iodide stock solution 
were added. The mixture was incubated at 55°C for 2 mins, thoroughly 
vortexed and then incubated for a further 13 mins. 5 /xl (per 5 fig DNA) of 
Glassmilk suspension was added, the mixture was vortexed and incubated at 
room temperature for 5 mins. The silica matrix, plus adhered DNA, was then 
pelleted by a 1 0  second pulse at room temperature in the microfuge, the 
supernatant was removed and was replaced with 50 volumes (v/v) of ice-cold 
New buffer (sodium chloride, ethanol and water - exact composition not 
available) and the pellet was thoroughly resuspended by pipetting. This last 
step was repeated twice more. The final removal of the supernatant was 
effected with great thoroughness. The washed pellet was resuspended in 10 fil 
HPLC water and incubated at 55°C for 3 mins. The silica matrix was then 
pelleted by pulsing in the microfuge for 30 seconds and the supernatant, 
containing DNA, removed to a fresh tube. This last step was repeated in a 
volume of 5 fil of HPLC water, the second supernatant was added to the first 
and the DNA suspension was stored at -20°C until use.
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2.11 Cloning of the virus cDNA
The technique employed for cloning of the PCR products obtained 
employed the plasmid pUC18 and the use of competent Escherichia coli (E. 
coli) cells.
2.11.1 Plasmid pUC18
Plasmid pUC18 is a 2686-base pair (bp) derivative of the 4362-bp 
pBR322 plasmid (Bolivar et al., 1977; Sutcliffe, 1978). This plasmid contains 
a number of useful improvements: the tetracycline antibiotic resistance gene 
of pBR322 has been deleted, but the ampicillin resistance gene and pBR322 
origin of replication have been retained (Norrander et al., 1983); a portion of 
the E. coli lac operon has been engineered into the pUC series of plasmids 
(Vieira and Messing, 1982; Messing and Vieira, 1982; Messing et ah, 1977); 
a polylinker containing a multiple cloning site (MCS) region has been 
engineered into the amino terminus of the lac Z gene encoding 
beta-galactosidase. This MCS permits linearisation of the plasmid with 13 
restriction enzymes (pUC18), thus allowing insertion of a variety of restriction 
fragments of foreign DNA into the plasmid. A map of this plasmid, also 
showing the MCS, in detail is given in Figure 2.1. The beta-galactosidase 
gene in the pUC18 plasmid is defective by itself, as is the gene in certain
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bacterial hosts (for example E. coli Sure™, Stratagene). However these 
inactivating mutations occur at different loci in the beta-galactosidase gene. 
Thus, although the E. coli host alone produces a defective enzyme, the host 
derived and pUClS-derived beta-galactosidase enzymes together complement 
each other (alpha complementation) to produce an active beta-galactosidase 
enzyme. This can be induced by isopropyl-beta-thio-galactopyranoside (IPTG) 
to hydrolyse the galactosidase analogue 5-bromo-4-chloro-3-indolyl-beta- 
galacto-pyranoside (X-gal) to produce the blue pigment, bromo-chloro-indole, 
in cells which have been successfully transformed. Thus, bacterial colonies 
resulting from transformation with wild-type pUC18 are ampicillin resistant 
and are blue in colour due to the hydrolysis of X-gal. However, insertion of 
foreign DNA into the MCS within the beta-galactosidase gene of pUC18 
results in a defective enzyme which is not complemented by bacterial enzyme. 
Therefore no hydrolysis of X-gal occurs and white ’colourless’ colonies are 
produced. Thus, a combination of ampicillin resistance and histochemistry 
(X-gal hydrolysis) permits rapid one-step identification of bacterial colonies 
containing recombinant plasmid DNA.
During the latter stages of this project, the vector, treated with Smal 
and calf intestinal phosphatase became commercially available (Pharmacia). 
However, during the early stages it was prepared in the laboratory.
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2.11.2 Blunt end {SmaJ) restriction digestion of pUC18.
The vector was cleaved with the restriction enzyme SmcH which 
produces a complementary blunt end to which the blunt ended amplified 
cDNA fragment may be ligated.
5 fjLg pUC18 was linearised by digestion with 20 units Smal in a final 
volume of 50 fx\, containing 33 mM Tris-acetate pH 7.9, 66 mM potassium 
acetate, 10 mM magnesium acetate, 0.5 mM DTT (incubation buffer A). 
Incubation was performed at 25°C for 1 hour.
2.11.3 Dephosphorylation of linearised pUC18.
Restriction enzyme digestion results in the exposure of 5’ phosphate 
groups. These groups are removed to prevent self-religation (Seeburg et al., 
1977; Ullrich et a l ,  1977) and to maximise the subsequent formation of 
recombinant molecules.
One unit of calf intestinal phosphatase (CIP (Boehringer)), in 1 ii\, was 
added to the digested plasmid and incubation was performed at 50°C for 30 
mins. A further unit of CIP was added and incubation continued for a further 
30 mins. The reaction was terminated by the addition of 10 /xg autodigested 
proteinase K, in 0.5 jLtl, and a further incubation at 37°C for 30 mins. The
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final volume was made to 100 jul with HPLC water, a PCI extraction and a 
back extraction were performed, and the pUC18 was precipitated by the 
addition of 2.5 volumes of ethanol together with 300 mM sodium acetate pH
5.2. The mixture was then cooled in a dry-ice/ethanol bath for 5 mins. The 
pUC18 was pelleted by centrifugation at 14,000 rpm for 20 mins at 4°C, 
washed with 70% ethanol and dried in a cool oven. The pellet was 
resuspended in 20 /A TE buffer pH 8 and the DNA was quantitated by 
spectrophotometric means and stored in aliquots at -20°C.
It is important to confirm that effective restriction digestion and 
phosphatasing has been effected. This was done by sampling the reaction at 
appropriate stages and by appropriate test ligations. These ligations, where 
effected, were performed on the pUC18 and lambda/Hind III in a final volume 
of 20 fxl containing 1 unit of T4 DNA ligase plus 66 mM Tris-HCl pH 7.5, 
5 mM magnesium chloride 1 mM DTT, 1 mM ATP (manufacturer’s xlO 
buffer). All samples were electrophoresed in a 1 % agarose gel in TAE buffer, 
the resultant DNA bands stained in a solution of ethidium bromide (0.5 /xg/ml 
in TAE buffer) and photographed on a UV transilluminator.
The confirmatory results of one such monitoring are shown in Figure
2.2. The photograph confirmed that pUC18 had been effectively digested 
(Lane 2), and did not re-circularise after phosphatasing (Lane 4). Lane 7 
confirmed that the ligase was performing efficiently.
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Legend to Figure 2.2 (see opposite page)
Samples run in a 1 % agarose gel.
Lane 1:
Lane 2:
Lane 3:
Lane 4:
Lane 5:
Lane 6:
Lane 7:
Uncut pUC18
Smal digested pud  8
Smal digested and phosphatased pUC18
Religated Smal digested and phosphatased pUC18
lambda/MTzdll molecular weight markers
0X174/H<2dn molecular weight markers
Religated lambda/H/wdll moloecular weight markers
The sizes of the molecular weight markers are shown in 
Appendix 2.
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Figure 2.2: Confirmation of the effective restriction
digestion and phosphatasing of pUC18
1 2 3 4 5 6
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2.11.4 Transformation of competent cells
Throughout the major part of this study the cells used for 
transformation were E. coli SURE™ supercompetent cells 
(Stratagene), which carry the F ’ episome which contains the lac PM15 
mutation and effects the alpha complementation of the 
beta-galactosidase gene.
An aliquot of these cells was thawed on ice and then gently mixed by 
hand. Then a 100 pX aliquot was removed into a pre-chilled Falcon 2059 
polypropylene tube for each transformation that was to be performed. A fresh 
1:10 dilution of B-mercaptoethanol was added to a final concentration of 25 
mM. The cells were gently swirled to mix and then placed on ice for 10 mins, 
swirling carefully at 2 min intervals. A volume of the diluted ligation mix 
calculated to
contain 24 ng of total DNA was added to the cells, careful mixing was 
effected and the cells were replaced on ice for 30 mins. The cells were then 
heat shocked at 42 °C for 45 seconds by placing the tube in a water bath. The 
cells were then returned to ice for a further 2 mins. 900 of pre-heated 
(42°C) SOC medium (2% (w/v) bacto-tryptone, 0.5% (w/v) yeast extract, 10 
mM sodium chloride, 10 mM magnesium chloride, 10 mM magnesium 
sulphate, 20 mM glucose) was added and the cells were then shaken at 225 
rpm at 37°C for 1 hour in a controlled environment shaker (G24 
environmental incubator shaker, New Brunswick Scientific Company
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Incorporated) to allow the transformed cells time to synthesise ampicillinase. 
The gene for ampicillin resistance is carried by the pUC18 plasmid and only 
those cells which have been transformed by this plasmid or by a recombinant 
cDNA-pUC18 plasmid will be able to replicate in the presence of ampicillin. 
Aliquots of 50 /xl, 100 /xl, and 200 jA of the transformation mix were then 
spread, in duplicate, onto LB plates (1 % (w/v) bacto-tryptone, 1 % (w/v) yeast 
extract, 86 mM sodium chloride, 1.5% (w/v) bacto-agar, 0.1 mg/ml 
ampicillin, 1 mM magnesium sulphate) containing 100/xg/ml ampicillin, to 
which stock IPTG (2% (w/v) in water) and X-gal (2% (w/v) in dimethyl 
formamide) were added to achieve a final concentration of 0.01 mg and 0.02 
mg of each chemical, respectively, per ml of agar. The plates were allowed 
to dry and were then inverted and incubated overnight at 37°C .
For the last few months of this study the TA Cloning System™ 
(Invitrogen) was employed in place of pUC18 and SURE™ E.coli competent 
cells. This system included all the reagents necessary to perform cloning from 
RT-PCR fragments, and was specifically designed to do so. The system takes 
advantage of the non-template dependent activity of Taq DNA polymerase 
which adds single deoxyadenosines to the 3’ end of the double-stranded PCR 
product. The vector is designed to provide single 3’ deoxythymidine molecules 
at the insertion site, thus specifically accepting the insertion of the PCR 
fragment. As seen in pUC18, the insertion site is found within the lac Z gene. 
The plasmid also contains both ampicillin and kanamycin resistance genes.
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The E coli competent cells were also supplied in this system, and also 
carried the F ’ episome effecting the alpha complementation of the beta- 
galactosidase gene described above.
The procedure was essentially as described previously for pUC18 and 
SURE™ cells; the essential differences were that there was no requirement to 
treat PCR fragments with kinase prior to cloning. The exact procedure is 
described in the Invitrogen manual and product information sheets.
2.12 Screening of recombinant cDNA clones
2.12.1 Strategy
Bacterial colonies identified as containing recombinant plasmids were 
streaked onto LB ampicillin plates containing IPTG and X-gal as described 
above. Streaked colonies were screened using a rapid screening methodology 
which identified recombinant pUC18 plasmid by its migration rate in agarose 
gel electrophoresis relative to wild type pUC18. Those plasmids which ran 
more slowly were selected as putatively recombinant. Larger scale 
preparations were made of the selected plasmids using the alkaline lysis 
method adapted from the methods of Bimboim and Doly (1979) and 
Ish-Horowicz and Burke (1981), and later the "Magic Miniprep" purification 
system marketed by Promega. The presence of the correct cDNA insert in the
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MCS of p u e  18 was confirmed by appropriate restriction digests to release the 
cDNA fragment, and agarose gel electrophoresis to confirm the cDNA 
fragment length.
2.12.2 M[aintenance and short-term storage of colonies.
Well separated white colonies were removed by sterile toothpick and 
streaked out onto master LB ampicillin plates containing IPTG and X-gal as 
described in Section 2.11.6. After incubation at 37°C overnight these were 
stored at 4°C as a temporary stock.
2.12.3 "Cracking" Procedure
In order to pre-screen white colonies to determine if they were running 
more slowly than standard pUC18, the "cracking" procedure was employed. 
This methodology is described in the Promega Protocols and Application 
Guide (1991).
Briefly, colonies were picked with a sterile toothpick and smeared into 
a 0.5 ml micro-centrifuge tube containing 50 lA of lOmM EDTA, pH 8.0. 50 
jLxl of 2x cracking buffer (584mM sucrose, 200mM NaOH, 0.5% SDS) was 
then added and the tubes vortexed. The samples were then incubated at 70°C
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for 15 minutes, and allowed to cool gradually to room temperature. 1.5 /xl of 
bromophenol blue dye and KCl [58 mM]f were then added, the samples 
vortexed again and stored on ice for 5 minutes. The tubes were centrifuged 
for 5 minutes at 4°C, and 50 fû of the supernatant loaded onto a 1% agarose 
gel. Electrophoresis in TAE buffer was performed, the gel stained in ethidium 
bromide and the samples compared against molecular weight markers and 
uncut pUC18.
2.12.4 Small scale extraction of plasmid DNA.
This protocol was adapted from the method of Bimboim and Doly 
(1979) and Ish-Horowicz and Burke (1981). It produces 3-5 /xg of plasmid 
suitable for restriction or sequencing.
Briefly, a colony was removed from the master plate (or cells from 
frozen culture) by toothpick into 1.5 mis of L-broth plus ampicillin (1.5% 
(w/v) bacto-tryptone, 0.5% (w/v) yeast extract, 86 mM sodium chloride, 0.1 
mg/ml ampicillin) and grown overnight with shaking at 225 rpm at 37°C. The 
cells were pelleted by centrifugation in an MCC tube for 2 mins at 14,000 
rpm at room temperature and the supernatant removed. The cells were 
resuspended by vortexing in 100 fû GTE (50 mM glucose, 10 mM disodium 
EDTA, 25 mM Tris-HCl pH 8) and incubated at room temperature for 5 
mins. 200 /xl of freshly made alkaline lysis buffer (1% v/v SDS, 200 mM
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sodium hydroxide) was added, mixing effected by two inversions and 
incubation performed on ice for 5 mins. 150 /xl of ice cold 5 M potassium 
acetate pH 4.8 was then added, the mixture was thoroughly vortexed, replaced 
on ice for 5 mins and then centrifuged at 14,000 rpm for 5 mins. A 400 /xl 
aliquot of the supernatant was carefully removed to a fresh tube and 2.5 
volumes of ethanol (-20°C) were added. The plasmid DNA was precipitated 
at room temperature for 2 mins and then pelleted by centrifugation at 14,000 
rpm for 5 mins at room temperature. The DNA pellet was resuspended in 
100 /xl of resuspension solution (50 mM Tris, pH 8, 100 mM sodium acetate) 
and 2 /xl of bovine pancreatic RNAase A (10 mg/ml in 10 mM Tris-HCl, pH 
7.5, 15 mM sodium chloride, boiled for 15 mins, cooled slowly to room 
temperature and then stored in aliquots at -20°C) was added. Bacterial RNA 
was digested for 45 mins at 37°C after which time the DNA was extracted by 
two PCI extractions. A chloroform extraction was then performed: an equal 
volume of chloroform : isoamyl alcohol (24:1) was added, the preparation was 
vortexed to produce an emulsion, centrifuged at 14,000 rpm for 3 mins at 
room temperature to separate the two phases and the upper aqueous phase 
transferred to a fresh tube. The plasmid DNA was then precipitated and 
pelleted by the addition of 2 volumes of ethanol, incubation at room 
temperature for 2 mins and then centrifugation at 14,000 rpm for 5 mins at 
room temperature. The pellet was washed with 70% ethanol, dried in a cool 
oven, resuspended in 25 /xl HPLC water and stored at -20°C. Later, the 
commercially available "Magic Miniprep” system (Promega) was used for 
small-scale plasmid DNA extraction. Details of this system are available in the
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Promega catalogue and Technical Information sheets.
2.12.5 Restriction digest analysis of plasmids
Since the Smal restriction site is destroyed during the process of 
cloning, removal of the cDNA fragment from pUC18 requires the use of 
restriction enzyme (RE) pairs located to either side of the Smal site in the 
MCS of pUC18, see Figure 2.1. Routinely, the restriction enzymes EcoRl and 
Hindlll (Boehringer) were used, with the supplied xlO reaction buffer (lOmM 
Tris, lOOmM NaCl, 5mM MgCl2 , ImM B-mercaptoethanol, pH 8.0). For 
inserts cloned into the TA vector, a single enzyme, EcoRI was used, as this 
site N^ 'as duplicated on either side of the insert sequence. When EcoEl alone 
was used, the xlO reaction buffer differed (50mM Tris, lOOmM NaCl, lOmM 
MgCh, ImM dithioerythritol, pH 7.5)
Restriction digests were performed on 10 /xl aliquots of the plasmid 
preparation (section 2.12.4) using 10-12 units of each of the appropriate 
enzyme pairs in a final volume of 30 /xl. Incubation was performed at 37°C 
for 1 hour. The products of the digestion were separated, alongside molecular 
weight markers, by electrophoresis in a 1 % agarose gel in TAE buffer for 1 
hour at 100 volts, stained in a solution of ethidium bromide (0.5 /xg/ml in 
TAE buffer) for 30 mins, and then photographed on a UV transilluminator.
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2.12.6 Long-term storage of colonies
Following identification of colonies containing plasmids with the 
expected insert by restriction digest and confirmatory sequence, these colonies 
were then maintained by freezing them in duplicate.
Two MCC tubes containing 300 /xl of L-broth plus ampicillin were 
inoculated with the colony by toothpick, and the tubes incubated at 37°C 
overnight with shaking at 225 rpm. Glycerol was then added to each tube to 
give a final concentration of 15%, the tubes vortexed, labelled and then 
stored; one at -20°C and one at -70°C. Subsequently, only the -20°C aliquot 
was used as an inoculum for amplifying the cells. The -70 °C aliquot was 
stored as a backup.
2.13 Nucleotide sequencing of the recombinant plasmid
Recombinant pUC18, containing cDNA inserts of the correct size, 
were then subjected to confirmatory sequencing. The sequence data produced 
was analyzed by computer comparisons with relevant sequences of yellow 
fever virus (Rice et a l ,  1985; Hahn et al., 1987), and with the sequence of 
pUC18. Confirmed cDNA inserts were then sequenced in their entirety, in 
duplicate, but where anomalies existed, in triplicate or more. These were 
subjected to more thorough computer comparisons and analyses. Finally,
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colonies containing the required recombinant pUC18 were then prepared for 
long term storage (Section 2.12.6).
2.13.1 Dideoxynucleotide sequencing.
DNA sequencing was performed on recombinant plasmid clones using 
the dideoxy chain termination methodology (Sanger et ah, 1977). This 
methodology consists of three different stages:
1. Annealing of the primer to the template DNA.
2. DNA polymerisation occurs using limiting concentrations of 
dNTPs (including one radiolabelled dNTP) to extend the primer 
by a few, or by several hundreds of, nucleotides.
3. The final stage consists of a set of four chain-extension 
termination reactions in which the radiolabelled chains are 
extended until terminated by the incorporation of a 
dideoxynucleoside (ddNTP). During this step, the chains are 
extended on average by 20 - 50 nucleotides.
The reactions are terminated by the addition of EDTA and formamide, 
denatured by heating and run on polyacrylamide electrophoresis gels.
All DNA sequencing reactions were performed using a Sequenase
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Version 2.0 kit (United States Biochemicals). This kit contains the enzyme 
Sequenase Version 2.0 (Tabor and Richardson, 1987) which is a genetic 
variant of the bacteriophage T7 DNA polymerase. This enzyme is a superior 
enzyme for sequencing, having amongst its properties high processivity, high 
speed, the ability to use popular nucleotide analogues and no 3’ to 5’ 
exonuclease activity.
2.13.2 Preparation of the sequencing gel.
DNA sequencing was performed in 40-cm-long, 0.4 mm thick, 5% 
(w/v) acrylamide-bisacrylamide (19:1) gels.
Both front and back plates were thoroughly cleaned with 7X detergent and 
hot tap water, rinsed with distilled water and then with ethanol and placed in 
a fume hood to dry. The larger back plate was coated with a 10 mis silane 
solution (0.3% (v/v) gamma- methacryloxypropyltrimethoxysilane (BDH) and 
0.15% acetic acid in ethanol); the excess was removed with a lint free tissue 
(Kimwipe) and the surface washed with ethanol and polished with a clean 
tissue. The smaller front plate was siliconised by the application of 10 mis of 
dimethyl dichlorosilane (BDH) and similarly the excess was removed, 
followed by an ethanol wash and polishing. The two treated surfaces of the 
plate were clamped together, with a 0.4 mm spacer arranged down each side. 
The plates were then taped together on both sides and the base, using 3M
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yellow electrical tape.
2.13.3 Preparation of the sequencing gel plates.
For each plate, 75 mis of sequencing gel was required which contained 
7 M urea (Sigma) and 5% (v/v) PAGE 1 Sequencing gel mix (acrylamide : 
bis-acrylamide, 38:2 (Northumbria Biologicals Limited)) in TBE buffer (89 
mM Tris-borate, pH 8.3, 2 mM disodium EDTA). The solution was heated 
to 37 °C to dissolve the urea and immediately before casting the gel, 0.1% 
(v/v) N,N,N’,N’-tetramethylethylene- diamine (Temed (Bio-Rad 
Laboratories)) and 0.06% (w/v) ammonium persulphate (freshly made) were 
added. The solution was mixed (avoiding bubbles) and then injected from a 
75 ml plastic syringe into the pre-prepared plate assembly, taking care to 
avoid trapping bubbles. Sharkstooth combs were correctly orientated and the 
gel was allowed to set for at least 1 hour. Prior to electrophoresis of the 
sequencing reactions, the electrical tape along the base of the gel was 
removed, the plate was placed in a Sequencing gel electrophoresis system, 
model S2 (Gibco-BRL) and the gel electrophoresed for 30 mins in TBE 
buffer. The sharkstooth combs were re-orientated correctly during this stage.
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2.13.4 DNA sequencing reactions.
2.13.4.1 Alkaline dénaturation of the recombinant plasmid.
In order for the primer to be able to bind to the priming site in the 
recombinant plasmid, the two DNA strands must first be separated. An 
alkaline dénaturation method based on that of Chen and Seeburg, (1985), and 
Zhang et al., (1988), was employed.
3-5 fig plasmid DNA (section 2.12.4) was denatured by the addition 
of 200 mM sodium hydroxide and 0.2 mM disodium EDTA. The preparation 
was mixed and incubated at room temperature for 30 mins. Neutralisation and 
precipitation were effected by the addition of 300 mM sodium acetate pH 4.8 
and 3 volumes of chilled ethanol and immediate placement in a dry-ice/ethanol 
bath for 5 mins. The DNA was pelleted by centrifugation at 14,000 rpm for 
20 mins at 4°C, washed with 70% ethanol and dried in a cool oven. The 
pellet was resuspended in 7 /cl HPLC water and immediately taken onto the 
next stage of sequencing.
2.13.4.2 Annealing template and primer.
A single annealing reaction was set up. The following were added to
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the 7 jû of denatured plasmid suspension: 1 jA primers (0.5 pmol), and 2 fil 
of X 5 reaction buffer (200 mM Tris-HCl pH 7.5, 100 mM magnesium 
chloride, 250 mM sodium chloride) to give a final volume of 10 /xl. The 
reaction mix was heated to 65 °C for 4 mins, cooled slowly to room 
temperature over a period of 30 mins and placed on ice.
2.13.4.3 Labelling reaction.
The following were added to the annealed template-primer suspension: 
1 /xl 0.1 M DTT, 1 fû dATP 5’-(a-p^S] thio) triphosphate (specific activity 
> 1000 Ci/mmol) (10 ixCi), and 2 pi of a 1:5 dilution of the x5 labelling mix 
in HPLC water (7.5 pM dGTP, 7.5 pM dCTP, 7.5 pM dTTP). Finally 2 pi 
of Sequenase Version 2.0 enzyme diluted 1:8 in ice-cold enzyme dilution 
buffer (10 mM Tris-HCl pH 7.5, 5 mM DTT, 0.5 mg/ml bovine serum 
albumin) were added, the reaction was carefully mixed and incubated at room 
temperature for 3 mins.
2.13.4.4 Termination reactions.
3.5 pi of the resultant labelling reaction mix was aliquoted into each 
of four 0.5 ml MCC tubes which contained 2.5 pi of one of each of the four 
termination mixes:
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ddG Termination mix: 80 pM dGTP, 80 pM dATP, 80 pM 
dCTP, 80 pM dTTP, 8  pM ddGTP, 50 mM sodium chloride.
ddA Termination mix: 80 pM dGTP, 80 pM dATP, 80 pM 
dCTP, 80 pM dTTP, 8  pM ddATP, 50 mM sodium chloride.
ddT Termination mix: 80 pM dGTP, 80 pM dATP, 80 pM 
dCTP, 80 pM dTTP, 8  pM ddTTP, 50 mM sodium chloride.
ddC Termination mix: 80 pM dGTP, 80 pM dATP, 80 pM 
dCTP, 80 pM dTTP, 8  pM ddCTP, 50 mM sodium chloride.
The reactions were incubated at 42°C for 5 mins, and then terminated 
by the addition of 4 pi of stop solution (95% formamide, 20 mM EDTA, 
0.05 % bromophenol blue, 0.05 % xylene cyanol FF) and thorough mixing was 
effected. The samples were then stored for up to one week at -20°C.
2.13.5 Sequencing primers.
Confirmatory sequencing was usually effected using the (-40) Universal 
primer (5’-GTTTTCCCAGTCACGAC-3’) (Sequenase kit). The region in 
pUC18 to which this primer anneals, just outside the MCS, is shown in Figure 
2.3.
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All other sequencing used a number of additional primers. M13 reverse 
primer (5’-AACAGCTATGACCATG-3’), a primer recommended for use with 
the kit, sequences the opposite strand from the Universal primer and the 
region to which it primes, just outside the MCS, is also shown in Figure 2.3. 
In the TA vector, the positions of these primers were more distant from the 
site of the insert, but this still enabled their use as sequencing primers. All 
other primers used during sequencing are listed in Table 2.2. These primers 
enabled sequence data to be obtained from regions placed more centrally in 
the longer (500-1200bp) cDNA fragments. They were also used to prime to 
the opposite strand of regions of cDNA containing strong secondary structure, 
thereby clarifying regions of sequence which were difficult to elucidate. In all 
cases the primers used were made to a concentration of 0.5 pmol/pl.
2.13.6 Alterations of sequencing reaction conditions.
It is possible to alter sequencing reaction conditions to provide 
maximum information about sequences close to the primer, or alternatively 
more distant from the primer. The alterations used were based on information 
given in the manufacturer’s protocol.
Reading sequences close to the primer:-
These changes to the standard protocol were used to obtain sequence 
data close to the primer (0 - 1 2 0  bases).
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Table 2.2: Oligonucleotide primers used for sequencing the 
structural protein genes of yellow fever virus
Name Sequence Position Orientation
YFSEQl S’-CCnTATTGATTGCCGCTG-S’ 1995-2013 Antisense
YFSEQ2 5’-GAATGCTGTTGATGACGGG-3’ 459-477 Sense
YFSEQ3 5'-AAGAACCCAACTGACAC-3' 1895-1911 Sense
YFSEQ4 5'-TCAAGAGGTGTTCAAGG-3' 239-255 Sense
From the Asibi sequence (Hahn etal., 1987 )
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Double the amounts of template and primer were used.
The labelling mix, used during the annealing of the primers, 
was subjected to greater dilution: 1 :1 0 .
The reaction times of the labelling and termination reactions 
were both reduced to 3 mins.
Electrophoresis was continued until the first dye front 
(bromophenol blue) ran 80% of the length of the gel. 
(Bromophenol blue co-migrates with DNA 35 bases long in a 
5% gel).
Reading sequences more distant from the primer:-
These changes were used to obtain sequence data more distant from the 
primer (350-500 bases).
The labelling mix, used during the annealing of the primers, 
was undiluted and 1.5 pi of [a-^^S]dATP was added.
The reaction time of the labelling reaction was extended to 5 
mins.
A higher concentration of buffer (X 1.2 TBE) was used both
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for making the sequencing gel and for the running buffer. This 
provided more buffering capacity for the longer running times 
employed.
Electrophoresis was continued for 2 - 3 hours beyond the 
passing of the second (xylene cyanol FF) dye front. (Xylene 
cyanol co-migrates with DNA 130 bases long in a 5% gel).
2.13.7 Denaturing gel electrophoresis.
Prior to loading, the four samples were heated at 75°C for 2 mins and 
then 2-5 pi was immediately loaded into adjacent wells in a noted order. 
Electrophoresis was effected at 65 watts for 1.5 - 8  hours. After 
electrophoresis, the front plate was removed and the gel on the back plate was 
fixed in a solution of 12% methanol and 10% glacial acetic acid in water. The 
gel was then washed in cold running water for 2 0  mins and dried in a hot 
(80 °C) oven for 1 hour. The gel was then monitored with a geiger counter, 
and exposed to RX X-ray film (Fuji) in a spring loaded metal cassette at room 
temperature. The film was developed after 1 - 3  days, depending on the 
intensity of the monitored counts.
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2.14 Computer analyses
The majority of the computer analyses performed during the course of
this study employed the Beckman Microgenie program (Queen & Korn, 1984)
for analysis, assembly of overlapping regions of sequence data, and direct one-to 
-one sequence comparisons.
However, for multiple alignments and cluster analyses, Clustal was 
used (Higgins and Sharp, 1988), and for some searches the databases and 
University of Wisconsin Genetics Computer Group suite of programs was 
utilized via the SEQNET site at Daresbury, Warrington.
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Chapter 3
Preliminary Studies
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3.1 Introduction
The initial portion of these studies was devoted to developing and 
refining experimental procedures to obtain nucleotide sequence data that was 
reliable, reproducible and consistent.
Although research had previously been carried out on optimizing the 
reverse transcriptase/polymerase chain reaction (RT-PCR) of flaviviruses 
(Whitby, 1992), this work was performed almost exclusively using tick-borne 
flaviviruses. As mosquito-bome flaviviruses were the subject of this study it 
was important to determine whether those procedures used in the extraction, 
purification, RT and PCR of tick-borne flaviviruses could be applied to 
mosquito-bome flaviviruses, or if modification would be necessary.
Initial studies on flavivirus RT-PCR had determined the correct 
concentrations and proportions of RT and PCR buffers, and a successful 
methodology had been developed (Whitby et ah, 1992); however one of the 
problems encountered was that of preparing and extracting a stock of RNA to 
use for the basis of these experiments, and the use and choice of dénaturants 
to combat the secondary structure of flaviviral RNA.
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3.2 Experimental work
All the methodologies employed in this chapter are described in detail 
in Chapter 2. Any modifications to these methods are noted where 
appropriate.
3.3 Primer design and application
Figure 3.1 shows the sequence of the 17D-204 ATCC (Rice et 
ah, 1985) genome covering the 5’-noncoding region and the portion of the 
genome encoding the structural proteins, and also the region coding for the 
NS2a protein. The primers used for amplification of the structural protein and 
NS2a genes in RT-PCR are marked. Table 3.1 details the sequence, 
orientation and annealing temperature of the primers themselves.
Primers YF7 and CAG were already present in the FRL, and had 
previously been employed in primer extension sequencing of YF viral RNA 
(vRNA) (Gibson et ah, 1990). All other primers utilized in this study were 
designed and manufactured specifically for this project.
Primer design was effected with the aid of computer analyses using the 
Microgenie programme. This enabled putative primer sequences to be 
examined for any significant homology to regions other than the ones to which
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Figure 3.1 Sequence of part of the 17D-204 ATCC genome* 
showing positions of the primers used for PCR in this study
1 0  2 0  3 0  4 0  . LEEI
AGUAAAUCCU GUGUGCUAAU UGAGGUGCAU UGGUCUGCAA AUCGAÜUUGC UAGÔÙÀÂÜAA""
_____________3JCL&. 8 0  9 0  1 0 0  1 1 0
ACACAUUUGG AUUAAUUUUA AUCGUUCGUU GAGCGAUUAG CAGAGAACUG ACCAGAA^U
1 3 0  1 4 0  1 5 0  1 6 0  1 7 0  1 8 0
GUCUGGUCGU AAAGCÜCAGG GAAAAACCCU GGGCGUCAAU AUGGUACGAC GAGGAGUUCG
9 0  2 0 0  2 1 0  '  2 2 0  2 3 0  2 4 0
CUCCUUGUCA AACAAAAUAA AACAAAAAAC AAAACAAAUU GGAAACAGAC CUGGACCUUC
2 5 0  2 6 0  2 7 0  2 8 0  2 9 0  3 0 0
AAGAGGUGUU
3 1 0
CACGGCCCAC 
3 7 0
AAGGAAAGUU 
4 3 0
UUCCCAUGAU 
4 9 0
ApUGACCUUG 
5 5 0
GAAAACAUUC 
6 1 0
GUGCCCAGAC 
6 7 0
CAUUGAUUGC 
7 3 0
AGCAGGCAGG 
7 9 0
UUUGAAGACC 
8 5 0
GAUUGAGAGA 
9 1 0
CCUUGUGGGA 
9 7 0
UCCGGCCÜAC
1 0 3 0  
UGGAGGAACU
1 0 9 0  
UGACAAGCCU
1 1 5 0  
GAGGAAAGUG
1210  
CACUGGAGAG
1 2 7 0  
UUCUGAUAGA
1 3 3 0  
CGCCAAAUUC
1 3 9 0  
GUAUGUCAÜC
1 4 5 0  
UAAGACUCUC
1 5 1 0  
AAAAGCUACA
1 5 7 0  
UGAGAUGGAA
1 6 3 0  
AUGGCAGAGÜ
1 6 9 0  
ÜCCGCAUGCC
1 7 5 0
AGCUCUUACC GGCGCAAUGA GGGUUACAAA GGACACAAf
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CAAGGAUUUA UCUUUUUCUU UUUGUUCAAC AUUUUGACUG GAAAAAAGAU
3 2 0 3 3 0 3 4 0 3 5 0 3 6 0
CUAAAGAGGU UGUGGAAAAU GCUGGACCCA AGACAAGGCU UGGCUGUUCU
3 8 0 3 9 0 4 0 0 4 1 0 4 2 0
AAGAGAGUGG UGGCCAGUUU GAUGAGAGGA UUGUCCUCAA GGAAACGCCG
4 4 0 4 5 0 4 6 0 4 7 0 4 8 0
GUUCUGACUG UGCAAUUCCU AAUUUUGGGA AUGCUGUUGA UGACGGGUGG
5 0 0 5 1 0 5 2 0 5 3 0 5 4 0
GUGCGGAAAA ACAGAUGGUU GCUCCUAAAU GUGACAUCUG AGGACCUCGG
5 6 0 5 7 0 5 8 0 5 9 0 6 0 0
UCUGUGGGCA CAGGCAACUG CACAACAAAC AUUUUGGAAG CCAAGUACUG
6 2 0 A in CAG k  6 5 0 6 6 0
UCAAUGGAAU ACAACUGUCC CAAUCUCAGU CCAAGAGAGG AGCCAGAUGA
6 8 0 6 9 0 7 0 0 7 1 0 7 2 0
UGGUGCUAUG GGGUGGAAAA CGUUAGAGUC GCAUAUGGUA AGUGUGACUC
7 4 0 7 6 0 7 7 0 7 8 0
UCUAGGAGGU CAAGAAGGGC CAUUGACUUG CCUACGCAUG AAAACCAUGG
8 0 0 8 1 0 8 2 0 8 3 0 8 4 0
CGGCAAGAAA AAUGGAUGAC UGGAAGAAUG GGUGAAAGGC AACUCCAAAA
8 6 0 8 7 0 8 8 0 8 9 0 9 0 0
UGGCUCGUGA GGAACCCCUU UUUUGCAGUG ACAGCUCUGA CCAUUGCCUA
9 2 0 9 3 0 9 4 0 9 5 0 9 6 0
AGCAACAUGA CGCAACGAGU CGUGAUUGCC CUACUGGUCU UGGCUGUUGG
9 8 0 9 9 0 1 0 0 0 1 0 1 0 1 0 2 0
UC^SCUCACU GCAUUGGAAU UACUGACAGG GAUUUCAUUG AGGGGGUGCA
1 0 4 0 1 0 5 0 1 0 6 0 1 0 7 0 1 0 8 0
UGGGUUUCAG CUACCCUGGA GCAAGACAAG UGUGUCACUG UUAUGGCCCC
1 1 0 0 1 1 1 0 1 1 2 0 1 1 3 0 1 1 4 0
UCAUUGGACA UCUCACUAGA GACAGUAGCC AUUGAUGGAC CUGCUGAGGC
1 1 6 0 1 1 7 0 1 1 8 0 1 1 9 0 1 2 0 0
UGUUACAAUG CAGUUCUCAC UCAUGUGAAG AUUAAUGACA AGUGCCCCAG
1 2 2 0 AJ7__ 19 4 0 . ______ k  1 2 5 0 1 2 6 0
GCCCACCUAG CUGAAGAGAA CGAAGGGGAC AAUGCGUGCA AGCGCACUUA
1 2 8 0 1 2 9 0 1 3 0 0 1 3 1 0 1 3 2 0
GGCUGGGGCA AUGGCUGUGG CCUAUUIIGGG yUGUGGCAUG
1 3 4 0 1 3 5 0 1 3 6 0 1 3 7 0 1 3 8 0
ACUUGUGCCA AAUCCAUGAG UUUGUUUGAG GUUGAUCAGA CCAAAAUUCA
1 4 0 0 1 4 1 0 1 4 2 0 1 4 3 0 1 4 4 0
AGAGCACAAU UGCAUGUAGG GGCCAAGCAG GAAAAUUGGA AUACCGACAU
1 4 6 0 1 4 7 0 1 4 8 0 1 4 9 0 1 5 0 0
AAGUUUGAUG CCCUGUCAGG CUCCCAGGAA GCCGAGUUCA CUGGGUAUGG
1 5 2 0 1 5 3 0 1 5 4 0 1 5 5 0 1 5 6 0
CUGGAAUGCC AGGUGCAAAC UGCGGUGGAC UUUGGUAACA GUUACAUCGC
1 5 8 0 1 5 9 0 1 6 0 0 1 6 1 0 1 6 2 0
AAAGAGAGCU GGAUAGUGGA CAGACAGUGG GCCCAGGACU UGACCCUGCC
1 6 4 0 1 6 5 0 1 6 6 0 1 6 7 0 1 6 8 0
GGAAGUGGCG GGGUGUGGAG AGAGAUGCAU CAUCUUGUCG AAUUUGAACC
1 7 0 0 1 7 1 0 1 7 2 0 1 7 3 0 1 7 4 0
GCCACUAUCA GAGUACUGGC CCUGGGAAAC CAGGAAGGCU CCUUGAAAAC
1 7 6 0 1 7 7 0 1 7 8 0 1 7 9 0 1 8 0 0
AU GACAACAACC UUUACAAACU
1 8 1 0  1 8 2 0  1 8 3 0  1 8 4 0  1 8 5 0  1 8 6 0
ACAUGGUGGA CAUGUUUCCU GCAGAGUGAA AUUGUCAGCU UUGACACUCA AGGGGACAUC
1 8 7 0  1 8 8 0  1 8 9 0  1 9 0 0  1 9 1 0  1 9 2 0
CUACAAAAUG UGCACUGACA AAAUGUCUUU UGUCAAGAAC CCAACUGACA CUGGCCAUGG
1 9 3 0  1 9 4 0  1 9 5 0  1 9 6 0  1 9 7 0  1 9 8 0
CACÜGUUGUG AUGCAGGUGA AAGUGCCAAA AGGAGCCCCC UGCAAGAUUC CAGUGAUAGU
1 9 9 0  2 0 0 0  2 0 1 0  2 0 2 0  2 0 3 0  2 0 4 0
AGCUGAUGAU CUUACAGCGG CAAUCAAUAA AGGCAUUUUG GUUACAGUUA ACCCCAUCGC
2 0 5 0  2 0 6 0  2 0 7 0  2 0 8 0  2 0 9 0  2 1 0 0
CUCAACCAAU GAUGAUGAAG UGCUGAUUGA GGUGAACCCA CCUUUUGGAG ACAGCUACAU
2 1 1 0  2 1 2 0 _?1 30  ...ÏE.EB 21Æ0 k .  2 1 5 0  2 1 6 0
UAUCGUUGGG ACAGGAGAUU CACGUCUCAC UUACCAGUGG CCCAAAGAGG GAAGCUCAAU
2 1 7 0  2 1 8 0  2 1 9 0  2 2 0 0  2 2 1 0  2 2 2 0
AGGAAAGUÜG UUCACUCAGA CCAUGAAAGG CGUGGAACGC CUGGCCGUCA UGGGAGACGC
2 2 3 0  2 2 4 0  2 2 5 0  2 2 6 0  2 2 7 0  2 2 8 0
CGCCUGGGAU UUCAGCUCCG CUGGAGGGUU CUUCACUUCG GUUGGGAAAG GAAUUCAUAC
2 2 9 0  2 3 0 0  2 3 1 0  2 3 2 0  2 3 3 0  2 3 4 0
GGUGUUUGGC UCUGCCUUUC AGGGGCUAUU UGGCGGCUUG AACUGGAUAA CAAAGGUCAU
2 3 5 0  2 3 6 0  2 3 7 0  2 3 8 0  2 3 9 0  2 4 0 0
CAUGGGGGCG GUACUCAUAU GGGUUGGCAU CAACACAAGA AACAUGACAA UGUCCAUGAG
2 4 1 0  2 4 2 0  2 4 3 0  2 4 4 0  2 4 5 0  2 4 6 0
CAUGAUCUUG GUAGGAGUGA UCAUGAUGUU UUUGUCUCUA GGAGUUGGGG CGGAUCAAGG
2 4 7 0  2 4 8 0  2 4 9 0  2 5 0 0  2 5 1 u ^ '^ { j'j^  2 5 2 0
AUGCGCCAUC AACUUUGGCA AGAGAGAGCU CAAGUGCGGA GAUGGUAUCU UCiAUAUUUAG
2 5 3 0  2 5 4 0  2 5 5 0  2 5 6 0  2 5 7 0  2 5 8 0
AGACUCUGAU GACUGGCUGA ACAAGUACUC AUACUAUCCA GAAGAUCCUG UGAAGCUUGC
2 5 9 0  ^  2 6 0 0  YfIÔÔ^
AUCAAUAGUG AAAGCCÜCUU
lA n q  Y F200 lA lP  k  3 6 2 9  3 6 3 9  3 6 4 9  3 6 5 9
UGGUUGGAGG AGUAGUGCUC UUGGGAGCAA UGCUGGUCGG GCAAGUAACU CUCCUUGAUU
3 6 6 9  3 6 7 9 ^ r ^  3 6 8 9  3 6 9 9  3 7 0 9  3 7 1 9
UGCUGAAACU CACAGUGGCU IGUGGGAUUGC AUUUCCAUGA GAUGAACAAU GGAGGAGACG
3 7 2 9  3 7 3 9  3 7 4 9  3 7 5 9  3 7 6 9  3 7 7 9
CCAUGUAUAU GGCGUUGAUU GCUGCCUUUU CAAUCAGACC AGGGCUGCUC AUCGGCUUUG
3 7 8 9  3 7 9 9  3 8 0 9  3 8 1 9  3 8 2 9  3 8 3 9
GGCUCAGGAC CCUAUGGAGC CCUCGGGAAC GCCUUGUGCU GACCCUAGGA GCAGCCAUGG
3 8 4 9  3 8 5 9  3 8 6 9  3 8 7 9  3 8 8 5 __________3 8 9 9
UGGAGAUUGC CUUGGGUGGC GUGAUGGGCG GCCUGUGGAA GUAUCUAAAU GCAGÜÜUCUC
__YF220ic#nq 3 9 1 9  3 9 2 9  3 9 3 9  3 9 4 9  3 9 5 9
UCUGCAÜCCU GACAAUAAAU GCUGUUGCUU CUAGGAAAGC AUCAAAUACC AUCUUGCCCC ^ ^ o o o V F 2 0 23 9 6 9  3 9 7 9  ^  3 9 8 9  ' 3 9 9 9  4 0 0 9  4 0 1 9
UCAUGGCUCU GUUGACACCU GUCACÜAUGG CUGAGGUGAG ACUUGCCGCA AUGUUCUUUU
4 0 2 9  4 0 3 9  4 0 4 9  4 0 5 9  4 0 6 9  4 0 7 9
GUGCCGUGGU UAUCAÜAGGG GUCCUUCACC AGAAUUUCAA GGACACCUCC AUGCAGAAGA
4 0 8 9  4 0 9 9  4 1 0 9  4 1 1 9  4 1 2 9  4 1 3 9
CUAUACCUCU GGUGGCCCUC ACACUCACAU CUUACCUGGG CUUGACACAA CCUUUUUUGG
4 1 4 9  4 1 5 9  4 1 6 9  4 1 7 ^ ^  4 1 8 9  4 1 9 9
GCCUGUGUGC AUUUCUGGCA ACCCGCAUAU UUGGGCGAAG GAGUAUCCCA GUGAAUGAGÔ,
4 2 0 9  4 2 1 9  4 2 2 9  4 2 3 9  4 2 4 9  4 2 5 9
CACUCGCAGC AGCUGGUCUA GÜGGGAGUGC UGGCAGGACU GGCUUUUCAG GAGAUGGAGA
YF 201
Taken from Rice et a l ,  1985.
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they were intended to anneal. In addition, regions of dyad symmetry could be 
detected. Putative primer sequences were also examined for any 
complementarity to any other primers which would be used in a PCR reaction 
with it, to avoid "primer dimer" annealing. Further factors involved in the 
selection of primer sequences were; a length of 18-25 nucleotides, a random 
base distribution and a G-C content of between 50 and 60% (YF vRNA has 
a G-C content of 49.7%).
Table 3.2 shows the primer combinations which were employed in RT- 
PCR throughout this study, along with the product size they were expected to 
amplify.
3.4 Viral RNA from different sources
Various methodologies have been described for the preparation of 
vRNA for use in the RT-PCR reaction in Chapter 2. Initially, virus was 
prepared in one of two ways; either by centrifugation of tissue culture fluid 
obtained from several flasks of infected cells (see Section 2.3.1) or by 
gradient centrifugation employing potassium tartrate-glycerol gradients (see 
section 2.3.2).
Initial studies were performed on YF virus strain Asibi vRNA 
extracted from virus concentrated from bulk infected tissue culture fluid. The
121
Table 3.2: Primer combinations nsed during this study; 
their positions and expected product sizes
Primer Set 
Sense-Antisense Positions
Expected Product Size 
(nucleotides^)
LEE1-YF7
CAG-YF7
AJ7-YF597
AJ7-YF100
YEEB-YFIOO
YF200-YF201
YF200-YF202
YE220-YF201
43-71/1293-1312
625-642-1293-1312
1223-1245/2220-2248
1223-1245/2531-2554
2120-2143/2531-2554
3604-3624/4119-4219
3604-3624/3920-3939
3889-3908/4199-4219
1269
687
1025
1331
434
615
335
330
Positions taken from 17D204 ATCC (Rice etal. , 1985)
Includes the length of the primers
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wild-type Asibi strain was chosen as the nucleotide sequence for this virus was 
known (Hahn et ah, 1987), and the primers used showed 100% homology 
with it.
The primer chosen for RT was YF7 (antisense: positions 1293-1312), 
and for PCR amplification primers CAG (sense: positions 625-642 on the 
17D-204 ATCC vaccine strain of YF virus (Rice et ah, 1985)) and YF7 
(antisense: positions 1293-1312) were employed. These primers were designed 
to regions of relative homogeneity as far as was known from published 
flavivirus sequences at that time, and would be expected to amplify a region 
of 6 8 8  bp (see Table 3.2).
Figure 3.2 shows the RT-PCR product obtained using this primer set 
on the wild-type Asibi strain vRNA (obtained by centrifugation of tissue 
culture fluid) run on an 1.5% agarose gel.
This product was cloned into SmcA cut pUC18 and two clones 
sequenced using the methodologies described in Chapter 2. The sequence of 
the two clones proved to be the same, and also to be identical to the published 
sequence of Asibi virus (Hahn et ah, 1987).
Thus the method of purification of vRNA from bulk infected 
tissue culture fluid had been shown to be successful, and the sequence 
obtained demonstrated complete agreement with the previously published
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Figure 3.2: Amplification of a 6 8 8  bp product of YF 
strain Asibi by RT-PCR
6 8 8  bp
Lane 1 :
Lane 2 :
Lane 3:
4>X.llAIHaeil\ molecular weight markers 
688 bp amplification product 
Negative control (no vRNA)
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sequence, showing that the error frequency for the PCR in this case was ^
1.5 X 10'  ^bases.
Other viral RNAs were prepared from bulk cell culture fluid: 17DD- 
Senegal, ITDD-Colombia, F W  and FNV-IP, and FNV-IP and 17DD-Senegal 
were prepared from gradient purified virus. The RNA extracted from these 
viruses was subjected to spectrophotometric analysis, and in all cases was 
shown to contain RNA. However, of these preparations, only that obtained by 
centrifugation of bulk tissue culture fluid infected with 17DD-Senegal was 
successfully amplified by the PCR reaction.
This region (CAG-YF7) of 17DD-Senegal vRNA was cloned and 
sequenced. Again, the two clones sequenced were found to be identical, and 
the results obtained differed from the sequence published for the 17D-204 
ATCC vaccine strain (Rice et al. , 1985) at only three positions. The changes 
found and their significance will be discussed in Chapter 4.
To improve the yield of the RT-PCR reaction, the use of dénaturants 
was employed, as described below in Section 3.5.
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3.4.1 Use of an in vivo system for propagation of virus
prior to vRNA extraction
As described in Chapter 2, and above, the method used initially for 
preparation of vRNA was from virions by either centrifugation of large 
quantities (200mls) of tissue culture fluid, or gradient purification of PEG 
precipitated virus. Both these methodologies were time consuming and 
expensive, as they required between 10 and 20 175cm  ^flasks of cells for each 
virus, and also several lengthy centrifugation steps.
In addition, some strains of YF virus did not grow to high titre in 
tissue culture, such as 17D-204, and though the BPL pre-treatment of virus 
(described in Section 3.5.2) allowed an increased success in the RT-PCR 
reaction, some vRNA preparations were not successfully amplified using the 
primers CAG and YF7. It was possible that the amount of RNA present in 
preparations obtained firom some strains (eg: 17D-204 UK, which grows to 
relatively low titre in tissue culture ( 1  x 1 0  ^pfu/ml)) was insufficient to allow 
amplification. Due to the RT-PCR system having an intrinsic specificity, the 
source of vRNA, and the presence of extraneous heterogenous nucleic acid 
should not affect final production of the desired product.
Hence an alternative system was employed to produce stocks of virus 
and vRNA; this was the inoculation of adult TO mice intracerebrally with
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strains of YF virus. For the methods employed see Section 2.3.3
Figure 3.3 shows a PCR band obtained using primers YFIOO and AJ7 
from a preparation of ITDD-Senegal vRNA derived from a mouse brain 
infected with the virus as described in Chapter 2. The band was excised 
cloned and sequenced (see Chapter 4). This therefore demonstrated the ability 
of the PCR to selectively amplify flavivirus RNA from heterogeneous RNA 
in a specimen. Flaviviral RNA extracted from mouse brain was also pre­
treated with BPL, as described above.
In the latter stages of this study, a procedure was utilized which relied 
on the addition of tRNA to small volumes of infected tissue culture fluid to 
act as a carrier for small quantities of vRNA during RNA extraction (Lewis 
et al. , 1992). This method was much less time-consuming and expensive, and 
was also found to be reliable except for those viruses with very low titres. It 
was noted that no RT-PCR was successful with less than 5 x 10* pfu 
equivalents of vRNA.
3.5 Dénaturation of the vRNA
During the course of these studies a number of dénaturants were 
employed at various stages in the methodology in an attempt to improve the 
yield of product from the PCR reaction, which was adversely affected by the 
recognised high degree of secondary structure observed in flaviviral RNA
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Figure 3.3: Amplification of ITDD-Senegal vRNA derived
from infected mouse brain
1331 bp
Lane 1: Amplified product of 17DD-Senegal vRNA from mouse
brain
Lane 2: Unsuccessful amplification of 17DD-Senegal using
primers later discarded 
Lane 3: Negative control (no vRNA)
Lane 4: </)X174//7ûeIII molecular weight markers
128
(Brinton, 1986; Chambers & Rice, 1987).
3.5.1 Dénaturation with formaldehyde
It was therefore decided to treat the YF virions with a dénaturant prior 
to vRNA extraction. Initial studies utilized formaldehyde for this purpose. The 
only variation to the RNA extraction protocol described in Section 2.4 was 
that the virions suspended in 500 fil of TNE were treated with 0.5 pil formalin 
containing 38% formaldehyde overnight at 4°C prior to RNA extraction. This 
was performed on tissue culture preparations of four YF virus strains; F W , 
FNV-IP, FNV-NT and P-16065. Following RT-PCR with primers CAG and 
YF7, however, no products were obtained for any of these vRNAs.
3.5.2 Dénaturation with B-propriolactone (BPL)
Previous studies (Hartman et ah , 1954) had utilized BPL to inactivate 
viruses, and this compound has been used to inactivate viruses for use in 
killed vaccine preparations. BPL inactivates the virus by alkylation of nucleic 
acids and proteins (Dimmock and Rose, 1987), and has been shown not to 
affect the biological properties of the sample to which it is added (Freeman 
et al., 1982). Therefore, BPL was examined as a potential dénaturant.
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The only experimental modification to the RNA extraction procedure 
described in Section 2.4 was that 0.25% (v/v) BPL (Sigma) was added to the virus 
suspended in 500 /xl of TNE, which was then buffered by the addition of one 
tenth volume of 500mM Tris-HCl pH 7.5. The suspension was then stored at 
room temperature overnight prior to RNA extraction.
Four YF viruses were subjected to this treatment; they were FNV-IP,
F W , FNV-NT and Y5. RT-PCR was then performed using the primers CAG 
and YF7. A product of the expected size was obtained for three of the vRNA 
preparations; namely FNV-IP, F W  and Y5, whilst without BPL none of 
these vRNA preparations gave rise to a visible product in RT-PCR.
It therefore appeared that the use of BPL as a dénaturant prior to the 
extraction of flavivirus RNA was useful in aiding the RT-PCR reaction, 
presumably by its’ dénaturant effect on the vRNA. Three of four preparations 
treated with BPL yielded PCR products when the same preparations, 
untreated, did not yield any visible product. The PCR products obtained were 
utilized to provide sequence data which is discussed later in the relevant 
chapters. No changes between two separate clones from the same product for 
each virus were observed in any of the sequences obtained, and thus the 
reproducibility of the results was demonstrated.
As a further comparison, a remaining aliquot of the 17DD-Senegal 
virus suspension which had been used without treatment with dénaturants to
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amplify the 688 bp fragment described above was subjected to BPL pre­
treatment as described above. A PCR reaction was then performed using both 
the treated and untreated vRNA, and the results are shown in Figure 3.4.
It can be seen that the band obtained from the BPL pre-treated vRNA 
is stronger in intensity than that obtained from the non-BPL treated vRNA, 
although the two samples originated from the same virus preparation, which 
was derived from infected mouse brain, and 500 ng of each vRNA was used 
in the RT-PCR. Sequence analysis of clones derived from the fragments 
obtained with BPL-treated 17DD-Senegal vRNA showed that there were no 
sequence differences over the 688 bp region between these clones and those 
derived from non-BPL treated vRNA. Thus BPL treatment does not result in 
errors in the sequence data produced over a 688 nucleotide region.
3.5.3 Dénaturation prior to first-strand synthesis with
methyl mercury hydroxide (MMH)
Previous studies performed on tick-borne flaviviruses (Whitby, 1992) 
suggested that MMH was more efficient at effecting dénaturation of flaviviral 
vRNA than heat alone, and this methodology, as described in section 2.7.1, 
was routinely employed in all the experiments described above. Comparisons 
showed that, using a dénaturation temperature of 94°C, MMH allowed more 
efficient amplification of PCR products, and in some cases was required for
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Figure 3.4: Amplification of ITDD-Senegal vRNA with
pre-treatment with BPL and without
6 8 8  bp
Lane 1: </)X174/HaeIII molecular weight markers
Lane 2: Amplification of 17DD-Senegal vRNA without pre­
treatment with BPL 
Lane 3: Amplification of 17DD-Senegal vRNA with pre­
treatment with BPL 
Lane 4: Negative control (no vRNA)
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the yield of any product.
However, in the latter parts of these studies a methodology was 
published which employed boiling dénaturation, rather than 94°C (Lewis et 
al, , 1992), and it was found that MMH was not required for the amplification 
of YF vRNA when temperatures of 100°C were employed.
3.6 Discussion
The aim of these initial studies was to determine that flaviviral RNA 
could be extracted, reverse transcribed and amplified by the PCR reaction 
with a high degree of reliability and reproducibility. Although 100% reliability 
was never achieved with the RT-PCR procedure (probably due to the vagaries 
of an RNA system with considerable secondary structure), the experiments 
described in this chapter helped define a system that allowed RT-PCR to be 
attempted with a high degree of success.
Due to the low yields of products sometimes obtained, pre-treatment 
of vRNAs with dénaturants was examined. Pre-treatment with BPL was found 
to allow the amplification of vRNAs which were otherwise not amplified; in 
addition it was shown to enhance the amplification of vRNA which could be 
amplified without it. However, the use of formaldehyde as a dénaturant was 
not successful in aiding RT-PCR of YF vRNA.
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In addition, the fidelity of the PCR reaction was examined by cloning 
and sequencing a region of the wild-type Asibi virus, for which sequence data 
had been published (Hahn et ah, 1987). No clonal differences were found, 
and the sequence was found to match exactly with that published.
A region of the 17DD vaccine from Senegal was also examined, and 
no clonal differences were found whether the vRNA was BPL pre-treated or 
not. This established a basis of reproducibility for the system. Formaldehyde 
was also examined as a possible dénaturant, but was found to be unsuccessful 
in this role.
RT-PCR was also shown to be possible from a crude preparation of 
flaviviral RNA obtained from mouse brain previously infected with the virus, 
allowing the amplification of some YF strains that did not grow to high titre 
in tissue culture. 17DD-Senegal vRNA grown in mouse brain was used as the 
basis for an RT-PCR reaction, and when the product was cloned and 
sequenced no variations were found from the sequence derived from vRNA 
prepared in tissue culture, thus establishing that different sources and 
treatment of vRNA did not affect the fidelity of the system.
Also a number of primers were designed to allow amplification of the 
regions of the genome of interest; specifically the structural protein genes. 
These primers, and vRNA prepared according to procedures described in this 
chapter, have been employed in RT-PCR, and resulting products cloned and
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sequenced. These studies will form the results described in subsequent 
chapters.
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Chapter 4
Comparison of the nucleotide and deduced amino acid 
sequence of the structural protein genes of the yellow
fever 17DD vaccine strain from Senegal with that of 
other yellow fever vaccine viruses
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4.1 Introduction
When this study commenced the only nucleotide sequence data 
available for YF vaccine viruses was the entire genomes of the 17D-204 
vaccine substrains from the ATCC (Rice et al. , 1985) and France (Dupuy et 
ah, 1989). No nucleotide sequence data was available for the 17DD 
substrain.
The 17DD vaccine is currently produced in one country; Brazil, and 
is used at passage level 286-288 from it’s parent, Asibi virus. The 17DD 
vaccine is widely used in South America and makes up 15 million of the 20 
million doses of YF vaccine manufactured each year. Previously, the 17DD 
substrain has been used as the vaccine virus manufactured in Senegal and 
Colombia.
The passage history of the 17D-204 and 17DD vaccine viruses 
diverged at 195 passages from Asibi, and hence 17DD viruses have since 
received over 90 further independent passages, and nearly forty more than the 
17D-204 vaccines, which are used at passage 233-240 from Asibi (see Figure 
4.1).
Despite the lack of analysis of 17DD vaccines at the molecular level, 
several workers have examined the reactivity of the E proteins of 17D vaccine 
substrains using monoclonal antibodies (MAbs) (Gould et ah, 1985; Ledger
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Figure 4.1: Derivation of the yellow fever 17D vaccine viruses 
and their WHO approved manufacturers
Asibi
Original 17D (pl76)
17DD
17D-204(p204)
Low(pl95)
France
Colombia S. Africa U.K. India
Senegal
U.S.A
Australia
Holland
WHO ALV free 17DD
High(p243)
Australia Russia Germany 
(p238-239)
Colombia
Brazil
Senegal.
(p286-288)
Adapted from Barrett, 1987
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et û/., 1992; Sil et al., 1992). In the main, these studies have emphasised the 
similarity between 17DD and 17D-204 vaccine substrains; for example Sil et 
al. (1992) reported a MAb, H6 , which recognised all 17D vaccine strains (ie: 
17D-204 and 17DD viruses) in HF, but did not react with any wild-type YF 
viruses.
However the two 17D substrains can be distinguished from one 
another. In particular, a monoclonal antibody was identified which reacted in 
HF tests with 17DD vaccine strains, but not with 17D-204 vaccine strains, or 
any other wild-type or vaccine strains of YF virus (Sil et al., 1992). This 
MAb, HIO, also demonstrated HAI activity against only 17DD vaccine 
viruses, and was found to neutralize the 17DD substrain produced in Brazil 
(ITDD-Brazil) by 1.0 logio reduction in virus infectivity titre. It did not 
neutralize either of the other two 17DD viruses (from Senegal or Colombia) 
however (Sil et al., 1992). Other workers (Gould et al., 1985; Schlesinger et 
al. , 1983) have also reported E protein reactive MAbs that recognise epitopes 
only present on 17D-204 substrain viruses (MAbs 864 and 8 A3), but not on 
17DD substrains. Thus, antigenically the E proteins of the two vaccine 
substrains can be distinguished.
In addition, 17DD has been noted to differ from 17D-204 genetically. 
Oligonucleotide Tj mapping revealed that 17DD substrains differed from 17D- 
204 in the absence of at least one oligonucleotide, and two in the case of the 
17DD vaccine from Brazil (Monath et al., 1983). Another difference is the
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N-glycosylation of the E protein. In the main, YF E proteins are not 
glycosylated, and this is true for Asibi and 17D-204 vaccine viruses (with one 
exception). However, the E proteins of the 17DD vaccine viruses have been 
shown to migrate more slowly in SDS-PAGE analysis (Barrett, 1987), and this 
has recently been shown to be due to N-glycosylation (Post et ah, 1992).
From the observations above, it is clear that, although 17D-204 and 
17DD vaccine strains appear to be very similar, they do differ, especially with 
regard to the E protein. The differences are physical (glycosylation), genetic 
(Ti mapping) and biological (MAb data).
In order to complement and interpret the physicochemical and 
biological studies described above, it was important to examine 17DD viruses 
at a molecular level. Thus, the 17DD vaccine from Senegal was chosen as a 
representative of the substrain, and was analyzed at the molecular level.
4.2 Experimental work
All procedures used in this chapter are described in Chapters 2 and 3.
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4.2.1 Virus
The ITDD-Senegal strain used was obtained from the Institut 
Pasteur in Dakar, Senegal, and was passaged in SW13 cells to provide 
working stocks. The batch number of the vaccine lot was 81.8.
4.2.2 RNA extraction and treatment
The ITDD-Senegal vRNA was treated in a variety of ways. The region 
amplified by primers CAG and YF7 was obtained from vRNA extracted from 
tissue culture fluid, and no clonal differences were observed whether or not 
BPL was used to pre-treat the vRNA prior to RT-PCR. The remaining 
portions of the genome coding for the structural protein genes were amplified 
from vRNA extracted from mouse brain; again treatment with BPL prior to 
extraction was performed.
4.2.3 Primers
The structural proteins of 17DD-Senegal were amplified using three 
primer sets. Primers CAG and YF7 were used to amplify the region between 
642 and 1293 (numbers refer to nucleotide positions in 17D-204 ATCC (Rice 
et ah, 1985)), which was sequenced to confirm the validity of the clones as
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described in Chapter 3,
In addition, primers LEEl and YF7 were used in RT-PCR to amplify 
positions 71 to 1293; and primers AJ7-YF100 to amplify 1245 to 2554.
RT-PCR, cloning and sequencing were all performed as described in 
Chapter 2.
4.3 Results
The primers employed amplified regions of the genome of 17DD- 
Senegal coding for all the structural proteins of the virus (C, prM, M and E). 
At least two clones were sequenced for each region; in some cases more (as 
650 bases of the LEE-YF7 and CAG-YF7 fragments overlapped).
The sequence was assembled and analyzed as described in Section 
2.14, utilizing the Microgenie system, and is presented in Figure 4.2.
4.4 Nucleotide and amino acid comparisons of the structural proteins 
of ITDD-Senegal with those of other YF viruses.
Table 4.1 shows the nucleotide and amino acid differences between
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Figure 4.2: Nucleotide and deduced amino acid 
sequence of the structural protein genes of the 17DD 
vaccine virus manufactured in Senegal
72 75 
TTAA
ISOC^ATGTTTTAATCGTTGAGCGATTAGCAGAGAACTGACCAGAA m TCTGGTCGTAAAGCTCAGGGAAAAACCCTGGGC
M S G R K A Q G K T L G
22 5
GTCAATATGGTACGACGAGGAGTTCGCTCCTTGTCAAACAAAATAAAACAAAAAACAAAACAAATTGGAAACAGA
V N M V R R G V R S L S N K I K Q K T K Q I G N R
3 0 0
CCTGGACCTTCAAGAGGTGTTCAAGGATTTATCTTTTTCTTTTTGTTCAACATTTTGACTGGAAAAAAGATCACA
P G P S R G V Q G F I F F F L F N I L T G K K I T
375
GCCCACCTAAAGAGGTTGTGGAAAATGCTGGACCCAAGACAAGGCTTGGCTGTTCTAAGGAAAGTTAAGAGAGTG
A H L K R L W K M L D P R Q G L A V L R K V K R V
4 5 0
GTGGCCAGTTTAATGAGAGGATTGTCCTCAAGGAAACGCCGTTCCCATGATGTTCTGACTGTGCAATTCCTAATT
V A S L M R G L S S R K R R S H D V L T V Q F L I
525
TTGGGAATGCTGTTGATGACGGGTGGAfeTGACCTTGGTGCGGAAAAACAGATGGTTGCTCCTAAATGTGACATCT
L G M L L M T G G V T L V R K N R W L L L N V T S
A  ^
60 0
GAGGACCTCGGGAAAACATTCTCTGTGGGCACAGGCAACTGCACAACAAACATTTTGGAAGCCAAGTACTGGTGC
E D L G K T F S V G T G N C T T N I L E A K Y W CA.
675
CCAGACTCAATGGAATACAACTGTCCCAATCTCAGTCCGAGAGAGGAGCCAGATGACATTGATTGCTGGTGCTAT
P D S M E Y N C P N L S P R E E P D D I D C W C Y
7 5 0
GGGGTGGAAAACGTTAGAGTCGCATATGGTAAGTGTGACTCAGCAGGCAGGTCTAGGAGGTCAAGAAGGtCCATT
G V E N V R V A Y G K C D S A G R S R R S R R A I
82 5
GACTTGCCTACGCATGAAAACCATGGTTTGAAGACCCGGCAAGAAAAATGGATGACTGGAAGAATGGGTGAAAGG
D L P T H E N H G L K T R Q E K W M T G R M G E R
9 0 0
CAACTCCAAAAGATTGAGAGATGGTTCGTGAGGAACCCCTTTTTTGCAGTGACAGCTCTGACCATTGCCTACCTT 
Q L Q K I E R W F V R N P F F A V T A L T  l A Y L
^  9 7 5
GTGGGAAGCAACATGACGCAACGAGTCGTGATTGCCCTACTGGTCTTGGCTGTTGGTCCGGCCTACTCAGCTCAC
V G S N M T Q R V V I A L L V L A V G P A Y S A H
1 0 5 0
TGCATTGGAATTACTGACAGGGACTTCATTGAGGGGGTGCATGGAGGAACTTGGGTTTCAGCTACCCTGGAGCAA 
C I G I T D R D F  I E G V H G G T W V S A T L E Q
1 1 2 5
GACAAGTGTGTCACTGTTATGGCCCCTGACAAGCCTTCATTGGACATCTCACTAGAGACAGTAGCCATTGATAGA 
D K C V T V M A P D K P S L D I S  L E T V A I D R
1200
CCTGCTGAGGCGAGGAAAGTGTGTTACAATGCAGTTCTCACTCATGTGAAGATTAATGACAAGTGCCCCAGCACT
P A E A R K V C Y N A V L T H V K I N D K C P S T
1 2 7 5
GGAGAGGCCCACCTAGCTGAAGAGAACGAAGGGGACAATGCGTGCAAGCGCACTTATTCTGATAGAGGCTGGGGC
G E A H L A E E N E G D N A C K R T Y S D R G W G
1 3 5 0
AATGGCTGTGGCCTATTTGGGAAAGGGAGCATTGTGGCATGCGCCAAATTCACTTGTGCCAAATCCATGAGTTTG 
N G C G L F G K G S  I V A C A K F T C A K S M S L
1 4 2 5
TTTGAGGTTGATCAGACCAAAATTCAGTATGTCATCAGAGCACAATTGCATGTAGGGGCCAAGCAGGAAAATTGG
F E V D Q T K I Q Y V I R A Q L H V G A K Q E N W
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1 5 0 0
AATACCAGCATTAAGACTCTCAAGTTTGATGCCCTGTCAGGCTCCCAGGAAGTCGAGTTCATTGGGTATGGAAAA
N T S I K T L K F D A L S G S Q E V E F I G Y G K
1 5 7 5
GCTACACTGGAATGCCAGGTGCAAACTGCGGTGGACTTTGGTAACAGTTACATAGCTGAGATGGAAACAGAGAGC 
A T L E C Q V  Q T A V D F G N S Y  l A E M E  T E  S
1 6 5 0
TGGATAGTGGACAGACAGTGGGCCCAGGACTTGACCCTGCCATGGCAGAGTGGAAGTGGCGGGGTGTGGAGAGAG
W I V D R Q W A Q D L T L P W Q S G S G G V W R E
1 7 2 5
ATGCATCATCTTGTCGAATTTGAACCTCCGCATGCCGCCACTATCAGAGTACTGGCCCTGGGAAACCAGGAAGGC
M H H L V E F E P P H A A T I R V L A L G N Q E G
1 8 0 0
TCCTTGAAAACAGCTCTTACTGGCGCAATGAGGGTTACAAAGGACACAAATGACAACAACCTTTACAAACTACAT
S L K T A L T G A M R V T K D T N D N N L Y K L H
1 8 7 5
GGTGGACATGTTTCTTGCAGAGTGAAATTGTCAGCTTTGACACTCAAGGGGACATCCTACAAAATATGCACTGAC
G G H V S C R V K L S A L T L K G T S Y K I C T D
1 9 5 0
AAAATGTTTTTTGTCAAGAACCCAACTGACACTGGCCATGGCACTGTTGTGATGCAGGTGAAAGTGCCAAAAGGA 
K M  F F V K N P T D  T G H G T V V M Q V K V P K G
2 0 2 5
GCCCCCTGCAGGATTCCAGTGATAGTAGCTGATGATCTTACAGCGGCAATCAATAAAGGCATTTTGGTTACAGTT 
A P C R I P V I V A D D L T A A I N K G I L V  T V
2 1 0 0
AACCCCATCGCCTCAACCAATGATGATGAAGTGCTGATTGAGGTGAACCCACCTTTTGGAGACAGCTACATTATC
N P I A S T N D D E V L I E V N P P F G D S Y I I
2 1 7 5
GTTGGGAGAGGAGATTCACGTCTCACTTACCAGTGGCACAAAGAGGGAAGCTCAATAGGAAAGTTGTTCACTCAG 
V G R G D S R L T Y Q W H K E G S S I G K L F T  Q
2 2 5 0
ACCATGAAAGGCGTGGAACGCCTGGCCGTCATGGGAGACGTCGCCTGGGATTTCAGCTCCGCTGGAGGGTTCTTC
T M K G V E R L A V M G D V A W D F S S A G G F F
2 3 2 5
ACTTCGGTTGGGAAAGGAATTCATACGGTGTTTGGCTCTGCCTTTCAGGGGCTATTTGGCGGCTTGAACTGGATA 
T S V  G K G I H T V F G S A F Q G L F G G L N W  I
2 4 0 0
ACAAAGGTCATCATGGGGGCGGTACTCATATGGGTTGGCATCAACACAAGAAACATGACAATGTCCATGAGCATG 
T K V  I M G A V L I W V G I N T R N M T M S M S M
2452r^^^^
ATCTTGGTAGGAGTGATCATGATGTTTTTGTCTCTAGGAGTTGGGGCGV
I L V G V I M M F L S L G V G A
Nucleotide numbering taken from the published 17D-204 (ATCC) sequence (Rice et a l, 
1985).
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Table 4.1 Notes
Codes for Amino Acids:
Nonpolar R groups:
A Alanine Hydrophobic
F Phenylalanine Hydrophobic
I Isoleucine Hydrophobic
L Leucine Hydrophobic
M Methionine Hydrophobic
P Proline Intermediate
V Valine Hydrophobic
w Tryptophan Intermediate
Polar but uncharged R groups:
C Cysteine Hydrophobic
G Glycine Intermediate
N Asparagine Hydrophilic
Q Glutamine Hydrophilic
s Serine Intermediate
T Threonine Intermediate
Y Tyrosine Intermediate
Positively charged R groups:
H Histidine
K Lysine
R Arginine
Hydrophilic
Hydrophilic
Hydrophilic
Negatively charged R groups:
D Aspatic acid Hydrophilic 
E Glutamic acid Hydrophilic
Hydrophibicity/hydrophilicity descriptions taken from Mandl et al. , 1989).
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Table 4.1: Nucleotide and amino acid differences in the structural 
proteins of 17D-204 ATCC* and 17DD-Senegal
Nucleotide Amino Acid
No. 17D*204
17DD
SEN No.
17D*
204
17DD
SEN
370 C U nc
391 G A C nc
643 A G prM nc
883 G A M nc
1004 U C E nc
1140 U C E56 V A
1436 G A E155 D S
1437 A G " " "
1558 C A nc
1946 u C E325 S P
2219 A G E416 T V
2220 C U "
2356 u c nc
* Taken from Rice etal. 1985 
no = no amino acid change
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17DD Senegal and the 17D-204 virus from the American Type Culture 
Collection (17D-204 ATCC (Rice et ah, 1985)). It can be seen that the 
structural protein genes of 17DD Senegal exhibit a very high degree of 
homology with 17D-204 ATCC at both the nucleotide (99.5%) and amino 
acid (99.5%) level, with only 13 nucleotides differing over the 2483 
sequenced. These coded for four amino acid changes between the two vaccine 
substrains, all of which were found in the E protein. No nucleotide differences 
were seen in the portion of the 5’-noncoding region sequenced (nucleotides 72- 
118)
4.5 Discussion
Over the 2334 nucleotides encoding the structural protein genes of 
ITDD-Senegal and 17D-204 ATCC (Rice et ah, 1985), there are only 13 
nucleotide differences between ITDD-Senegal and 17D-204 ATCC strains, 
giving rise to a variance of just 0.5%. Thus the two viruses are nearly 
identical, even though the ITDD and 17D-204 substrains of ITD have a 
divergent passage history from passage 195, after which 17D-204 was 
passaged a further 35-40 times and 17DD a further 93 times (Barrett, 1987). 
It is also interesting to note that within the structural proteins the majority of 
differences are found in the E protein gene, even allowing for the fact that this 
gene encodes the largest of the structural proteins.
147
It is also pertinent that the four coding changes are all found in the E 
protein, resulting in amino acid differences between the two vaccine strains 
at positions 56, 155, 325 and 416 (Table 4.1). These changes equate to a 
0.8% amino acid divergence between the E protein sequences of the two 
viruses, and reinforce the fact that, as the major antigenic and immunogenic 
determinant of the virus, the E protein appears subject to greater pressure 
from passage, resulting in the changes observed.
At amino acid position 155 in the E protein, two nucleotide changes 
at positions 1436 and 1437 combine to give rise to a serine in 17DD-Senegal, 
whilst in 17D-204 an aspartic acid is found. This change is particularly 
interesting, since it gives rise to a potential N-glycosylation site (sequence N- 
X-T/S). In several other flaviviruses, a potential N-linked glycosylation site 
is found at an analogous position, including all members of the dengue 
subgroup, members of the TBE complex and members of the IE subgroup 
(Rice et al. , 1990). This may explain previous work which had suggested that 
the E protein of 17DD-Senegal migrated at a slower rate than that of either 
Asibi or 17D-204 when run in SDS-PAGE gels (Barrett, 1987). Thus the 
examination of ITDD-Senegal at a molecular level has revealed a plausible 
explanation for one of the physical differences observed between it and ITD- 
204.
Whilst the work described in this chapter was nearing completion, a 
paper was published describing the nucleotide and deduced amino acid
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sequence of the E protein gene of the 17DD vaccine strain manufactured in 
Brazil (ITDD-Brazil) (Post et ah, 1992). When the nucleotide sequences of 
the two ITDD vaccine strains were compared, it was found that they differed 
by only three nucleotides, at positions 1(X)4, 2111 and 2143. There were no 
amino acid differences between the two strains. The two ITDD vaccine strains 
differ by only one passage; 17DD-Brazil is at passage 286, and ITDD-Senegal 
at passage 287. However, methods of sub-culture and vaccine preparation may 
differ in the two countries, perhaps accounting for the nucleotide variation. 
However, the changes are all silent, and hence are probably neutral mutations, 
without great significance in either the attenuation process or the alteration of 
epitopes recognised by MAbs. All four amino acids, which were found to be 
different in ITDD-Senegal as compared to lTD-204 ATCC, were identical in 
both the ITDD viruses; there was no variation at the amino acid level in the 
E protein. As Post et ah (1992) did not publish the sequence of the rest of the 
structural protein genes, no comparisons can be made for C, prM and M 
between the two ITDD viruses.
Thus, the potential N-glycosylation site found at position 155 within 
the E protein was also found in 17DD-Brazil. Post et ah (1992) also 
performed immunoprécipitation and SDS-PAGE electrophoresis to demonstrate 
that the E protein of ITDD-Brazil did in fact migrate more slowly than that 
of 17D-204. It was shown that this was due to N-linked glycosylation by 
treating the immunoprecipitated E with endoglycosydases, following which the 
E protein of ITDD-Brazil ran with a similar mobility to that of lTD-204 (Post
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et al., 1992). Since the amino acid sequence of ITDD-Senegal is identical to 
that of ITDD-Brazil, it can be assumed that the same N-linked glycosylation 
site is being utilized.
As mentioned in Section 4.1, it was known that, in addition to the 
physical differences between the mobility of the E proteins of ITDD and 17D- 
204 vaccine substrains, there was antigenic variation as determined by MAb 
HIO. This E protein specific MAb distinguished between ITDD and 17D-204 
vaccine strains in HE and HAI tests, and recognised a ITDD specific epitope. 
Table 4.2 shows the amino acid differences between the E protein sequences 
of 17D vaccine strains and their wild-type parent, Asibi virus. The 
information contained in this Table helps in identifying changes in the E 
protein which may be important in the makeup of the ITDD epitope. ITDD 
differs from 17D-204 at four positions: 56, 155, 325 and 416. However, the 
amino acids seen in 17DD viruses at positions 56 and 325 are shared with 
Asibi virus. Therefore, those changes which are unique to 17DD vaccine 
strains, namely those found at positions 155 and 416 may independently or 
together form part of the epitope which distinguishes 17DD vaccine strains 
from 17D-204 vaccine strains. However, the epitope is conformational in 
nature (Barrett, personal communication) and will also involve other amino 
acids.
It is interesting to note that one of the two amino acid positions 
mentioned above, namely 416, is the only one at which there is a genuine
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Table 4.2; Amino acid differences in the Envelope 
proteins of Asibi and yellow fever 17D vaccine strains
Asibi^ *^  17DD-Sen 17DD-Bra^ '=>
52 G R R R R
56 A V A A V
153 N N N N T
155 D D S S D
170 A V V V V
173 T I I I I
200 K T T T T
299 M I I I I
305 S F F F F
325 P S P P S
331 K R R R R
380 T R R R R
407 A V V V V
416 A T V V T
Sequences taken from Hahn etal{19^1) (a), 'Rictetal (1985) (b), and Post eta l (1992) (c).
The E protein of 17D-204 from France (Dupuy ,1989) was identical to that of 17D-204 ATCC.
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variation between all the viruses, namely Asibi, 17DD and 17D-204 
substrains. From an alanine in Asibi, a change to a threonine is found in the 
two 17D-204 viruses, whilst a valine is present in the two 17DD viruses.
In addition. Table 4.2 contains information which can be used in 
deductions about the 17D specific epitope, shared by both 17DD and 17D-204 
substrains, but absent in Asibi virus, which is recognised by MAb H6  (Sil et 
a l ,  1992).
At position 56, an alanine is found in Asibi, whilst a valine is seen in 
the 17D-204 substrains. However, this position is probably not associated with 
the 17D epitope recognised by MAb H6 , since in 17DD-Senegal, as in Asibi 
virus, an alanine is present. Similarly, at position 325 the same amino acid, 
proline, is found in both the 17DD-Senegal substrain and Asibi viruses, whilst 
a serine is found in the 17D-204 substrain viruses. It seems likely that these 
amino acid differences are not associated with the 17D epitope, since Asibi 
virus would also be expected to react with MAb H6 , unless the epitope shows 
a high degree of conformation. However, a number of amino acid differences 
from Asibi virus are shared by both the 17D-204 and 17DD vaccine 
substrains, namely those at positions 52, 170, 173, 200, 299, 305, 331, 380 
and 407. It is likely that the epitope recognised by this MAb is also 
associated with one or more of the nine amino acid positions listed above, as 
common changes are found at these positions in both 17D-204 and 17DD 
vaccine substrains.
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Although attenuation is probably multi-factorial it is likely to involve 
the E protein for reasons discussed in Chapter 1. Therefore the deductions 
drawn in the previous paragraph may also be applied to attempts to define 
attenuation. Whilst the 17D-204 vaccine sequence was the only attenuated 
derivative for which the nucleotide and deduced amino acid sequence was 
available, it was difficult to assess which of the mutations seen over the E 
protein might contribute to attenuation. Despite the fact that the ITDD 
substrain virus is very similar to the 17D-204 substrain virus, the sequence of 
its E protein does throw some light on changes that may not be involved in 
attenuation, when compared to the wild-type parent Asibi. Those changes 
mentioned above, namely 56 and 325, are unlikely to be involved in 
attenuation, since the amino acids found at these positions are identical in both 
ITDD and Asibi. However, at nine positions in the E proteins of 17D-204 and 
ITDD viruses the same amino acid substitution firom Asibi virus is found 
(positions 52, 170, 173, 200, 299, 305, 331, 380 and 407; see Table 4.2). If 
the attenuation of YF virus during the passage of Asibi to produce 17D 
vaccine strains is associated with the E protein then it would appear that 
amino acid substitutions at one or more of these positions is involved.
Thus the results presented in this Chapter begin to answer some of the 
questions posed by previous studies on the biological and physical properties 
of YF vaccines. Unfortunately, the speculation on epitopes and attenuation 
cannot be practically examined without expression and manipulation of the E
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protein to allow analysis with MAbs, and preferably the use of an infectious 
clone.
In conclusion, the 17D vaccine viruses maintained in different centres 
exhibit a very high degree of homology at the molecular level over the portion 
of the genome coding for the structural proteins, even though they have been 
through different and varied passage histories in different laboratories (Barrett, 
1987). Amino acid differences between 17D-204 and 17DD substrains in the 
structural proteins are confined to the E protein.
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Chapter 5
Comparison of the nucleotide and deduced amino acid 
sequence of the structural protein genes of the 
wild-type French viscerotropic strain of yellow 
fever virus and the live vaccine strain, French 
neurotropic vaccine, derived from it.
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5.1 Introduction
As stated in Chapters 1 and 4, the 17D vaccine strain of YF virus was 
developed by passaging the wild-type strain, Asibi, 176 times through chicken 
embryo tissue, mainly with nervous tissue removed. Further passages in the 
same tissue followed to produce the vaccines used today (Barrett, 1987).
Sequence data for the structural protein genes of 17D-204 (Rice et al. , 
1985; Dupuy et al. , 1989) and 17DD substrains (Chapter 4; Post et al. , 1992) 
demonstrated their similarity at a molecular level, reinforcing previous 
physicochemical and biological studies which had suggested that the two 
substrains were closely related.
Despite the increased knowledge of the molecular biology of the 17D 
strain of YF virus, the molecular basis of attenuation of YF virus remains 
unclear. However, the FNV vaccine strain of YF virus offers another 
attenuated variant of YF virus which can be examined at the molecular level 
to complement both biological and antigenic studies previously performed on 
it (Gould et al., 1985; Sil et al., 1992), and to compare with the sequence 
data determined for the 17D vaccine substrains.
The FNV vaccine strain of YF virus was developed almost 
concurrently with 17D, but by a very different route involving the passage of 
the wild-type F W  serially through mouse brain (Mathis et al., 1928).
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Following 128 passages an attenuated variant was generated, with the first 
vaccines used at passage 237 (see Figure 5.1). In contrast to the 17D system, 
nervous tissue was not removed; rather the system used for passage was rich 
in it. As would be expected, the two viruses appear relatively dissimilar 
biologically; however there are also some features that they share; namely 
attenuation of viscerotropic disease and lack of mosquito competence (Theiler 
and Smith, 1937b; Deubel et ah , 1981). Although no longer used as a vaccine 
due to relatively high levels of post-vaccinal encephalitic sequelae (WHO, 
1971), FNV was used up until 1980, as described in Section 1.4.2.
Previous antigenic studies (Gould et ah , 1985; Sil et ah , 1992; Ledger 
et ah, 1992) have examined the relationship of FNV with the 17D vaccine 
viruses and their respective wild-type parents. Cluster analysis with MAbs and 
polyclonal antibodies in HAT and neutralization tests found that the FNV virus 
w'as more closely related to the 17D-204 and 17DD vaccine viruses than to 
wild-type viruses. The wild-type F W  was found to group very closely with 
Asibi virus in such tests, which was not surprising as F W  and Asibi virus 
were both isolated in 1927 from neighbouring countries in Africa, and 
presumably from the same epidemic of YF.
In 1989, the author examined F W  and FNV with MAbs prepared 
against an FNV virus isolate (obtained from the Institut Pasteur, Paris), which 
were found to distinguish between F W  and FNV. In 1992, Sil et ah extended 
this study with a detailed analysis of F W  and FNV with MAbs produced
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Figure 5.1: Derivation of the French neurotropic vaccine viruses
Mayali* (Senegal, 1927) 
(French viscerotropic virus [FW])
Original FNV virus (pl28)
First FNV administered (p237)
Later vaccines (p260)
* Name of the patient, Franscois Mayali, from whom the 
virus was isolated by Mathis et. al., 1928
Figure adapted from Barrett, 1987
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against a range of YF vaccine strains employing PRNTs and HAIs. The FNV 
vaccine viruses were found to be distinct from other YF viruses, including 
17D vaccines, but more closely related to 17D viruses than wild-type viruses.
In 1987 F W  and FNV viruses were included in a Tj oligonucleotide 
mapping study of YF viruses (Deubel et ah, 1987). The results showed that 
F W  and Asibi shared 96.4% homology, F W  and FNV 83.6% and Asibi and 
17D-204 79.6%. Since then no further studies have been published examining 
F W  or FNV at the molecular level.
Despite the findings above Sil et ah (1992) found that one E protein 
specific MAb, H5 (raised against 17DD-Brazil), recognised an epitope which 
is found on FNV and both 17D-204 and 17DD vaccine substrains in IIF and 
HAI tests. The epitope was not found on wild-type YF viruses examined 
(except Y5, see Chapter 7). Another group has also reported similar results 
(Gould et ah, 1985). This epitope was thus termed the "vaccine epitope". 
Since two different attenuation processes (FNV and 17D) result in the 
generation of this epitope, it would suggest that it may be important, if not in 
the attenuation process itself, then perhaps as a marker of attenuation.
Prior to these studies, 17D-204 was the only attenuated YF virus which 
had been sequenced, and FNV represented another attenuated strain which had 
been derived by a very different route and yet shared an E protein epitope 
with 17D. The structural proteins of FNV virus were therefore cloned and
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sequenced, as were those of its’ parent wild-type, strain F W , to enable 
molecular comparisons between the two viruses to be made.
5.2 E?q>erimental work
All procedures used in this chapter are described in Chapters 2 and 3.
5.2.1 Virus
F W  was obtained from the Division of Vector-Borne Infectious 
Diseases, Centers for Disease Control, Fort Collins, Colorado, USA, and the 
FNV strain used was obtained from the Institut Pasteur in Paris, France, as 
batch number PX +11. Both viruses were passaged in SW13 cells to provide 
working stocks.
5.2.2 Oligonucleotide primers
The primers employed were as described in Chapter 4.
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5.3 Results
Two clones for each of the fragments covering the structural protein 
genes were sequenced for each of the two viruses.
The results in this chapter represent the second wild-type/attenuated 
derivative pairing examined at the molecular level, following that of Asibi and 
17D-204 (Hahn et ah, 1987; Rice et ah, 1985), and thus present an 
opportunity to examine the similarities and differences between both attenuated 
derivatives. In addition, the sequence of the structural protein genes of F W  
allow a comparison to be made with Asibi, to assess the variation between the 
two African wild-type strains.
5.4 Comparison of the nucleotide and deduced amino sequences of the 
structural proteins of F W  and FNV
The nucleotide and deduced amino acid sequences of the structural 
protein genes of F W  and FNV were compared, and the results are shown in 
Table 5.1.
The region examined covered 2377 nucleotides, coding for a total of 
778 amino acids comprising the proteins C, prM, M and E. The total number
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Table 5.1: Nncleotide and amino acid changes between the 
structural protein genes of F W  and its* vaccine derivative, FNV
Position
nt F W ---- FNV
Position
AA
F W - — FNV
233 A G C39 R G
250 U A -
271 U C -
357
370
U
U
C
c c
C80 V A
373 G A -
386 A G C90 s G
554
694
G
U
A
C
prM prM25
V M
854 c U M M35 L F
1036 u c -
1042 u c -
1134 c u E54 A V
1223 G A E84 E K
1306 G A -
1398 A G
E
E142 Q R
1432 U A E153 N K
1653 G A E227 G E
1718 A G E249 N D
2193 U C B407 V A
2239 U C -
2344 G A E457 M I
2437 U C
Nucleotide positions are taken from the sequence of 17D-204 ATCC (Rice etal. , 1985)
Amino acid positions refer to the number of the amino acid from the start of that protein (ie: C39 
is the 39th amino acid of the Capsid protein).
1- No amino acid substitution
of nucleotide changes between the wild-type and vaccine was 23, giving rise 
to 13 amino acid substitutions. These were distributed throughout the 
structural proteins as shown in Table 5.2, which also displays the percentage 
changes seen. For comparison. Table 5.3 shows the changes observed over the 
same region between Asibi and 17D-204 viruses. No nucleotide variation was 
seen in the portion of the 5’-noncoding region sequenced between F W  and 
FNV viruses (nucleotides 72-118).
The differences found between F W  and FNV viruses equate to 
homologies of 99.0% and 98.4% over the nucleotides and amino acids 
respectively of the structural proteins, with the highest percentage variation 
found in the C (capsid) protein at both the nucleotide and amino acid levels.
5.5 Comparison of the nucleotide and deduced amino acid sequence of 
the structural proteins of F W  and Asibi viruses
Asibi was isolated from a patient named Asibi in Ghana in 1927, while 
the F W  strain was isolated from Francois Mayali in Senegal, also in 1927 
(Barrett, 1987). Comparison of the sequence of the structural proteins of F W  
and Asibi revealed that the two strains were very similar at the molecular 
level. Table 5.4 lists the nucleotide and amino acid positions throughout the 
structural protein genes at which the two strains differ. It can be seen that the 
majority of nucleotide changes (7 out of 8) are found in the E protein, where
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Table 5.2: Summary of the differences between F W  and FNV viruses
over the structural protein genes
Protien Total Length nt/AA
No. of Changes 
nt/AA
%  Change 
nt/AA
363/121 7/3 1.93/2.48
prM* 267/89 2 / 1 0.75/1.12
M 225/75 1/1 0.44/1.33
1479/493 13/8 0.88/1.62
Total I  2334/778 2 3 /1 3 0.99/1.67
• Does not include the portion coding for the mature M protein
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Table 5.3: Summaiy of the differences between Asibi and 17D-204 ATCC viruses
over the structural protein genes
Protien Total Length nt/AA
No. of Changes 
nt/AA
% Change 
nt/AA
C 363/121 2/0 0.55/0
prM* 267/89 0/0 0/0
M 225/75 2/1 0.89/1.33
E 1479/493 15/12 1.01/2.43
Total 2334/778 19 /13 0.81/1.67
* Does not include the section coding for the mature M protein. 
Adapted from Hahn e ta l, 1987.
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Table 5.4: Nucleotide and amino acid variations between the structural 
protein genes of the wild-type strains of YF virus, F W  and Asibi
Position  ^ Position ^
nt F W  Asibi AA F W  Asibi FNV 17D
233 A G c C39 R G G G
1653 A G E227 G E E E
1819 U C -
1965 G A E331 R K R R
E
2092 U C -
2142 A C E390 H F H H
2239 U C -
2257 C u
*
Sequence of Asibi taken from Hahn etal. 1987
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7 nucleotide changes give rise to 3 amino acid substitutions (at positions 227, 
331 and 390, numbered from amino acid 1 of the E protein). Only one 
nucleotide change is found in the remainder of the structural proteins, and is 
located in the C protein gene. This also gives rise to an amino acid changes, 
at C protein position 39 (C39). It was noted that 17D, FNV and Asibi viruses 
had the same amino acid difference from F W  at positions C39 and E227 
(Table 5.4). The variation between Asibi and F W  over the structural proteins 
is thus 0.29% at the nucleotide level and 0.51% at the amino acid level.
The results obtained from F W  are also of some help in attempting to 
identify antino acid positions which may be associated with biological markers 
or attenuation, and will be examined further in Section 5.7.
5.6 Comparison of the two wild-tvpe vaccine pairs (Asibi/17D and 
FW /FNV)
The results presented in this chapter allow a comparison of the two 
vaccine strains, FNV and 17D (further sub-divided into 17D-204 and 17DD 
substrains), with each other and also their respective wild-type parent strains. 
Figure 5.2 shows a cluster analysis based on the amino acid sequences of the 
structural protein genes of F W , Asibi (Hahn et ah, 1987), FNV, 17D-204 
(Rice et al. , 1985) and 17DD-Sen (from Chapter 4). This shows that F W  and 
Asibi viruses group very closely together, as do 17D-204 and 17DD-Senegal
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Figure 5.2: Cluster analysis of wild-type and vaccine strains of YF virus 
based on the amino acid sequences of their structural proteins
ASIBI
F W
17D-204
17DD
FNV
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viruses. This is to be expected, as both pairs of viruses are very similar over 
their structural proteins, as described in both this and the previous Chapter. 
However, Figure 5.2 also shows that FNV and the 17D viruses group 
relatively distant from one another. To examine the these differences at the 
amino acid level. Table 5.5 lists the changes found in the structural protein of 
these viruses.
Table 5.5 shows that there is no common amino acid substitution found 
in all the vaccine strains in the E protein, but different to the wild-type 
strains. As stated above, the two vaccine viruses differ relatively greatly from 
one another, although both exhibit the same number of amino acid differences 
(13) from their respective parents over the structural protein genes. However, 
at the nucleotide level, FNV was slightly less homologous to FNV than 17D- 
204 was to Asibi (0.99% and 0.81% divergence respectively).
Interestingly, there is one amino acid substitution common to both 
FNV and 17D vaccine viruses and different to the wild-types; this is coded for 
by nucleotide position 854, which is located in the M protein gene, where a 
C in both Asibi and F W  is replaced by a U in both 17D (17D-204 and 
17DD) and also FNV viruses. This leads to a leucine at position 35 in the M 
protein of the wild-type viruses being replaced with a phenylalanine in the 
vaccine strains.
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Table 5.5: Amino acid changes in the structural 
proteins of yellow fever viruses
Wild Type Vaccine
POSITION ASIBI F W FNV 17D204 17DD
C39 G R G G G
C80 V V c A V V
C90 S s G S S
prM25 V V prM M V V
M35 L L M F F F
E52 G G G R R
E54 A A V A A
E56 A A A V A
E84 E E K E E
E142 Q Q R Q Q
E153 N N K N N
E155 D D D D s
E170 A A A V V
E173 T T E T I I
E200 K K K I 1
E227 E G E E E
E249 N N D N N
E299 M M M I I
E305 S S S F F
E325 P P P s P
E331 K R R R R
E380 T T T R R
E407 V V A V V
E416 A A A 1 V
E457 M M I M M
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Footnote: Sequences of viruses are taken from 
Rice etal., 1985; Hahn etal, 1987 and Post etal , 1992
5.7 Discussion
The results presented in this chapter help to confirm previous studies 
which had suggested that wild-type Asibi and F W  viruses were very similar, 
and also that 17D and FNV vaccine viruses were relatively dissimilar.
The points above will be discussed in more detail in the following 
pages. However, two groups have reported the presence of a "vaccine 
epitope" which was present on the E protein of all three vaccine strains (FNV, 
17D-204 and 17DD (Gould et a l ,  1985; Sil et a l ,  1992). In addition the 
known neurovirulence of FNV as compared to the viscerotropic nature of 
wild-type YF viruses is another important consideration. Below, the nucleotide 
sequence of each structural protein is analyzed.
C protein: Perhaps one of the surprises regarding the results presented 
in this Chapter was the extent to which F W  and FNV differed over the C 
protein gene. During the attenuation of Asibi, only two nucleotide changes 
were seen over this region for the 17D-204 strains, with an additional two 
found in 17DD-Senegal (see Chapter 4). None of these changes coded for an 
amino acid substitution, and thus the C proteins of Asibi and 17D vaccine 
viruses were identical in amino acid sequence.
However, over the structural protein genes of the FNV virus, the
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biggest variation from the wild-type parent F W  at both the nucleotide and 
amino acid level was seen in the C protein (see Tables 5.1 and 5.2), with 7 
nucleotide changes leading to three amino acid substitutions. However, an 
examination of the variation in the C protein found between F W  and Asibi 
(Table 5.4) shows that at amino acid position 39, F W  differs from Asibi 
virus as well as from the FNV virus. The amino acids at this position are in 
fact identical in Asibi, FNV and also 17D viruses, which would suggest that 
it is not directly involved in attenuation.
The remaining two amino acid substitutions are at positions 80 and 90. 
Both are potentially conservative; valine to alanine at position 80 and serine 
to glycine at position 98. As such, they would not be predicted to have a 
significant effect on the structure of the C protein, and the importance of these 
changes is unclear. As stated in Section 1.5.5 the function of the highly 
positively charged C protein is believed to be to offset the negatively charged 
RNA with which it is associated. The substitutions at positions 80 and 90 
replace amino acids with ones which are similarly charged, and thus may not 
affect the overall charge of the C protein. Amongst other flaviviruses 
sequenced, there appears to be considerable divergence of the amino acids 
which constitute the C protein itself; however regions of hydrophobicity and 
hydrophilicity are conserved. The only one of the three substitutions observed 
which would alter the charge is that at position 39, where the hydrophilic 
positively charged arginine residue seen in F W  is replaced with an 
intermediate and uncharged glycine residue. Glycine is also found at this
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position in 17D and Asibi viruses.
Interestingly, one of the silent changes from F W  to FNV, the 
replacement of a U with a C at nucleotide 370 is also seen in Asibi strain to 
17DD-Senegal, whilst a C is found in 17D-204. This suggests that perhaps 
even silent changes may not be as random as they may appear, since the two 
vaccine viruses have undergone very different passages to lead to their 
attenuation.
Another interesting point is that the attenuation process of F W  to 
FNV appears to have led to a substitution in the C protein (position 39) which 
leads to an amino acid identical to that seen in Asibi and 17D vaccine strains. 
This would perhaps suggest that some positions allow "switching", where the 
amino acid can change due to some selection pressure, such as that of 
attenuation or natural environmental genetic pressure. This may be due to the 
importance of maintaining the overall charge and hydrophilicity profile of the 
C protein, as described above; but it is interesting that certain changes appear 
more common than others which also would not affect either the charge or 
hydrophilicity. It is also possible that an error in the RT-PCR reaction or in 
sequencing was responsible for the apparent amino acid difference observed 
in FW ; however both clones contained the nucleotide difference giving rise 
to this perceived change.
prM protein: In the prM portion of the M protein gene, two
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nucleotide changes are seen between F W  and FNV, and one (at position 554) 
gives rise to an amino acid substitution at position 25 in the prM protein, 
where the valine found in F W  is replaced in the FNV virus with a 
methionine. prM is absolutely conserved at both the nucleotide and amino acid 
level between Asibi virus and 17D vaccine strains. The "pr" portion of M is 
essentially hydrophilic; however this conservative replacement of one 
hydrophobic amino acid with another may not affect the overall structure of 
the protein.
Membrane protein; Perhaps one of the most interesting results is the 
determination of a common amino acid substitution as a result of a nucleotide 
change at position 854. This gives rise in both FNV and 17D vaccine strains 
to a phenylalanine replacing the leucine which is seen in the wild-type Asibi 
and F W  viruses at position 35 in the M protein. Again this is a conservative 
substitution, but the fact that an identical change is seen in both wild- 
type/vaccine pairs may be significant. It should also be noted that it occurs in 
a hydrophilic region of the M protein. Over the structural proteins, this 
position is the only one at which a shared amino acid substitution was 
observed for FNV and 17D vaccine strains. Unfortunately, the importance of 
this change cannot be determined without expression work or the use of an 
infectious clone; however it is relevant to note that purified dengue-2 M 
protein has been shown to elicit a neutralizing antibody response in vivo 
(Brinton, 1986), and is thought to be a component of the viral spike, and 
hence be involved in some way with the binding and entry of virus to cells.
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This amino acid position would thus require further study in order to elucidate 
more clearly the importance or otherwise of this substitution.
E protein: Over the E protein the FNV virus displays 8 amino acid 
substitutions from F W . Two of these, at positions 142 and 227, may be of 
particular importance since theoretically they significantly alter the 
hydrophobicity of the E protein in these regions. However, as with 17D-204 
changes from Asibi virus, it is difficult to attempt to speculate which changes 
(if any) may be important in the attenuation process without comparison with 
other wild-type and attenuated strains of YF virus. It was for this reason that 
the study on F W  and FNV was performed.
The similarity of F W  and Asibi over the structural protein genes 
supports the results reported by previous workers that the viruses are closely 
related. As stated previously, the two viruses were isolated in the same year 
(1927) in neighbouring African countries (Asibi virus in Ghana; F W  in 
Senegal). The two isolates are believed to originate from the same epidemic 
of YF. Previous studies on these viruses have shown that, although they are 
related, they do differ, when examined with MAbs (Sil et al. , 1992) and also 
by T1 oligonucleotide mapping (Deubel et al. , 1987). It is interesting to note 
that, despite the fact that these two viruses were isolated at very similar 
locations and times and each virus has been through 8 passages since isolation, 
they do differ over the region examined, demonstrating the heterogeneity of
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wild-type YF virus, although it is possible that the differences observed were 
as a result of their passage history. Altogether four amino acid differences 
were seen; one in the C protein and three in the E protein (see Table 5.4). In 
the C protein, the amino acid found in F W  at position 39 is unique to FW  ^
when compared to other YF viruses; of the three positions where the two 
viruses differ in the E protein, at only one (position 227) is an amino acid 
found which is unique to FW ’ when compared to other YF virus strains 
(Table 5.5). Here, a glutamic acid is found in all other strains sequenced, 
whilst in F W  a glycine is seen. However this position is unlikely to be 
important in attenuation, since the same amino acid, glutamic acid, is found 
in FNV, Asibi and 17D viruses (Table 5.5).
The other positions at which F W  differs from the published Asibi 
sequence (Rice et ah, 1985) are 331 and 390. However, the amino acid at 
position 390 in the Asibi virus E protein 390 has now been confirmed to be 
a histidine, as is found in all other YF strains so far sequenced at this position 
(Rice, personal communication). Again these results are useful in eliminating 
the amino acid change at position 331 from possible involvement in either 
attenuation or the "vaccine epitope", since at this position the same amino acid 
is found in F W , 17D-204 and 17DD viruses, and in this case it is Asibi virus 
which appears to have a unique amino acid at this position. Thus, it is likely 
that these amino acid substitutions are not involved in the attenuation process 
of FNV or 17D (Table 5.5).
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Previous studies using MAbs raised against the YF virus E protein 
(Gould et al. , 1985; Sil et al. , 1992) have suggested that the FNV and 17D 
vaccine strains of YF virus differ considerably, which is to be expected, given 
that their routes of attenuation are different, as described earlier. The results 
obtained confirm that these two viruses are relatively dissimilar over the E 
protein; in fact they differ more from each other than from their respective 
parents (see Figure 5.3 and Table 5.5), with 25 nucleotide and 17 amino 
acids differing between them. FNV is closer to its’ parent F W , in terms of 
both number of nucleotide changes and resultant amino acid substitutions (13 
and 8 respectively) than 17D-204 is to Asibi (15 nucleotide and 12 amino acid 
substitutions). However, since the vaccine strains are some 234-288 passages 
removed from their parents, and have had the additional selection pressure of 
adaptation to animals (or cell cultures derived from animals) which are not 
natural hosts for YF virus, it is somewhat surprising that there are so few 
nucleotide changes over the structural proteins. Over the total length of the 
structural protein genes, 2334 nucleotides, the variation for each at the 
nucleotide level is 0.99% and 0.81% respectively for FW /FNV and 
Asibi/17D-204 viruses. Both have an identical percentage amino acid 
divergence over the structural proteins of 1.67% (see Tables 5.2 and 5.3).
It has been demonstrated that the E protein of FNV shares an epitope 
with both 17D-204 and 17DD substrains of the 17D vaccine which has been 
termed a "vaccine epitope" (Gould et al. , 1985; Sil et al. , 1992). Since there 
are no common vaccine substitutions observed in the E protein (see Table
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Figure 5.3; Summary of the nucleotide and amino acid differences 
between the envelope protein genes of wild-type 
and vaccine strains of yellow fever virus
Nucleotide changes
1 1 ^< k b g
ASIBI - 7 16 15
F W 3 - 13 16
FNV 9 8 - 25
17D-204 12 11 17 -
Iem
Ü
•o?
0 e1
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5.5), it can be assumed that the vaccine epitope is not the result of a single 
specific amino acid change in the E protein. Thus, the actual epitope 
recognized may not include mutation(s) arising by direct substitutions, but 
rather the epitope may result from a similar conformational change in the E 
protein which can be induced by different substitutions, perhaps in different 
regions of the E protein. However, it is interesting to note that a cluster of 
amino acid substitutions are seen at positions 52, 54 and 56 for 17D-204, 
17DD and FNV viruses, and it is possible that these amino acids may 
constitute the vaccine epitope. Expression studies would be necessary to 
answer this question. However, there is also a cluster of changes seen around 
amino acids 153-155, with variation from the norm seen at 153 for FNV virus 
(and also 17D-204 WHO (Post et ah, 1992)), 154 in the wild-type South 
American YF virus, B4.1, and at position 155 in the 17DD vaccine strains. 
Hence it may be that certain regions of the E protein are liable to a greater 
variation than other regions, possibly due to exposure on the surface of the 
virus.
The FNV virus differs from it’s parent F W , and most other strains 
of YF, including the 17D vaccine strain, in that it exhibits neurotropism for 
monkeys and humans, rather than the viscerotropism normally associated with 
wild-type YF virus. For example, inoculation of 5x10* pfii of FNV virus by 
the intracerebral route was a lethal dose for a Cynomolgus monkey at 6  days 
post-infection (Ledger, 1990).
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This enhanced neurotropism of the FNV virus is almost certainly as a 
result of its’ passage through mouse brain. Assuming that the E protein plays 
a role in virulence, it is interesting to note that at amino acid position 84 in 
the E protein, glutamic acid is found in all other YF viruses so far sequenced, 
and also in the mosquito-bome dengue viruses. However in the FNV virus, 
the amino acid found at this position is lysine, and this residue is also seen in 
all mosquito-bome neurotropic flavivirus E proteins that have been studied 
including West Nile, St. Louis encephalitis, and several strains of Murray 
Valley encephalitis and Japanese encephalitis (Castle et al. , 1986; Trent et al. , 
1987; Lobigs et al., 1988; Nitayaphan et al., 1990). According to 
hydrophilicity studies, the region in which residue 84 is found is located on 
a hydrophilic region of the protein, and would thus be expected to be located 
on the exterior of the protein. However further studies would be required to 
determine whether or not this change has any effect on the alteration of 
tropism seen from F W  to FNV.
In conclusion, the structural proteins of wild-type YF viruses F W  and 
Asibi have been shown to differ, and although a common substitution in the 
E proteins of YF vaccines has not been found which could be responsible for 
the common vaccine epitope shared by 17D-204 and FNV vaccines, there is 
a common change in the M protein, which may be involved in virus binding 
to and entering cells. Also, the differences in tissue tropisms of F W  
(viscerotropic) and FNV (neurotropic) cannot yet be attributed to specific 
amino acid substitutions in the E proteins of these viruses (ie: the virus protein
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that will bind to cell receptors), although the substitution at residue 84 
requires further study in this respect.
Unfortunately, without further studies utilizing either expression work, 
or an infectious clone, the hypotheses suggested in this Chapter cannot be 
conclusively examined.
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Chapter 6
Molecular analysis of the envelope protein gene 
of a yellow fever virus isolated 
from a fatal case of 17D-204 post vaccinal 
associated human encephalitis
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6.1 Introduction
As stated in Chapters 1 and 5, wild-type YF virus is viscerotropic in 
nature in man, causing liver disease and haemorrhagic fever (Monath, 1985). 
However, some vaccine strains have been associated with neurovirulence in 
man. This has been associated mainly with the FNV vaccine virus (which is 
discussed in Chapter 5) and is probably due to the extensive passage of this 
virus in mouse brain (Mathis et ah, 1928).
In comparison, the 17D vaccine strains derived from the wild-type 
Asibi virus continue to be effective, with very few cases of post-vaccinal 
encephalitis reported since the introduction of the seed lot system in 1945 
(Barrett, 1987). Strain Asibi was passaged through chicken embryonic tissue, 
mainly with the nervous tissue removed to produce the attenuated 17D strain. 
Problems with the 17D vaccines have been in the main associated with the 
lack of quality control in the early years of vaccine production leading to 
over-attenuation (see Section 1.4.3).
Since the introduction of the seed-lot system only 18 cases of post­
vaccinal encephalitis have been recorded, the majority of which occurred in 
children under the age of 4 months. As a result, the vaccination of children 
under the age of 6  months (1 year in some countries) was prohibited (WHO, 
1959). This figure is, however, remarkably low, considering that some 700 
million doses of the vaccine have been administered world-wide (based on an
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average 15 million doses per annum since 1945). The most recent documented 
case of 17D associated post-vaccinal encephalitis occurred in South Africa in 
1989, when a 13 year old boy developed encephalitis 7 days after inoculation 
with the 17D-204 vaccine manufacture at the National Institute for Virology, 
South Africa (Schoub et al. , 1990). The boy recovered, and since no attempt 
was made to isolate YF or other viruses from him, the exact nature of the 
encephalitis and its’ link (if any) with the 17D vaccine administered cannot be 
assessed.
Only one fatal case of 17D associated post-vaccinal encephalitis has 
been documented since the introduction of the seed lot system (Anonymous, 
1966). Single doses of the same vaccine lot (lot no. 6145) of the 17D-204 
vaccine manufactured by the National Drug Company (USA) were 
administered to an apparently healthy 39 month old female and to both of her 
parents. Neither of the parents demonstrated any unusual reaction; however, 
6  days after vaccination, the child developed early symptoms of neurological 
disorder, resulting in death 12 days post-vaccination. Post-mortem 
examination of brain tissue revealed findings compatible with acute viral 
encephalitis, and virus (one of which was named P-16065) that was 
serologically indistinguishable from 17D vaccine virus was isolated.
P-16065 provides a unique example of a neurovirulent YF  virus 
associated with the 17D vaccine strain. Although this is the only recorded case 
of fatal 17D post-vaccinal encephalitis, the neurotropic potential and the
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limitation of the vaccines’ use in infants presents a major problem. This is 
particularly important, as infants, especially in some countries in Africa, are 
at high risk from YF. Therefore, in order to improve the effectiveness of the 
currently available vaccines, the mechanism of neurovirulence of the 17D 
vaccine needs to be defined, particularly at the molecular level.
This virus, and also the batch of 17D-204 USA vaccine used to 
inoculate the girl (lot 6145) have already been subjected to biological analysis 
in the University of Surrey, showing that the two strains are very similar, but 
can be distinguished from one another by E protein specific MAbs (Ledger 
1990). Table 6.1 summarises these results. Initial T  ^oligonucleotide mapping 
could not distinguish between 17D-204 USA 6145 and P-16065 viruses 
(Barrett, personal communication).
Thus the envelope protein genes of P-16065 and 17D-204 USA (6145) 
were amplified, cloned and sequenced; and also in vivo studies were 
undertaken. The results obtained are presented and discussed in this Chapter.
6.2 Experimental work
6.2.1 Viruses.
Both 17D-204 USA (6145) and P-16065 were obtained from Dr
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Table 6.1: Sammary of MAbs that distinguish between 17D-204 
USA (lot 6145) and P-16065
MAb Specificity Test
17D~204(USA)
#6145
P-16065
B26 intermediate nF +
PRNT +
E21 intermediate EF + +
PRNT +
S24 wild-type specific EF
PRNT - f
186
Charles Calisher (Centers for Disease Control, USA). 17D-204 USA (6145) 
was originally manufactured by the National Drug Company of the U.S.A. P- 
16065 was available as suckling mouse brain (smb) passage 3 of the original 
human brain material. This was given a further passage to generate a seed for 
studies, and one further passage in mouse brain to generate working stocks of 
virus.
Batch 6145 was available as a freeze-dried 10 dose lot of the original 
vaccine. Unfortunately, the original material and smb passages 1 and 2 of P- 
16065 have been lost. Therefore lot 6145 was given five passages in smb to 
generate a vaccine virus with as near a passage history as P-16065 as possible.
6.2.2 Monkey virulence tests.
Monkey virulence tests were performed according to recommended 
procedures for vaccine control (WHO, 1959). Male cynomolgus monkeys 
were inoculated intracerebrally into the left frontal lobe with 0.25 ml live P- 
16065, FNV (Institut Pasteur) or 17D-204 6145 viruses (10  ^pfii). Following 
inoculation the animals were monitored daily for clinical signs. This work was 
performed by David Wood, Frank Taffs and co-workers at the National 
Institute for Biological Standards and Control, U.K.
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6.2.3 Molecular analysis of the E protein genes of P-16065 and 
17D-204 USA (6145)
Both virus strains were amplified in mouse brain or tissue culture to 
produce vRNA prior to extraction, and both were pre-treated with BPL. RNA 
extraction, RT-PCR, cloning and sequencing were performed as described in 
Chapters 2 and 3.The primers used for amplifying the E protein genes of 17D- 
204 USA (6145) and P-16065 were CAG-YF7, AJ7-YF597 and YFEB- 
YFIOO (see Chapters 3 and 4).
6.3 Results
6.3.1 Virulence in monkeys
Although this part of the study was performed by collaborators, it was 
important to determine the phenotype of P-16065 as a background to the 
sequence studies. A summary of the monkey studies is described below.
Male cynomolgus monkeys were inoculated i.e. with either P-16065, 
FNV or 17D-204 USA 6145. At day 12 post-inoculation a generalised 
weakness was observed in the limbs of the P-16065 infected monkey followed, 
on day 13, by total paralysis in both hind limbs. By 14 days post-inoculation
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this had extended to partial paralysis in the right fore limb and total paralysis 
in the remaining limbs, at which time the animal was sacrificed. During this 
time a parallel monkey inoculated with 17D-204 USA 6145 did not exhibit any 
signs of neurological involvement, and survived in a healthy state beyond 2 1  
days post-inoculation. In comparison, the monkey inoculated with FNV died 
on day 6  post-infection.
6.3.2 Nucleotide and deduced amino acid sequence of the £  
proteins of 17D-204 USA (6145) and P-16065
The nucleotide and deduced amino acid sequences of the E protein 
genes of the two viruses were determined. Differences between the two 
viruses are shown in Table 6.2. As can be seen, P-16065 differed from 17D- 
204 USA 6145 by only two nucleotides, at positions 1437 and 1880 (numbers 
refer to the 17D-204 sequence (Rice et al. , 1985)). At position 1437 an A in 
17D-204 USA 6145 is replaced with a G in P-16065, whilst at position 1880 
an A in 17D-204 USA 6145 is replaced with a C in P-16065. Both nucleotide 
changes proved to code for amino acid substitutions, resulting in a substitution 
from an aspartic acid at amino acid position 155 in the E protein of 17D-204 
USA 6145 to a glycine in P-16065 (resulting from the nucleotide change at 
position 1437), and from a lysine at amino acid position 303 in the 17D-204 
USA 6145 E protein to a glutamine in P-16065 (resulting firom the nucleotide 
substitution at position 1880).
189
Table 6.2: Nncleotide and amino acid differences between the envelope 
protein genes of 17D-204 USA (6145) and P-16065
Position 17D-204USA ^ Position 17D-204USA ^
n f  (6145) p -16065 ^  (6145) P'16065
1437 A G 155 D
1880 A C 303 K
Taken form the sequence of 17D-2G4 ATCC (RiceetâZ, 1985)
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In addition, clonal variation was observed at position 1718, where, in 
17D-204 USA (6145) (and also Asibi and 17DD viruses) an A was found. In 
initial sequencing, an A was also found at this position in P-16065 clones; 
however for one clone a G was clearly present. The other nucleotide changes 
described above for P-16065 were also seen in this clone, and no further 
additional differences were seen. This nucleotide change would code for an 
amino acid substitution at position 249 in the E protein. For reasons 
mentioned in the Discussion, this change may be significant. Hence, the 
region containing this change was subjected to further analysis. Further RT- 
PCR reactions were performed on the region (primers AJ7-YF597), utilizing 
the same stock of P-16065 derived from mouse brain, and a further five 
clones were sequenced over this region. However, none contained the 
nucleotide change at position 1718. Thus, only one out of a total of 8 cDNAs 
contained the nucleotide change at position 1718.
6.4 Discussion
Determining the nucleotide sequence of the E protein gene of P-16065 
and 17D-204 USA (6145) viruses is an important step in understanding the 
neurovirulent nature of P-16065; however without detailed studies previously 
performed on this virus the results would be difficult to interpret. In order to 
fully understand the nature of both the neurotropism and the slight antigenic 
differences exhibited by P-16065 as compared to 17D-204 USA (6145) it is
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first necessary to briefly discuss some of the studies previously performed on 
the two viruses.
P-16065 was available for study only as a stock that had been passaged 
3 times through suckling mouse brain (smb3). In order to perform antigenic 
studies it was passaged twice further, thus producing passage smb5. In order 
to ensure that any differences found between P-16065 and 17D-204 USA 6145 
were not due to the passage history of P-16065, 17D-204 USA was passaged 
5 times through suckling mouse brain (smb5), and a 17D-204 vaccine from 
the United Kingdom a further 14 times (smbl9) (Barrett, personal 
communication).
Barrett et al. (1990) have previously shown that P-16065 displays 17D- 
204 vaccine E protein epitopes (17D-204,17D and vaccine specific epitopes). 
The results obtained in the molecular analysis of the E protein genes of 17D- 
204 USA 6145 and P-16065 also suggest that the two viruses are very similar 
(see Table 6.2). This confirms previous analysis of the two viruses with E 
protein specific MAbs (Ledger, 1990). The two viruses were examined in IIF 
and PRNT tests with nearly 90 MAbs ranging from YF type-specific through 
flavivirus intermediate to fiavivirus group common (Ledger, 1990; Ledger et 
al. , 1992). Of these only three distinguished between the two strains; these are 
summarised in Table 6.1. MAb S24, a wild-type YF virus specific MAb 
raised against the South American wild-type YF strain B4.1 was positive in 
both nF and PRNT tests with P-16065, and also with the parent wild-type
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strain Asibi (and other wild-type YF viruses). MAb S24 failed to either 
neutralize or exhibit reactivity in IIF with 17D-204 USA (6145).
In contrast, MAb B26 (raised against the ITDD-Brazil vaccine strain) 
neutralized 17D-204 USA (6145) to approximately four logs, but did not 
neutralize P-16065, although the epitope appeared to be present on both 
viruses in IIF tests. Similarly, MAb F21, raised against the neurotropic 
vaccine strain FNV (described in Chapter 5) neutralized P-16065 but not 17D- 
204 USA (6145) virus; again IIF tests suggested that the epitope was present 
on both viruses. However, the failure of the vast majority of MAbs to 
distinguish between the two viruses confirms the vaccine-like nature of P- 
16065. In the majority of tests, especially with MAbs, P-16065 appears 
vaccine-like. These results indicate that P-16065 differs from 17D-204 USA 
6145 at a minimum of one epitope on the E glycoprotein, and that the 
biological activity of two epitopes present on 17D-204 USA 6145 are different 
to those on P-16065. It is noteworthy that F21 was raised against the 
neurovirulent FNV-IP vaccine strain, and also that this MAb demonstrates 
flavivirus intermediate specificity, recognising an epitope that is present on 
many fiaviviruses which demonstrate a neurovirulent potential (Barrett et al. , 
unpublished observations).
Further studies have examined the two viruses in vivo. It has been 
demonstrated that both are not disseminated in mosquitoes, in contrast to wild- 
type strains (Barrett, personal communication). The mouse virulence studies,
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however, were able to distinguish between the two viruses. Although both 
viruses killed adult mice with similar ASTs when inoculated by the i.e. route, 
it was found that i/n inoculation of virus showed P-16065 to be neuroinvasive. 
This virus killed mice with a pfu/LDgo of 10^  \  which is comparable with the 
virulence of Asibi small-plaque variant (10^ "* pfu/LD^o) (Barrett & Gould
1986), whilst 17D-204 USA 6145 failed to kill any mice when inoculated by 
the i.n. route (Table 6.3). P-16065 was used at the 5th passage in mouse 
brain, and it was possible that the increased neurovirulence of the virus was 
due to its passage history. To test this, two 17D vaccine substrains, 17D-204 
USA 6145 and 17D-204 UK were examined after 5 passages in suckling 
mouse brain, and the results indicated that such passaging of the virus was 
insufficient to account for any increase in neurovirulence. Although 17D-204 
UK did prove neuroinvasive following 19 passages in suckling mouse brain 
with 10^  ^  pfii/LDjo, this was 10-fold less virulent than P-16065 despite having 
had 15 more passages. Sodium aurothiomalate pretreatment of mice has been 
shown to enhance the neurovirulence of YF viruses, providing a useful 
technique for distinguishing closely related YF viruses (Gibson et a l ,  1990). 
However the use of this drug did not significantly alter the ASTs of mice 
inoculated with either virus (Barrett, personal communication). Table 6.3 
summarises the results of these in vivo studies in mice.
Furthermore, P-16065 was fully neurovirulent, causing almost total 
paralysis of a monkey by 14 days post-inoculation, whereas the original 
vaccine strain (6145) which had passed the WHO neurovirulence test in
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Table 6.3: Intranasal and intracranial virulence of 17D-204 and 
P-16065 stains in adult mice
Intracranial inoculation * Intranasal inoculation
Virus AST* (days± SEM) log 10 pfu/LDjQ AST (days± SEM)
17D-204USAsmbl NT# >5.1 -
17D-204USAsmb5 9.2+0.3 >53 -
17D-204UKsmb5 NT >5.1 -
17D-204UKsmbl9 NT 3.7 13.4+0.5
P-16065 8.5 ±0.2 2.8 14.6+0.7
* Mice were inoculated with 100 pfu of virus
AST - average survival time
NT - not tested
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monkeys prior to release also failed to demonstrate any neurovirulence in the 
monkey virulence study reported in this chapter.
Thus, the two viruses have been shown to be very similar in biological 
analysis with the neurovirulence of P-16065 being the major difference 
between them. Initial Tj oligonucleotide mapping of P-16065 and 17D-204 
USA 6145 viruses had indicated little or no apparent genetic change between 
the two viruses (Barrett, personal communication). Since P-16065 and 17D- 
204 USA 6145 were found to be very similar in most of the tests performed 
on them in previous studies, and those differences that were found appeared 
to relate to the E glycoprotein (altered tropism and altered reactivity with 
MAbs that recognise epitopes on the E glycoprotein) the portion of the 
genome coding for this gene was amplified and sequenced for P-16065 and 
compared with that of 17D-204 USA (6145). In view of the similarity of the 
two viruses it is not surprising that they are also similar at the molecular 
level, at least in the portion of the genome coding for the E protein. There 
were only two nucleotide changes coding for two amino acid substitutions 
(positions 155 and 303) between the E protein sequences of the two viruses.
At position 155 in the E protein, an aspartic acid is found in the parent 
Asibi, and also in the three 17D-204 vaccine viruses which have so far been 
sequenced over this region (Rice et al., 1985; Hahn et al., 1987; Dupuy et 
a l ,  1989; Post et a l ,  1992). However, in 17DD-Brazil (Post et a l ,  1992) 
and 17DD-Senegal (see Chapter 4), a serine is found, producing a further
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potential N-llnked glycosylation site. In P-16065, a glycine is present at 
position 155. Further amino acid substitutions in this region are found for the 
wild-type South American isolate, B4.1 (position 154) (Ballinger-Crabtree and 
Miller, 1989) and for both the neurotropic vaccine strain FNV (see Chapter 
5) and the 17D-204 WHO strain (Post et ah, 1992) at position 153. This may 
indicate that these amino acid positions are highly variable between stains of 
YF virus. The change at 155 in P-16065 does not give rise to a glycosylation 
site, as it does in the 17DD vaccine strains. These positions are also found in 
a region where a number of other fiaviviruses have ’gaps’ when the sequences 
of their E proteins are aligned (WN, and dengue viruses). However, the fact 
that the change found in P-16065 differs from that seen in 17D vaccine strains 
may be significant.
The substitution at position 303 from a lysine in the parent vaccine to 
a glutamine in the neurovirulent revertant is not found in other published YF 
virus E protein sequences, where a lysine is invariably found at position 303. 
A glutamine is not seen at the corresponding position for any other flavivirus 
so far sequenced. This change causes an alteration in the hydrophilicity of the 
E protein in this region (see below), and also alters the charge in this region. 
Since the MAbs used to distinguish between 17D-204 USA (6145) and P- 
16065 viruses recognise E protein epitopes (Ledger et ah, 1992), it would 
therefore appear that one or both of these substitutions (positions 155 and 303) 
is/are responsible for the change resulting in P-16065 gaining the epitope 
recognised by MAb S24 and the alteration in the biological properties of the
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epitopes recognised by MAbs B26 and F21. It is thus postulated that this 
change ( possibly in conjunction with the change at 155) is associated with the 
phenotypic marker associated with neurovirulence. Whether or not the change 
has an effect on the tropism and virulence of the virus cannot be assessed 
from the studies described in this chapter. However, it is interesting to note 
that in the attenuation of Asibi to 17D-204, substitutions in the E protein are 
found at positions 299 and 305. Figure 6.1 shows hydrophilicity plots for this 
region for Asibi, 17D-204, P-16065 and FNV viruses. It can be seen that the 
changes at 299 and 305 alter the hydrophilicity of the E protein in the 17D- 
204 virus as compared to Asibi virus. In P-16065 the additional change at 
amino acid 303 alters both the predicted structure (beta sheet) and also affects 
the hydrophilicity, such that the region between 299 and 305 becomes largely 
hydrophobic rather than hydrophilic, as is seen in the Asibi virus E protein. 
It is possible that these substitutions are instrumental in the attenuation of the 
virus, perhaps affecting receptor binding, and that the alteration at amino acid 
303 in P-16065, which is not accompanied by any other changes in that 
region, affects the receptor binding such that the tropism of the virus is 
altered, not to the original viscerotropism found in wild-type YF virus, but to 
neurotropism. The predicted hydrophilicity of the neurotropic FNV virus is 
identical to Asibi virus over this region. However these hypotheses could only 
be assessed by the use of site-directed mutagenesis of an appropriate infectious 
clone, or by expression and site-directed mutagenesis of the portion of the 
genome coding for the E protein of the virus. Position 303 in the YF virus E 
protein is located very near to one of the 12 cysteine residues (Cys^ °°) found
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Figure 6.1: Notes
Positive values represent hydrophilic stretches of amino acids.
Calculated using the Microgenie package.
Residues 271-330 in the E proteins of Asibi, 17D-204, P-16065 
and FNV viruses are shown. A change in hydrophilicity is seen 
between residues 299 and 307 in 17D-204 and P-16065 virus 
E proteins.
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Asibi
Figure 6.1: Hydrophilicity plots of a portion of
the E protein of yellow fever viruses
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in flavivirus E proteins, which are strictly conserved and are thought to be 
involved in stabilizing the antigenic domains proposed by Heinz et al. , 1990). 
Residue 303 forms part of domain B (as designated by Heinz (see Section 
1.5.5)), and this domain has been implicated in modulating pathogenicity in 
vivo, in TBE, MVE and JE viruses (Holtzmann et a l ,  1989; Lobigs et a l ,  
1990; Cecilia and Gould, 1991). In addition, this residue is located in a region 
which has been shown to be of greater than average variability when the 
sequences of the E proteins of fiaviviruses are aligned (Chambers et al., 
1990).
Of further interest is the appearance in one clone of P-16065 sequenced 
of a nucleotide change which would also give rise to an amino acid change at 
position 249. Although this change was only observed in one of eight clones 
sequenced over this region, and may be an RT-PCR or cloning artefact, the 
position and nature of the change make it difficult to dismiss it as such 
without further discussion.
In Chapter 5, an identical change is described in the E protein gene of 
the neurovirulent FNV virus at nucleotide 1718, which consequently also gives 
rise to the same amino acid, aspartic acid, being found in FNV and P-16065 
E proteins at position 249. The change will give rise to an alteration of the 
charge in that region of the E protein. Such a change, found in two YF virus 
strains which both exhibit neurotropic potential may be relevant, even though 
the change was observed in only one of eight clones in P-16065. The only
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other occasion on which a clonal difference was observed during these studies 
was seen in the structural protein genes of the wild-type YF strain, Y5, and 
is described in Chapter 7. In addition, the analogous amino acid found at this 
position in TBE viruses, which cause encephalitic disease, is also an aspartic 
acid. However, for mosquito-bome fiaviviruses, both viscerotropic and 
neurotropic, a serine is found at the analogous position. Amino acid 249 lies 
in Domain A as defined by Heinz et al. (1990). Domain A has been shown 
to undergo a pH-dependant conformational change (Guirakhoo et al., 1989), 
and is possibly involved in endocytic fusion of the virus (Chambers et al., 
1990).
The chance of a random nucleotide change during the RT-PCR and 
cloning of P-16065 producing an amino acid change identical to one in FNV 
is approximately 0.00008% or 1/13000, and hence this position is worthy of 
further study. The best way to proceed forward would be site-directed 
mutagenesis of an infectious clone.
All results obtained to date suggest that P-16065 is a non-attenuated 
neurovirulent virus which antigenically, genetically and biologically closely 
resembles the vaccine virus used in the immunization of the child. It is unclear 
how this variant virus arose; however there are three possibilities which would 
explain this. Firstly, it is possible that the vaccine virus killed the child due 
to an abnormal immune response allowing virus multiplication without host 
restriction. This seems unlikely, since P-16065 although closely related to
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17D-204 USA 6145 has been shown to genetically differ from it. The results 
of the monkey and mouse virulence tests suggest that the childs’ death was 
due to a neuroinvasive and neurovirulent revertant, rather than an inadequate 
immune response. The child had no history of immune problems, and was 
apparently healthy when vaccinated. She had previously received other 
vaccinations including smallpox with no side-effects. Although it remains 
possible that the passage of P-16065 five times in mouse brain altered the 
virus, such a process has not proved reproducible with 17D-204 USA (6145).
The second possibility is that the vaccine may have been 
heterogeneous, containing a small population of variant neurovirulent YF 
virions that were selectively enriched in the child. Whilst YF vaccine viruses 
are known to contain sub-populations (Liprandi, 1981), it would appear likely, 
if such a sub-population existed, that more individuals would have suffered 
from post-vaccinal incidents. Lot 6145 was used to inoculate several million 
people, in addition to the child and her parents prior to this incident, and 
many more subsequently. No other adverse reactions were reported (Barrett, 
1987). However, the possibility that some characteristic of the childs’ immune 
system allowed a sub-population to multiply and cause neurovirulence cannot 
be excluded. In addition the presence of a clonal variation seen in only one 
clone sequenced, but identical to a substitution seen in the neurovirulent FNV 
strain would perhaps add some weight to this possibility. Liprandi (1981) 
discovered that there were two main subpopulations within a 17D-204 UK 
vaccine; however a third minority population was detectable. Further,
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following one passage in mouse brain, the numbers of this subpopulation 
(which was lethal for mice when inoculated by the i.e. route) were enhanced. 
Gould et al. (1986) examined these subpopulations with MAbs and discovered 
that they could be distinguished from one another. In addition, just one 
passage of IE virus through different cell lines gives rise to amino acid 
changes in the E protein (H. Ni, personal communication), and passage of 
wild-type YF virus one or two times in HeLa cells gives rise to attenuated 
variants (Dunster 1990). However, whether or not these are due to the 
selection of sub-populations remains unclear. The fact that more clonal 
variation was not observed throughout these studies would suggest that such 
sub-populations are small, as virus was not plaque-purified prior to molecular 
analysis.
Passage of 17D-204 USA (6145) five times through mouse brain did 
not enhance it’s neurovirulence for mice (Table 6.3), and a further 14 
passages were required before 17D-204 UK virus began to exhibit enhanced 
neurovirulence. The passage of the FNV virus through mice brain over 250 
times can be assumed to have contributed to its’ neurotropic phenotype (see 
Chapter 5). If such sub-populations exist in 17D vaccines, then it appears that 
they are not easily selectable. In addition to the studies reported above, Meers 
in 1959 reported the passage of 17D virus in mouse brain and found that only 
after 17 such passages did the 17D vaccine become as neurotropic as the FNV 
virus. However, it is possible that some unusual event or series of events 
involving the childs’ immune system and the vaccine sub-populations could
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have allowed a neurovirulent sub-population to predominate.
The evidence reported previously suggests that P-16065 is a fully 
virulent neurotropic virus displaying a mutation in tissue tropism and/or 
virulence, situated on the E protein at a single epitope. From the studies 
performed in this Chapter it would appear that this epitope is either associated 
with amino acid 303, 155 or both (or possibly with amino acid 249. Since 
1966, greater than 250 million doses of 17D-204 vaccine have been 
administered, and only one further similar case has been reported (Schoub et 
al., 1990). Unfortunately, in that case, as stated in Section 6.1, no serological 
investigation was performed, and no virus was isolated from the patient, who 
recovered. Thus, the increased neurovirulence of P-16065 appears to be a 
property of the virus itself, but may have required the involvement of host 
factors in the child to arise.
The third possibility is that some virions in the vaccine may have 
mutated to produce a lethal revertant virus. The reason why such a mutation 
should have occurred is not clear; however the possibility of YF 17D-204 
vaccines giving rise to neurovirulent revertants in the future, by whatever 
mechanism, cannot be ignored. Since only two amino acid substitutions 
separate P-16065 and 17D-204 USA 6145 over the E protein, it is important 
that quality control of vaccine production is maintained at a high level. It has 
been suggested that the possession of the 17D-204 strain specific or vaccine 
epitope be used as a marker for the attenuation of virulence of YF virus and
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for vaccine production quality control. However, investigations with the 
neurovirulent P-16065 indicate that such a procedure should not be adopted. 
By this criteria P-16065 would pass as a vaccine strain. It is suggested that in 
addition to monkey neurovirulence tests, a combination of wild-type specific 
MAbs and the presence of neuroinvasiveness following i.n. inoculation of 
mice may be useful as potential indicators of neurovirulence in routine 
production screening protocols.
Unfortunately the importance or otherwise of the changes at positions 
155 and 303 cannot at present be assessed. Expression studies would perhaps 
help to determine which position is associated with the epitopes recognised by 
MAbs B26 and F21 and S24; however an infectious clone would be necessary 
to establish their importance in neurovirulent disease.
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Chapter 7
Comparison of the nucleotide and deduced amino acid 
sequence of the structural protein genes of the 
wild-type YF virus, Y5, with those of other YF viruses
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7.1 Introduction
Prior to these studies, the nucleotide and deduced amino acid sequence 
was available for only one wild-type YF virus from Africa; strain Asibi, 
which was isolated in Ghana in 1927, from which the 17D vaccines were 
derived (Rice et a l ,  1985). In addition, the sequence of the genes encoding 
the structural proteins, and also the non-structural protein NSl, of a South 
American wild-type YF virus, B4.1, had been determined and published 
(Ballinger-Crabtree and Miller, 1989).
F W  virus, another wild-type YF strain originating from Africa, was 
isolated at a similar location and time to Asibi virus (Senegal in 1927), and 
the sequence of the genes encoding its’ structural proteins is described in 
Chapter 5. Asibi and F W  proved to be very similar at both the nucleotide 
and the amino acid level over the portion of the genome encoding the 
structural proteins. It was thus decided that, in order to study the antigenic 
variation of wild-type YF virus over time, the structural protein genes of 
another African wild-type YF virus would be analyzed at the molecular level. 
A strain named Y5 was chosen for reasons described below.
Like F W , Y5 virus was isolated from Senegal. However, twenty-six 
years separated the isolation of the two viruses. F W , as described in Chapter 
5, was isolated from a human case of YF in 1927 (Mathis et ah, 1928); Y5 
virus was isolated in 1953, also from a human (Fitzgeorge & Bradish, 1980).
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Y5 virus was interesting in a number of ways. It appeared to be a relatively 
’mild’ strain of YF, causing a moderate form of viscerotropic YF disease in 
the human from which it was originally isolated, and subsequent experiments 
in vivo in mice confirmed this. Briefly, Fitzgeorge and Bradish (1980) found 
that Y5 virus-infected mice had extended average survival times and an 
increase in pfu/LDgg.
However, there was also another reason why Y5 virus was chosen 
rather than another African wild-type strain. Chapter 5 describes the presence 
of a "vaccine epitope", recognised by MAb H5, which was found to be 
present on the E proteins of both FNV and 17D vaccine viruses, despite the 
fact that there were no common amino acid substitutions found in their 
respective E proteins.
In order to demonstrate the relevance and potential importance of this 
epitope it is necessary to discuss in some detail previous work which utilized 
H5 and other MAbs to examine the E proteins of wild-type and attenuated YF 
viruses (Gould et al., 1985; Sil et a l ,  1992).
In Section 1.4.4 the attenuation of wild-type YF viruses by six or 
fewer passages through HeLa cells is described. This work was performed 
initially by Hardy (1963a and b), and repeated and extended by Barrett et a l
(1990). Following six passages in HeLa cells, three wild-type YF strains were 
found to be attenuated in mice (Asibi, F W  and B4.1 viruses), and in the case
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of the HeLa passaged Asibi virus, also in monkeys. In addition to in vivo 
studies, the original wild-type strains and their attenuated HeLa passaged 
derivatives were examined with E protein specific MAbs (Sil et ah, 1992). 
Table 7.1 summarises the reactivity of these MAbs with the attenuated HeLa- 
passaged viruses, the 17D and FNV vaccine strains, and also Y5 virus and 
other wild-type YF viruses.
From Table 7.1 it can be seen that the vaccine epitope recognised by 
MAb H5 is not only present on the E protein of the conventional vaccine 
strains (17D and FNV viruses), but also on the E protein of viruses which 
have been passaged through HeLa cells, and have been shown to have become 
attenuated in this process (Sil et ah, 1992). The specificity of the MAbs is 
shown, and it can be seen that there are four (S17, S18, S24 and S56) which 
recognise epitopes found only on wild-type YF viruses. The epitope 
recognised by MAb H5, and the epitope(s) recognised by MAbs S18 and S24 
appear to be mutually exclusive; the attenuated derivatives exhibit that 
recognised by MAb H5, irrespective of their method of attenuation (mouse 
brain (FW ), chick embryo tissue (Asibi) or HeLa cells (F W  and Asibi)), 
whilst the wild-type viruses exhibit those recognised by MAbs S18 and S24.
In addition, studies on MAb neutralization resistant escape mutants of 
wild-type YF virus strains treated with the wild-type YF virus specific MAbs 
S18 and S24 have shown that these viruses also exhibit the epitope recognised 
by MAb H5, and appear to have lost those recognised by MAbs S18 and S24
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(irrespective of which of these MAbs was used to produce them (Sil et al, , 
1992)). These MAbs have also been used to examine a wider range of wild- 
type stains of YF virus, from both South America and Africa, and in all cases 
these exhibit the epitopes recognised by MAbs S18 and S24 (which may 
recognise the same or closely related epitopes). From this work it appears that 
attenuation of YF virus is associated with the loss of the epitope(s) recognised 
by MAbs S18 and S24, and the appearance of that recognised by MAb H5. 
These epitopes are thus significant; if not in terms of the attenuation process 
itself then certainly as a marker associated with attenuated strains of YF virus.
In Table 7.1 it can be seen that the only wild-type YF virus which does 
not follow the pattern described above is Y5. As expected it displays the 
epitopes recognised by the wild-type specific MAbs S18 and S24, but in 
addition the epitope recognised by the vaccine (or attenuated-strain) specific 
MAb, H5, is also present in IIF and HAI tests (Sil, 1990). The presence of 
these two, otherwise mutually exclusive, epitopes is interesting, especially 
when, as described above, it is remembered that Y5 is an atypical strain of 
wild-type YF virus causing only a very mild form of disease in mice 
(Fitzgeorge and Bradish, 1980; Barrett and Gould, 1986).
In addition to the unique presence of both vaccine and wild-type 
epitopes, Y5 was also found to appear different to other strains of wild-type 
YF virus isolated from Africa in analyses previously performed using MAbs 
. Firstly, Gould et al. (1985) reported a number of MAbs raised against the
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FNV vaccine strain; one MAb (411) exhibited a pattern of reactivity 
identical to that described for MAb H5, in that it recognised an epitope 
present on all vaccine strains of YF virus examined, and also on Y5, but not 
any of the other 21 wild-type strains examined (Gould et ah, 1985). Whilst 
this MAb may recognise the same epitope as MAb H5, the data acts as 
independent evidence that Y5 is atypical. Secondly, in a study employing 
MAbs raised against both vaccine and wild-type strains of YF virus, Sil
(1991) found that Y5 tended to group separately from other wild-type YF 
viruses based on cluster analysis of HAI test results. The other wild-type YF 
strains examined in this study grouped together as South American or African 
isolates. Y5 was the only wild-type out of nine examined that did not follow 
the orthodox grouping.
The only other strain of wild-type YF virus for which sequence data 
was available, B4.1 (which was a plaque purified isolate of a Peruvian isolate 
of YF virus named 1899/81) (Mendez et ah, 1984), differed significantly 
from Asibi virus at the nucleotide level over the region encoding the structural 
proteins (8 6 .1 % homology); however many of the changes were silent, and 
the amino acid homology was much higher (96.3%). The majority of the 
amino acid differences were found in the E protein, although the highest 
percentage was found in the C protein (Ballinger-Crabtree and Miller, 1989).
The determination of the sequence of the genes encoding the structural 
proteins of Y5 virus would thus give the opportunity to compare them against
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two strains also isolated from Africa but pre-dating Y5’s isolation by 26 years. 
This third wild-type African isolate could also be compared against the South 
American wild-type virus, B4.1, and against the vaccine viruses (17D-204, 
17DD and FNV). For these reasons the structural protein genes of Y5 virus 
were analyzed at the molecular level, and the results obtained are presented 
and discussed in this Chapter.
7.2 Experimental work
All procedures used in this Chapter were performed as described in 
Chapters 2 and 3, unless otherwise stated.
7.2.1 Vims
Y5 was obtained from Dr. Roy Fitzgeorge, PELS, CAMR, UK. The 
virus was passaged once in SW13 cells to provide working stocks.
7.2.2 Primers, RNA, cloning and sequencing
Primers used were as described in Chapters 3 and 4. Y5 was amplified 
in vivo in mouse brain or tissue culture to provide RNA for RT-PCR (see
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Chapters 2 and 3).
7.3 Results
Two clones for each of the fragments covering the structural protein 
genes were sequenced; three were sequenced for the portion amplified by 
primers AJ7-YF597, as clonal variation was observed in this region. Briefly, 
two nucleotide differences were detected in the two clones containing cDNA 
prepared by RT-PCR. Thus, the procedure was repeated to identify the 
sequence in this region. Other than P-16065 virus, these nucleotide differences 
were the only ones identified by the sequencing of PCR fragments throughout 
the course of the thesis studies. The variation, at nucleotide 1696 was either 
a U or a C. In Asibi and F W  a C is found at this position, and in the third 
Y5 clone sequenced, a C was again found. The presence of a U at this 
position would not give rise to an amino acid substitution.
The nucleotide sequence and deduced amino acid sequence of the 
structural protein genes of Y5 virus is presented in Figure 7.1.
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Figure 7.1: Nucleotide and deduced amino acid 
sequence of the structural protein genes of 
the African wild-type YF virus, Y5
72 75  
TTAAc
IS O
TTTTAATCGTTGAGCGATTAGCAGAGAACTGACCAGAACmTGTCTGGTCGCAAAGCTCAGGGAAAGACCCTGGGC
M S G R K A Q G K T L G
2 2 5
GTCAATATGGTTCGACGAGGAGTTCGCTCCTTGTCAAACAAAATAAAACAAAAAACAAAACAAATTGGAAACAGA
V N M V R R G V R S L S N K I K Q K T K Q I G N R
3 0 0
CCTGGACCTTCAAGAGGTGTTCAAGGATTTATCTTTTTCTTTTTGTTCAACATTCTGACTGGAAAGAAGATCACG 
P G P  S R G V Q G F I F F F L F N I L T G K K I  T
3 7 5
GCCCACCTAAAGAGGTTGTGGAAAATGCTGGACCCAAGACAAGGCCTGGCTGTTCTGAGGAAAGTCAAGAGAGTG
A H L K R L W K M L D P R Q G L A V L R K V K R V
4 5 0
GTAGCCAGTTTGATGAGAGGATTGTCCTCAAGGAAACGCCGCTCCCACGATGTTCTGACTGTGCAATTTCTGATC
V A S L M R G L S S R K R R S H D V L T V Q F L I
5 2 5
CTGGGAATGCTGCTGATGGCGGGTGGAbTAACCTTGGTGCGGAAAAACAGATGGCTACTCCTGAATGTAACATCT 
L G M L L M A G G V T L V R K N R W .  L L L N V T S
6 0 0
GAGGACCTTGGGAAGACCTTCTGTGTGGGTACGGGCAACTGCACAACAAATATTTTGGAAGCCAAGTACTGGTGT
E D L G K T F C V G T G N C T T N I L E A K Y W C
6 7 5
CCAGATTCAATGGAATATAACTGTCCTAACCTCAGTCCAAGAGAGGAGCCGGATGACATTGATTGTTGGTGTTAC
P D S M E Y N C P N L S P R E E P D D I D C W C Y
p!>750
GGAGTGGAAAATGTCAGAGTTGCGTATGGCAAGTGTGACTCAGCAGGCAGGTCAAGAAGGTCAAGAAGAGCTATT
G V E N V R V A Y G K C D S A G R S R R S R R A I
8 2 5
GACTTGCCCACGCATGAAAACCATGGCCTGAAGACTCGGCAAGAAAAATGGATGACTGGAAGAATGGGGGAGAGG
D L P T H E N H G L K T R Q E K W M T G R M G E R
9 0 0
CAACTCCAAAAGATTGAGAGATGGCTTGTGAGGAATCCCTTCTTTGCAGTAACAGCCTTGACCATCGCCTATCTC
Q L Q K I E R W L V R N P F F A V T A L T I A Y L
9 7 5
GTGGGCAGCAACATGACGCAACGAGTCGTGATTGCCCTGCTGGTTTTGGCTGTTGGTCCGGCTTACTCAbcCCAC
V G S N M T Q R V V I A L L V L A V G P A Y S A H
1 0 5 0
TGCATTGGAATCACTGATAGGGATTTCATTGAGGGGGTGCACGGAGGAACCTGGGTTTCAGCCACCTTAGAGCAA
C I G I T D R D F I E G V H G G T W V S A T L E Q
1 1 2 5
GACAAGTGTGTCACTGTCATGGCCCCTGACAAGCCTTCACTGGACATCTCACTAGAGACAGTGGCCATTGACGGA
D K C V T V M A P D K P S L D I S L E T V A I D G
1200
CCTGCTGAGGCGAGAAAGGTGTGTTACAATGCAGTCCTCACTCATGTGAAGATCAATGACAAGTGCCCTAGCACT 
P A E A R K V C Y N A V L T H V K I  N D  K C P S T
1 2 7 5
GGTGAGGCCCACCTAGCTGAGGAAAATGAGGGGGATAATGCGTGTAAGCGCACTTATTCGGATAGAGGCTGGGGA
G E A H L A E E N E G D N A C K R T Y S D R G W G
1 3 5 0
AACGGCTGTGGCCTGTTCGGGAAAGGAAGCATCGTGGCATGCGCCAAATTTACTTGTGCCAAAACCATGAGCTTG 
N G C G L F G K G S I V A C A  K F T C A K T M S L
1 4 2 5
TTTGAGGTTGACCAGACAAAGATCCAGTACGTCATCAGAGCACAACTACATGTTGGGGCAAAGCAGGAAAATTGG
F E V D Q T K I Q Y V I R A Q L H V G A K Q E N W
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1 5 0 0
AACACCGACATCAAAACTCTCAAGTTTGATGCCATGTCAGGCTCTCAGGAAGCCGAGTTCACTGGGTATGGAAAA 
N T D I K T L K F D A M S G S Q E A E F  T G Y G K
1 5 7 5
GCTACTCTGGAATGTCAGGTGCAAACTGCAGTAGACTTTGGCAACAGCTACATCGCTGAGATGGAAAAGGAGAGC
A T L E C Q V Q T A V D F G N S Y I A E M E K E S
1 6 5 0
TGGATAGTGGACAGGCAATGGGCTCAGGATTTAACCCTGCCATGGCAGAGCGGCAGTGGTGGGGTGTGGAGGGAA
W I V D R Q W A Q D L T L P W Q S G S G G V W R E
1 7 2 5
ATGCACCATCTTGTTGAATTTGAACCTCCTCATGCCGCAACTATTAGAGTGCTGGCCCTAGGAAACCAGGAAGGC
M H H L V E F E P P H A A T I R V L A L G N Q E G
1 8 0 0
TCTTTAAAAACAGCCCTTACAGGTGCAATGAGGGTTACAAAGGACACGAATGACAACAATCTGTACAAACTACAT
S L K T A L T G A M R V T K D T N D N N L Y K L H
1 8 7 5
GGCGGACATGTCTCCTGCAGAGTAAAATTGTCAGCTTTAACACTCAAGGGGACATCTTACAAGATGTGCACTGAT
G G H V S C R V K L S A L T L K G T S Y K M C T D
1 9 5 0
AAGATGTCTTTTGTTAAGAACCCGACTGACACTGGCCATGGCACTGTTGTGATGCAGGTTAAAGTGCCAAAAGGA
K M S F V K N P T D T G H G T V V M Q V K V P K G
2 0 2 5
GCTCCCTGCAAGATCCCAGTGATAGTAGCTGATGATCTTACAGCGGCAATCAATAAAGGCATTTTGGTTACAGTT
A P C K I P V I V A D D L T A A I N K G I L V T V
2100
AACCCCATCGCCTCAACCAATGATGATGAAGTGTTGATCGAAGTGAATCCACCCTTTGGAGATAGTTACATTATA
N P I A S T N D D E V L I E V N P P F G D S Y I I
2 1 7 5
GTTGGGACAGGAGATTCACGTCTCACCTATCAATGGCACAAAGAGGGAAGTTCAATAGGAAAGCTGTTCACCCAG
V G T G D S R L T Y Q W H K E G S S I G K L F T Q
2 2 5 0
ACTATGAGAGGCCAGGAGCGCCTGGCTGTCATGGGAGACGCTGCCTGGGATTTCAGCTCTGCTGGAGGGTTCTTC
T M R G Q E R L A V M G D T A W D F S S A G G F F
2 3 2 5
ACGAAGACTTCGATTGGGAAAGGAATTCACACGGTGTTTGGCTCTGACTTTCAGGGACTTTTTGGTGGCTTGAGC 
T S  I  G K G  I  H T V F G S D  F Q G L F G G L S  W I
2 4 0 0
TGGATAGTCATCATGGGCGCGGTCCTTATATGGGTCGGCATCAACACAAGGAACATGACAATGTCCATGAGCATG
T K V I M G A V L I W V G I N T R N M T M S M S M
2 4 5 2
ATCCTAGTAGGAGTGATCATGATGTTCTTGTCTCTGGGAGTTGGGGCG
I L V G V I M M F L S L G V G A
^ c lœ tid e  numbers are taken from the published sequence of 17D-204 (ATCC) (Rice et al.,
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7.4 Comparison of the nucleotide and deduced amino acid sequence of 
the structural proteins of Y5 with those of other wild-tvne YF 
strains
As mentioned in the Introduction to this Chapter, the structural protein 
genes of three other wild-type YF strains were available; Asibi (Hahn et al. ,
1987), F W  (see Chapter 5) and B4.1 (Ballinger-Crabtree & Miller, 1989). 
Table 7.2 summarises the number and percentage of nucleotide and amino 
acid differences between these three and Y5 virus over the structural proteins. 
It can be seen that at the nucleotide level Y5 differs relatively greatly from the 
other three wild-type YF viruses, with the biggest variation seen in the prM 
protein between Y5 and the other two African wild-type viruses (11.2%), and 
in the E protein when compared to the South American virus, B4.1 (16.1%). 
The greatest total variation is seen between Y5 and B4.1 viruses. The 
nucleotide homology seen between these two viruses is less than 90% in all 
four structural proteins (C, prM, M and E). The greatest variation is seen 
over the E protein, where the two viruses differ by over 16%. Y5 differs from 
the other two African wild-type viruses by approximately 8.5% over the total 
length of the structural protein genes, and from the South American wild-type 
virus by nearly 15%. An alignment of the nucleotide sequences of the four 
wild-type viruses showing the positions at which they differ is presented in 
Appendix 1.
However, in comparison to the large numbers of nucleotide
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differences, there are relatively few amino acid differences observed between 
the three African wild-type viruses (Y5, F W  and Asibi) (10 to 12 amino 
acids, 1.4 to 1.8%), although all differ to a larger extent from the South 
American virus, B4.1 than other African viruses. Compared to the other 
African viruses, the E protein of Y5 shows a greater variation at the amino 
acid level than either C, prM, or M proteins. No variation between the 
portion of the 5’ non-coding region sequenced (nucleotides 72-118) was seen 
between Y5 and the other wild-type African viruses, although B4.1 does differ 
over this region by three nucleotides, at positions 80, 117 and 118.
Table 7.3 lists the positions over the C, prM and M proteins at which 
the four strains differ, whilst Table 7.4 compares the E proteins of the four 
strains. From these tables it can be seen that unique amino acids for Y5 are 
found at amino acid position 119 in the C protein, and positions 124, 164, 
215, 325, 405, 407, 416, 430, and 441 in the E protein.
Figure 7.2 shows a cluster analysis of the four wild-type YF strains, 
based on the nucleotide sequence homologies of their structural protein genes, 
whilst Figure 7.3 shows a cluster analysis based on the amino acid sequences 
of their structural proteins. It can be seen that F W  and Asibi viruses group 
together, as expected from their similarity (see Chapter 5) in both Figures, 
and, although Y5 is separate from them, it is closer to the African viruses 
than it is to the South American isolate, B4.1. The greatest divergence seen 
in both cases is in B4.1 virus, which exhibits homologies of 85% at the
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Table 7.3: Amino acid difilerences between wild-type YF viruses over
C, prM and M proteins
Position* Y5 Asibi ♦ F W  B 4 .f
CIS R R R a
C39 G G R G
055 V V V I
€59 K K K R
067 R R R K
€70 K K K R
€82 R R R K
€103 H H H Y
€104 D D D E
€119 A T T T
prM7 N N N S
prM39 Y Y Y N
M48 T T T A
* Position refers to protein and amino acid number in that protein, with the 
N-terminal amino acid defined as 1.
* Taken from Hahn etal. , 1987
^Taken from Ballinger-Crabtree and Miller, 1989
221
Table 7.4: Amino acid differences between wild-type YF viruses over
over the E protein
Position Y5 Asibi* F W B 4 .f
62 N N N s
90 N N N H
124 1 S S S
142 Q Q Q E
154 T T T A
164 M L L L
191 G G G s
215 M L L L
227 E E G E
243 R R R K
270 D D D G
271 N N N s
318 V V V A
325 A P P P
331 K K R R
335 I I I w
343 A A A S
344 F F F V
360 D D D E
405 R K K K
407 Q. V V A
416 1 A A A
430 I V V V
436 I M M M
441 D A A A
450 S N N S
468 T T T M
See legend of Table 7.3 (opposite)
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Figure 7.2: Cluster analysis of wild-type YF viruses based on the 
nucleotide homologies of their structural protein genes
Asibi
F W
Y5
B4.1
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Figure 7.3: Cluster analysis of wild-type YF viruses based on the 
amino acid homologies of their structural proteins
Asibi _
F W  J
Y5
B4.1
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nucleotide level, and nearly 5 % at the amino acid level when compared to Y5. 
It is noteworthy that the wild-type YF viruses F W  and Y5, which were 
isolated from the same country but 26 years apart, differ from each other by 
8.6% at the nucleotide level, but only 1.5% at the amino acid level.
7.5 Comparison of the sequence of the E protein gene of Y5 with those 
of other YF viruses
Table 7.5 shows the number of nucleotide and amino acid changes 
observed over the structural proteins between Y5 and those YF vaccine 
viruses that have been sequenced: FNV (Chapter 5), 17D-204 (Hahn et al., 
1987; Dupuy et al., 1989) and 17DD (Chapter 4; Post et ah, 1992). The 
amino acids of the other three wild-type viruses are also shown at these 
positions, but Table 7.5 does not include those positions at which variation is 
seen in the wild-type viruses other than Y5 virus for the sake of succinctness. 
The level of nucleotide homology that Y5 exhibits over the structural protein 
genes with F W , Asibi, 17D-204, 17DD and FNV is similar at around 
91.5%.
However, at the amino acid level, the most similar viruses to Y5 are 
the two African wild-types, F W  and Asibi (Figure 7.3). FNV and 17D-204 
viruses both have 22 amino acid differences (2.8% divergence), whilst the two 
17DD vaccine viruses differ by 21 amino acids from Y5 (2.7% divergence).
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Table 7.5: Positions in the stmctnral proteins where Y5 virus differs from
vaccine strains of YF vims
Position Y5 FNV 17D-204* 17DD F W Asibi* B4.1
C80 V A V V V V V
C90 s G S s s S s
C119 A T T T T T T
prM25 V M V V V V V
M35 L F F F L L L
E52 G G R R G G G
E54 A V A A A A A
E56 A A V A A A A
E84 E K E E E E E
E124 I S S S S S S
E142 Q R Q Q Q Q R
E153 N K N N N N N
E155 D D D s D D D
E164 M L L L L L L
E170 A A V V A A A
E173 T T I I T T T
E200 K K 1 I K K K
E215 M L L L L L L
E249 N D N N N N N
E299 M M I I M M M
E305 S S F F S S S
E325 A P s P
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P P P
Table 7.5: ..continued
Position Y5 FNV 17D-204* 17DD F W Asibi* B4.1
E331 K R R R R K R
E380 T T R R T T T
E405 R K K K K K K
E407 Q. A V V V V A
E416 T A T V A A A
E430 I V V V V V V
E441 D A A A A A A
E450 s N N N N N s
E457 M I M M M M M
Position refers to protein and amino acid number in that protein, with the 
N-terminal amino acid defined as 1.
*  Taken from Rice eta l ,1985.
* Taken from Hahn etal. , 1987
’'‘Taken from Ballinger-Crabtree and Miller, 1989
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From Table 7.5 it can be seen that most of those changes described as 
unique to Y5 when compared against the other wild-type viruses, are also 
unique when comparisons are made with the vaccine strains, namely those at 
position 119 in the C protein and at positions 124, 164,215,405, 430 and 441 
in the E protein. However, at a number of positions there is a range of amino 
acids seen; for example in the E protein at positions 325, 407 and 416. The 
variation seen at these positions will be examined in the discussion.
7.6 Discussion
Since Y5 was the first African wild-type virus isolated since 1927 for 
which sequence data was determined, it was difficult to have prior 
expectations about the similarities or differences that would be observed. In 
comparison to YF vaccine virus, wild-types have been poorly studied, 
especially with MAbs. It was known that Y5 was unusual for a wild-type virus 
in that it exhibited both vaccine and wild-type epitopes simultaneously, and 
also that it was a weakly virulent strain for mice.
However, the number of changes observed at the nucleotide level was 
higher than anticipated, with the homology between Y5 and the other two 
wild-type Afiican strains, F W  and Asibi being just over 90%, whilst that 
between Y5 and the South American wild-type strain B4.1 was just over 85 %.
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However, at the amino acid level, Y5 appeared much more similar to 
the other African wild-type viruses. Both the majority and the highest 
percentage of amino acid variation was seen in the E protein when the three 
African wild-types were compared (see Table 7.2). Although B4.1 showed the 
greatest variation to the African wild-types at the amino acid level in the C 
protein, several of the changes observed in this protein proved to be 
conservative replacements that would not be predicted to affect the structure 
of the protein (see below). In the following pages the implications and 
relevance of the variation among YF viruses at the molecular level is 
discussed with respect to each of the four structural proteins.
C protein: Over the C protein there are 10 amino acid positions at 
which variation is observed in wild-type YF viruses (see Table 7.3). As 
mentioned in Chapter 5, the C protein is a highly positively charged protein 
in which the residues arginine and lysine are common. At four of the positions 
where B4.1 differs from the African wild-type viruses, the change is from an 
arginine to a lysine or vice versa (positions 59, 67, 70 and 82). The 
substitution of a positively charged amino acid with another would therefore 
presumably not affect the structure or function of the protein to a large 
degree. It is possible that the variation of these residues could be a 
characteristic of South American and African strains which have evolved 
separately for a long period of time.
At position 18 a positively charged arginine is found in the African
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wild-type viruses, and a glutamine in the South American virus, B4.1. At 
position 39, a positively charged residue, arginine is observed in F W , but an 
uncharged glycine in the other three wild-type viruses. The difference at 
position 18 means that, in that region, the C protein of African viruses is 
hydrophilic whilst than that of the South American virus, B4.1, is neutral. The 
change at position 39 reduces the hydrophilicity in FW  ^compared to the other 
three wild-type viruses, but the region remains hydrophilic. It is difficult to 
predict what effect, if any, these changes would have on the function of the 
C protein.
The change at position 119 in the C protein observed in Y5 virus
(where an alanine is seen as opposed to a threonine in the other YF virus
strains) is interesting, as this falls within the cleavage site between C and prM
(Chambers et al. , 1990). The consensus cleavage sequence for YF viruses
based on the results presented in this thesis and those previously published is
LLMTGG $ VTLVRK. The enzyme which effects cleavage at this site is
thought to be a host-specified signalase (see Section 1.5.4). However, in Y5,
the threonine preceding the cleavage point is replaced with an alanine to 
«
produce the sequence LLMAGG $ VTLVRK. This is the first cleavage site 
which has been shown to differ among YF viruses. However the signalase 
enzyme exhibits a preference for small neutral residues in the -1 and -3 
positions in the cleavage site. The change observed in Y5 virus is at the -3 
position, and both alanine and threonine are amino acids discovered to be 
acceptable at this site by von Heijne (1984). At the analogous position in other
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flaviviruses, such as Den-1, JE, MVE and SLE viruses, an alanine is also 
seen. However, such a change is an interesting point, perhaps reflecting on 
the evolution of African YF viruses since 1927, when F W  and Asibi were 
isolated.
Although the African wild-type viruses were very similar at the amino 
acid level across the C protein, the South American virus B4.1 did differ to 
a much larger degree despite the fact that many of the changes would not 
affect the charge of the protein as described above.
prM: Table 7.2 shows that, over the structural protein genes, the
highest nucleotide divergence is seen in the prM protein gene between Y5 and 
the other African wild-type viruses, Asibi and F W , with homologies of less 
than 90%. The genes encoding the "pr" portion of the M proteins of Y5 and 
B4.1 exhibit only 85% homology. However, this does not result in a large 
number of amino acid changes, even when the South American virus is 
compared with the African ones. In fact, over the prM proteins, all three 
African isolates have an identical amino acid sequence to one another, and 
B4.1 only differs from them at two positions. One is at amino acid 7, where 
the asparagine found in the African viruses is replaced by a serine in the B4.1 
virus. Although this position is close to the N-terminus of prM, it is in fact 
just outside the cleavage site mentioned above. The other difference is at the 
39th residue in the M protein, where the tyrosine seen in the African viruses 
is replaced by an asparagine in B4.1 virus. Neither change appears to have a
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substantial effect on the predicted hydrophilicity of the prM protein. It is 
interesting that, in all wild-type YF viruses so far sequenced, the prM protein 
appears to be highly conserved at the amino acid level, and that the 26 years 
separating the isolation of F W  and Asibi viruses from Y5 virus have not 
resulted in any amino acid changes in this region, although the nucleotide 
homology observed in the genes encoding them is less than 90%. However, 
the true function of the "pr" portion of the M protein and the fate of it in 
flavivirus infected cells remains unclear.
M protein: A similar situation is observed in the M protein gene. 
Again, the nucleotide divergence between Y5 and the two earlier African 
strains is high (nearly 10%), but once again the amino acid sequences of the 
three viruses are identical over this region. As in the prM protein, B4.1 
differs from the African viruses in the M protein at just one amino acid 
position, number 48, where the substitution of an alanine by a threonine is 
observed in the South American virus. Despite the fact that both prM and M 
are relatively small proteins, it is interesting that they appear to be highly 
conserved in isolates which are separated by decades and are from different 
continents. Although these two proteins are small, the number of nucleotide 
changes observed in them is high; the highest percentage divergence in the 
structural protein genes is observed in prM between Y5 virus and the other 
two African viruses (11.2%). It is difficult to speculate on the importance of 
this apparently strict conservation. It may be that the proteins that these genes 
encode are specifically required in an exact conformation or role that allows
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little variation in YF viruses. There is obviously a degree of mutation 
occurring in these two proteins at the molecular level, as a large number of 
silent nucleotide substitutions are seen; however there appears to be little 
variation at the amino acid level. It is also interesting to note that this 
conservation appears to have been maintained in the processes that lead to the 
attenuation of both FNV and 17D vaccine viruses. The 17D vaccine substrains 
are identical to their parent, Asibi virus, at the amino acid level over the C 
and prM proteins, and exhibit only one amino acid substitution in the M 
protein. The FNV vaccine virus displays three amino acid differences from 
its’ parent F W  over the C protein; two are conservative and the other is at 
a position (residue 39) where the amino acid found in FNV is the same as 
that found in all other YF viruses sequenced to date. However, in the prM and 
M proteins, the same pattern of high conservation is seen, with just one amino 
acid substitution seen in each. However, the number of nucleotide changes is 
very much smaller. It is also interesting to note that, in the M protein, the 
amino acid found at position 35 in the wild-type Y5 virus is a leucine. In 
Chapter 5 it was reported that both 17D and FNV vaccine viruses share a 
common substitution (phenylalanine) at this position from the leucine also seen 
in Asibi and F W  viruses. The results obtained from Y5 virus have shown 
that a leucine is also found at M35 in a third African wild-type virus; leucine 
is seen at M35 in the South American wild-type virus, B4.1, too. In addition, 
unpublished data on a fourth African wild-type virus, Dakar1279, also report 
a leucine at position M35 (Venn, personal communication). Thus a leucine 
has been observed at this position for all five wild-type viruses for which data
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is available (FW , Asibi, Y5, B4.1 and Dakarl279), and a phenylalanine is 
found in all four attenuated vaccine viruses so far studied (FNV, 17DD- 
Senegal, 17D-204 ATCC and 17D-204 France). Furthermore, this amino acid 
is in a region of the M protein which is hydrophilic, and as such might be 
more likely to be involved in interactions with the host system. It would 
therefore seem that this particular change is worthy of further study.
E protein: In comparison with the C, prM and M proteins, the number 
of changes seen between Y5 and the other two wild-type African viruses in the 
E protein at both the nucleotide and amino acid level are relatively high. 
However, the E protein is the largest of the structural proteins. Table 7.2 
shows that at the nucleotide level, the homologies observed between Y5 and 
F W  and Asibi are around 91%, a figure similar to those seen for prM and 
M. However, in the E gene, more of these give rise to amino acid differences, 
and the homologies are the lowest for the E protein at the amino acid level 
between the viruses over the structural protein genes (with a divergence of 
over 2% observed). When the African viruses are compared to the South 
American wild-type, B4.1, the difference is even greater, with 221 nucleotides 
differing in the E protein gene between Asibi and B4.1. There are 18 amino 
acid differences between the E proteins of the two viruses, giving a divergence 
of 14.9% at the nucleotide level and 3.7% at the amino acid level. The figures 
for Y5 as compared to B4.1 are even greater; 238 nucleotides and 25 amino 
acids (16% and 5% difference respectively). Thus the differences observed in 
Y5 when compared to the earlier African wild-type isolates, F W  and Asibi,
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do not result in Y5 being genetically and antigenically closer to the South 
American wild-type virus. Some aspects of the similarities and differences of 
the four wild-types, and also the sequence of Y5 virus E protein when 
compared to attenuated YF viruses are worthy of further mention.
Firstly, it is significant that there are no amino acid differences 
between the four wild-type strains over amino acids 98-111, the region which 
is highly conserved in the E proteins of all flaviviruses so far sequenced , and 
which is proposed to undergo a pH dependent conformational change and to 
be involved in acid-catalysed fusion of the virus (Roehrig et al. , 1989; Heinz 
et a l ,  1990). When comparisons are extended to the attenuated vaccine 
viruses, this axiom still holds true. Such a result is not surprising however, 
if this region is important in acid-catalysed fusion, as the structure of the 
protein in this region would presumably have to be preserved to allow the 
requisite conformational change to occur.
One of the differences observed between the E proteins of South 
American and Afiican isolates of YF virus is their electrophoretic mobility 
and carbohydrate content (Deubel et ah, 1987), suggesting that there are 
differences in glycosylation of the E protein between these viruses. Ballinger- 
Crabtree and Miller (1989) demonstrated that the E protein of the South 
American virus, B4.1, was heavier than that of Asibi virus, and that treatment 
with tunicamycin (which blocks glycosylation of proteins), resulted in the E 
protein running at the same level as that of Asibi in radio immune
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precipitation (RIP) reactions. Asibi and F W  viruses contain potential 
glycosylation sites in their E proteins at positions 309 and 470 (sequence: N- 
X-S/T). However, that at position 470 is located in the hydrophobic C- 
terminal portion of the E protein, and hence is unlikely to be utilized. The 
published sequence of B4.1 reveals the presence of a third potential 
glycosylation site, where the presence of a serine at position 271 allows the 
asparagine at 269 to form part of a potential glycosylation site. It was 
postulated that this site might be responsible for the differences in E protein 
mobilities observed between South American and African YF viruses 
(Ballinger-Crabtree and Miller, 1989). In Y5, an asparagine is found at 
position 271, as it is in Asibi and F W  viruses, thus confirming the similarity 
of the African viruses in this respect, and the lack of a glycosylation site at 
this position. None of the amino acid differences seen in Y5 as compared to 
the other wild-type viruses either create or destroy potential glycosylation 
sites.
As there are a large number of positions at which amino acid variation 
is seen between Y5 and the other African wild-type viruses over the E protein 
(more than are seen during the attenuation of F W  to produce FNV), it is 
difficult to speculate on their relevance to the biology of the virus. However, 
the comparisons shown in Tables 7.4 and 7.5 reveal some interesting points.
At position 325 three different amino acids can be found in YF viruses. 
Usually a proline is seen (17DD, F W , Asibi and B4.1 viruses), but in 17D-
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204 a serine is found, and in Y5 an alanine is present at this site. There are 
two other positions in the YF virus E protein at which there is a variation of 
three amino acids seen. These are 407 and 416. At position 407, a valine is 
seen in the 17D vaccine viruses, and the two wild-type viruses, Asibi and 
F W . In FNV and B4.1 viruses there is a conservative substitution, and an 
alanine is observed. However in Y5, a non-conservative change is seen, with 
a glutamine present. This alters the hydrophilicity of the E protein in this 
region. It is also interesting to note that in other mosquito-bome flaviviruses, 
a valine is invariably found in this position. It is therefore interesting to find 
a relatively high degree of variation among the strains of one mosquito-bome 
flavivirus.
At position 416 a similar conservation is seen throughout mosquito- 
bome flavivimses so far sequenced, where a threonine is found, as it is in the 
17D-204 vaccine strain, and in Y5. However, in FNV, Asibi, F W  and B4.1 
an alanine is seen, whilst in 17DD vimses a valine is seen. Again, this is a 
high degree of variation at a position which does not appear to vary among 
other mosquito-bome flavivimses. Hydrophilicity studies show that all three 
amino acid positions (325, 407 and 416) are located in regions of the E 
protein which are predicted to be hydrophilic.
The results presented in this Chapter reinforce the difference of Y5 
vims at the molecular level, both to other African wild-type YF vimses, and 
also to the South American wild-type, B4.1, and confirm the results obtained
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by Sil (1991) in antigenic studies. It is difficult to speculate which amino acids 
which may be responsible for the vaccine epitope recognised by MAb H5, 
which is present on Y5 alone of the wild-type YF virus strains examined, and 
also found on YF virus strains which have been attenuated by very different 
processes (see Section 7.1). It seems likely that a single amino acid is not 
responsible for this epitope, as there is no common amino acid change found 
in the vaccine viruses and Y5 E proteins, compared to the other wild-types. 
It is possible that amino acid 416 is involved in this epitope, as Y5 shares an 
amino acid, threonine, with 17D-204 and 17DD vaccine viruses, although 
different from Y5 and 17D-204 (valine) is also different from Asibi, F W , 
FNV and B4.1 viruses, which have an alanine present at this position. 
However, an alanine is also found in the FNV virus, and hence it is unlikely 
that 416 is the amino acid involved in the vaccine epitope in the FNV E 
protein. Changes at amino acids 315 and 407 are also deserving of further 
investigation.
Further studies are required to determine whether or not the amino acid 
at M35, and that at E416 are important in attenuation, and if E416 is involved 
in the vaccine epitope. However, the results presented in this Chapter are 
important in demonstrating that, although wild-type YF viruses from Africa 
differ to quite a large extent at the nucleotide level over the structural protein 
genes, this is not reflected in such a large variation at the amino acid level. 
Also the relative invariability of the prM and M proteins in both wild-type and 
vaccine YF viruses is confirmed.
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Chapter 8
Molecular analysis of the NS2a protein genes of 
wild-type and vaccine strains of yellow fever virus
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8.1 Introduction
The studies performed and described in the previous chapters have 
concentrated on the structural protein genes of YF virus strains. This was 
because these genes (C, prM/M and E) encode the flavivirus structural 
proteins which are the most studied and best understood of flavivirus proteins. 
They also undergo significant interactions with the host system; for example 
the E protein is the major antigenic and immunogenic determinant of 
flaviviruses (Heinz, 1986), and M is also known to interact with host cells 
(Brinton, 1986).
The genes encoding the non-structural proteins (NSl, 2a, 2b, 3, 4a, 4b 
and 5) comprise three-quarters of the genome. As stated in Chapter 1, they 
are relatively poorly studied and understood in comparison to the structural 
proteins. However they play an important role in virus replication, and are 
worthy of further examination.
This Chapter describes the examination at the molecular level of the 
gene encoding the NS2a protein of YF virus strains. NS2a was chosen for a 
number of reasons; mainly since that this gene exhibited the greatest 
divergence of all the viral proteins at a percentage level in the attenuation of 
the wild-type Asibi virus to give rise to the 17D-204 vaccine strain. In 
addition, the percentage differences seen in the structural genes of the viruses
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discussed previously could be compared with those found in this non-structural 
gene. The gene encoding NS2a in YF virus is 501 nucleotides in length, and 
thus the protein it gives rise to is 167 amino acid residues in total. Between 
Asibi and 17D-204 viruses there were six nucleotide changes, giving rise to 
five amino acid substitutions (Hahn et al. , 1987). The percentage differences 
are 1.2% and 2.99% respectively. It is interesting to note that not only is 
there such a relatively high degree of divergence (the respective figures for the 
E gene and protein are 1.01% and 2.42%), but also that 5 of the 6 nucleotide 
changes give rise to amino acid substitutions. In other non-structural genes 
(NS3 and NS5) there are more nucleotide differences, but most are silent 
changes. Only the E protein exhibited a similarly high ratio of nucleotide 
changes resulting in amino acid substitutions to silent changes.
As mentioned briefly in Chapter 1, NS2a is a small protein which 
exhibits regions of hydrophobicity, suggesting that it is membrane associated 
(Chambers et al., 1990). Relatively little has been published on NS2a, and 
sequence data is only available for the Asibi strain (Rice et al. , 1985) and two 
17D-204 viruses (ATCC and France (Hahn et al. , 1987; Dupuy et al. , 1989)). 
The latter are identical over this region. Sequence data from other members 
of the Flaviviiidae suggests that the regions of hydrophobicity in the NS2a 
protein are well conserved, although the actual residues themselves are not. 
Studies on the NS2a protein of dengue virus (Falgout et al. , 1989) suggested 
that the N-terminal portion was important in the cleavage of NSl from NS2a, 
perhaps acting in cis\ however the mechanism involved was unclear. More
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recently, using expression of WN virus gene cassettes in vaccinia virus, it was 
found that the presence and proper processing of the NS2a-NS2b-NS3 region 
was necessary for the efficient cleavage of C-prM by signalases to occur 
(Yamshchikov and Compans, 1993). The significance of this remains unclear.
Despite the fact that the nature and function of NS2a is not well 
understood, the variation observed in this protein between 17D-204 and Asibi 
viruses indicates that it is worthy of further study. In addition, any data 
obtained would be the first sequence data for the non-structural proteins of 
other YF strains apart from the two 17D-204 vaccine strains and their parent, 
Asibi virus. Therefore the genes encoding the NS2a proteins of a number of 
YF virus strains were amplified by RT-PCR, cloned and sequenced, and the 
results obtained are presented and discussed below.
8.2 Evperimental work
All methods and procedures used were as described in Chapters 2 and 
3 unless stated otherwise.
8.2.1 Viruses
The viruses examined were: the wild-type/vaccine pair F W  and FNV
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(described in Chapter 5); the 17D-204 vaccine strain produced in the United 
Kingdom by Wellcome Laboratories, batch number not known (17D-204 UK); 
and the wild-type virus Y5 (described in Chapter 7).
8.2.2 Primers
The primers employed were described in Chapter 3, and their 
sequences and the positions to which they anneal to the published Asibi virus 
RNA (Hahn et al., 1987) are shown in Table 8.1.
8.2.3 RNA
The RNA produced for the virus strain examined has been mentioned 
in previous Chapters, except for that of 17D-204 UK, which was extracted 
from tissue culture fluid with the aid of tRNA as a carrier as described in 
Chapter 2.
8.3 Results
The region of the genome encoding the NS2a protein was examined for 
four virus strains: the wild-type viruses F W  and Y5 (see Chapters 5 and 7),
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Table 8.1: The sequences, positions and annealing temperatures 
of primers used for amplifying the NS2a gene of YF virus during this study
Primer Name Orientation Position Sequence
Predicted Annealing 
Temperature Ç C)
YF200
YF201
YF202
YF220
Sense 3604-3624 5’-TGGAGGAGTAGTGCrCITGGG-3’ 61
Antisense 4199-4219 5'-TAGACCAGCTGCTGCGAGTGC-3' 63
Antisense 3920-3939 5’-GCnTCCTAGAAGCAACAGC-3’ 55
Sense 3889-3908 5’-TGCAGTTTCrcrCTGCATCC-3’ 55
Position refers to the published 17D-204 (ATCC) sequence (Rice^/a/ . 1985)
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and the vaccine strains FNV (see Chapter 5) and 17D-204 UK. For each virus 
duplicate clones were sequenced. An alignment of the nucleotide sequences of 
the NS2a genes of the four viruses examined, together with those published 
for Asibi (Hahn et ah, 1987) and 17D-204 ATCC (Rice et al., 1985) viruses 
is shown in Figure 8.1.
8.3.1 Comparison of the NS2a protein genes of FW  and
FNV
Table 8.2 shows the nucleotide and amino acid positions in the NS2a 
protein gene at which the wild-type F W  and its’ vaccine derivative FNV 
differ. It can be seen that there are eight nucleotide changes over the NS2a 
protein gene, which is 501 nucleotides in length. These lead to three amino 
acid substitutions, at positions 25, 48 and 122 over the NS2a protein which 
is 167 residues in length.
8.3.2 Comparison of the NS2a protein gene of 17D-204 UK
with that of other 17D-204 vaccine viruses
The analysis of the 17D-204 vaccine strain produced by Wellcome 
Laboratories in the United Kingdom confirmed the low level of variation 
between 17D-204 viruses at the molecular level which was mentioned in
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Figure 8.1; Alignment of the nucleotide sequences
of the NS2a protein genes of YF viruses
3740
A s i b i  GTGGGATTGCATTTCCATGAGATGAACAATGGAGGAGACGCCATGTATATGGCGTTGATT
F W  .................................................................................................................................................. ..
FNV............ C ............
1 7 0 -2 0 4  ..........................................................................................................................................................
Y5  C . . T ................................................................... C ..............................
3800
A s i b i  GCTGCCTTTTCAATCAGACCAGGGCTGCTCATCGGCTTTGGGCTCAGGACCCTATGGAGC
F W  ..........................................................................................................................................................
FNV  G...................................................................................................... ..
1 7 0 -2 0 4   .....................................................................................................................................................
Y5  G............T ............................................... T ............G . . G ...............
3860
A s i b i  CCTCGGGAACGCCTTGTACTGACCCTAGGAGCAGCCATGGTGGAGATTGCCTTGGGTGGC
F W ............  G............................................................................................................
FNV  G....................G . . . G  G  ........................................................................
1 7 0 -2 0 4  .  .........................................G........................................................................................................
Y5............... G .................... G. .A ...C ....................................A. . .C .................. T
3920
A s i b i  ATGATGGGCGGCCTGTGGAAGTATCTAAATGCAGTTTCTCTCTGCATCCTGACAAAAAAT
F W   T ____
FNV  T ____
1 7 0 -2 0 4  ^ -G ...................................................................................................................................... T ____
Y5  A . . C . . G ....................C ........................................... C . T ____
3980
A s i b i  GCTGTTGCTTCTAGGAAAGCATCAAATACCATCTTGCCCCTCATGGCTCTGTTGACACCT
F W   A ...................................................................................................................................
FNV  C ...................................................................
1 7 0 -2 0 4   .....................................................................................................................................................
Y5  GT............................................................. A ............C
4040
A s i b i  GTCACTATGGCTGAGGTGAGACTTGCCACAATGCTCTTTTGTACCGTGGTTATCATAGGG
F W  ..........................................................................................................................................................
FNV ..........................................................................................................................................................
1 7 0 -2 0 4  «  ..................................................................G........... T ...................G..........................................
Y5 . . G . . C  A ................... G.................................. T ............C . . T ......................................
2 4 5
4100
A s i b i  GTCCTTCACCAGAACTCCAAGGACACCTCCATGCAGAAGACTATACCTCTGGTGGCCCTC
F W  ..........................................................................................................................................................
FNV  T ........................................................................................................................................
17D -204 ............................................T ...........................................................................................................
Y5  C ............CT T . . .
4160
A s i b i  ACACTCACATCTTACCTGGGCTTGACACAACCTTTTTTGGGCCTGTGTGCATTTCTGGCA
F W  ..........................................................................................................................................................
FNV ..........................................................................................................................................................
17D -204  .......................................................................................................................................................
Y5..............  T .................................................................................... .......................................................
4181
A s i b i  ACCCGCATATTTGGGCGAAGG
F W  ....................................................
FNV ....................................................
17D -204 .............................................................
Y5 ....................................................
Numbering taken from the sequence of 17D-204 ATCC (Rice et al. , 1985)
17D-204 = 17D-204 UK, which differs from 17D-204 ATCC and 17D-204 France at one 
nucleotide position, 4054, where a C is found rather than a T as in the other two 17D-204 vaccine 
viruses.
2 4 6
Table 8.2: Nucleotide and amino acid differences between the NS2a
protein genes of F W  and its* vaccine derivative, FNV
Position
nt
3734
F W — ► FNV
U
Position
AA F W — ► FNV
3752 24 V
3808
3821 48
3826
3928 U
G
3953 U
4046 U 123 H
Nucleotide positions taken from the published 17D-204 ATCC virus sequence (Rice etaL, 1985) 
Amino add positions numbered from the beginning of the NS2a protein.
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Chapter 4. Over the NS2a protein gene it varied from the two 17D-204 
viruses for which data is available (ATCC (Rice et ah, 1985) and France 
(Dupuy et ah, 1989) by just one nucleotide. This was at position 4054, where 
in the two 17D-204 strains mentioned above a U is found. However, in the 
17D-204 UK vaccine virus, a C was seen at this position. In the parent Asibi 
virus, a C is also found at position 4054, and the studies performed in this 
Chapter determined that a C is also found at this position in Y5, F W  and 
FNV viruses.
8.3.3 Comparison of the NS2a protein gene of Y5 with
that of other wild-type YF viruses
The nucleotide sequence of the Y5 virus NS2a protein gene was 
compared with the sequence of that published for Asibi (Hahn et ah, 1987) 
and that determined for F W  (this Chapter). Unfortunately the sequence of the 
NS2a protein gene of the South American wild-type virus, B4.1, has not been 
published, and thus comparison of African and South American viruses was 
not possible. A summary of the differences seen at the nucleotide and amino 
acid levels between the three wild-type YF viruses is shown in Table 8.3.
It can be seen that, as reported for the sequence of the structural 
proteins, Y5 appears different to the other African wild-type YF viruses at the 
nucleotide level (6.8% divergence). However, at the amino acid level there
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Table 8.3: Summaiy of the nucleotide and amino acid differences
between the NS2a protein genes of wild-type YF viruses
Amino acid 
differences
1
Nucleotide
Asibi - 1 3
differences F W 3 2
Y5 35 34 -
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are only two amino acid positions at which Y5 differs from F W  (25 and 90), 
and three at which it differs from Asibi (25, 79 and 90). This results in 
divergence at the amino acid level of 1.2% and 1.7% respectively. FW  ^was 
found to differ from Asibi at only one amino acid position, 79, where the 
isoleucine found in F W  is also seen in 17D-204 and FNV viruses.
8.4 Discussion
The non-structural protein genes of YF have been relatively poorly 
studied at the molecular level compared to the structural proteins. Although 
it is thought that the structural proteins, especially the E protein, may be 
involved in interactions with receptors and the immune system (Chambers et 
ah, 1990), it must be remembered that virulence is multi-factorial, and as 
such the role and importance of other proteins, including the non-structural 
proteins, must be considered.
NS2a was studied primarily because of the number of amino acid 
substitutions observed in this protein in the 17D-204 vaccine strain when 
compared to its’ parent Asibi virus (Hahn et ah, 1987). However, the results 
obtained in this Chapter suggest that 17D-204 virus is unusual in the number 
of amino acid changes observed. At the nucleotide level, Y5 is very different 
from all the other viruses, showing some 93.2% homology with the other 
wild-type African viruses (FW  and Asibi). Figure 8.2 shows a cluster
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Figure 8.2: Cluster analysis of YF viruses based on the
nucleotide sequence of their NS2a protein genes
Asibi
F W
FNV
17D-204
Y5
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analysis based on the nucleotide sequences of the NS2a protein genes of F W , 
FNV and Y5 (reported in this Chapter), 17D-204 (Rice et al. , 1985, and also 
reported in this Chapter), and Asibi (Hahn et al., 1987).
It can be seen that the two wild-types isolated in 1927 from Africa 
(Asibi and FW ) group closely together. The FNV vaccine is closer to them 
than the 17D-204 vaccine virus, whilst Y5 virus is the most distant from the 
other viruses. However, when a similar comparison is performed based on the 
amino acid homologies of the NS2a proteins of these viruses (Figure 8.3), it 
can be seen that the groupings are different.
When comparison is based on the amino acid sequences, it can be seen 
that the two viruses which group together most closely are F W  and Y5. 
Despite the high nucleotide divergence seen, the NS2a protein sequences of 
F W  and Y5 are very similar. Asibi virus groups with the other two African 
wild-types, but shows more divergence from them. The two vaccine viruses 
are not found to group together (as they were not when their structural 
proteins were examined), and 17D-204 vaccine virus is more remote from the 
wild-types than is the FNV virus.
Over the NS2a protein gene, Y5 is observed to show similar 
characteristics to those observed in the C, prM and M proteins, where a 
relatively low nucleotide homology with other African wild-type YF viruses 
does not translate to a high amino acid divergence. As observed in C, prM
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Figure 8.3: Cluster analysis of YF viruses based on the amino acid
sequences of their NS2a proteins
Asibi
F W
Y5
FNV
17D-204
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and M proteins, the majority of the nucleotide differences between the viruses 
prove to be silent, and at the amino acid level the three African wild-type 
isolates appear very similar.
FNV virus differs from it’s parent , F W , at only three amino acid 
positions. At one, amino acid 24, the isoleucine observed in F W  is replaced 
by a valine in FNV virus. Table 8.4 lists the ten positions over the NS2a 
proteins at which amino acid variation is found in YF viruses, it can be seen 
that, although Asibi and 17D-204 viruses share an isoleucine with F W , a 
valine is also found in the wild-type Y5 virus. This suggests that the amino 
acid at this position is variable. At the other two positions at which FNV 
differs from F W , the amino acids seen in FNV are unique to that virus. 
These are at positions 48, where a threonine is replaced by an alanine in 
FNV, and at 123, where a histidine in F W  virus is replaced by a tyrosine in 
FNV vaccine virus. The significance of these changes is not clear; however 
both are non-conservative substitutions, and would be expected to alter the 
predicted hydrophilicity of the NS2a protein in those regions.
From Table 8.4 it can be seen that, at four of the five positions at 
which 17D-204 differs from Asibi those amino acids are unique to 17D-204 
virus (positions 61, 110,112, 115, and 126. In particular there is a cluster of 
three changes between amino acids 110-115; no variation is found between the 
other four YF viruses in this region. It would therefore appear that the 
attenuation of Asibi to 17D-204 virus has for some reason produced a higher
254
Table 8.4: Amino acid differences between the NS2a proteins of YF viruses
Position* Asibi F W  Y5 FNV 17D-204
25 I I Y V I
48 X T  T A T
61 M M M M Y
79 K I I I I
90 T T V T T
110 T T T T A
112 L L L L F
115 T T T T A
123 H H H Y H
126 S S S S F
Amino acid position relative to amino acid 1 in the NS2a protein
255
rate of change at the amino acid level in the NS2a protein than that of F W  
to FNV. This may be due to the different passage histories by which the two 
attenuation process occurred. It has already been noted that the FNV virus 
appears different to the 17D-204 virus over the structural protein genes (see 
Chapter 5), and so these results are not surprising. The sequence of 17D-204 
UK confirmed that of 17D-204 ATCC (Rice et û/. ,1985) and 17D-204 France 
(Dupuy et a l ,  1989), with only one nucleotide difference found in the UK 
vaccine virus as compared to the others. It remains to be seen whether the 
17DD vaccines will differ from 17D-204 over this region. Until the function 
of the NS2a protein is understood in more detail it is difficult to speculate on 
the importance of these changes, or why the 17D-204 vaccine strains exhibit 
a greater divergence from Asibi virus than FNV virus does from F W . The 
cluster of changes found in 17D-204 vaccine strains between 110-115 are 
worthy of further study, as these changes are unique to these strains. 
However, hydrophilicity studies showed that the regions of hydrophilicity and 
hydrophobicity were conserved between all six YF viruses for which data is 
now available
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Chapter 9
General Discussion
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The initial aim of these studies was to utilize molecular biology 
techniques, taking advantage of the polymerase chain reaction (PCR), to 
amplify, clone and sequence the portions of the genome coding for the 
structural protein genes of a number of different YF viruses. The intention 
was then to combine the information thus determined with biological and 
antigenic data obtained previously by other workers, both at the University of 
Surrey and elsewhere. Previous work had identified important phenotypic 
differences between strains of YF virus, including E protein epitopes which 
appeared to be associated with attenuation of YF virus (Gould et al., 1985; 
Barrett et ah, 1990; Sil et ah, 1992), a neurovirulent disease pattern 
associated with certain vaccine strains (P-16065 and FNV viruses), and 
differences amongst wild-type viruses isolated at different locations and times 
(Y5).
Flaviviral RNA is relatively difficult to amplify by PCR, and the early 
part of this study was devoted to refining a procedure which allowed, by and 
large, successful and repeatable amplification of the regions of the genome of 
interest. This included the design and manufacture of a number of 
oligonucleotide primers for PCR, the use of different methods of denaturing 
and extracting the vRNA and the use of in vivo and in vitro systems for 
amplifying the virus prior to extraction of vRNA. The validity of these 
different approaches was tested by demonstrating that the nucleotide sequences 
of cDNA clones derived from different dénaturation and amplification 
procedures were identical for the same virus.
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Once the methodologies had been tested and confirmed as being 
successful, the remainder of the study examined a number of YF viruses at the 
molecular level. A decision was made to concentrate on the structural protein 
genes of YF virus for a number of reasons. Firstly, the structural proteins of 
YF virus are well studied, in comparison to the non-structural proteins, and 
their functions and roles are reasonably well understood. The envelope (E) 
protein of flaviviruses is known to be the major immunogenic and antigenic 
determinant of the virus (Chambers et al., 1990), and previous studies had 
confirmed differences between YF viruses based on their interaction with E 
protein specific MAbs (Gould et al., 1985; Barrett et al., 1990; Sil et al., 
1992). The structural proteins of the virus are more likely to interact directly 
with the host, and this has been shown to be true for both the E and M 
proteins (Chambers et al., 1990; Brinton, 1986 Roehrig et al., 1992).
The 17D vaccine strains of YF virus are used today throughout the 
world to protect against YF; yet prior to this study no sequence data existed 
for the 17DD substrain. The results presented in Chapter 4, examining the 
17DD vaccine originating from Senegal, are interesting in a number of 
respects. Firstly, they help confirm a physical difference observed between the 
E proteins of 17DD vaccines and the other 17D substrain, 17D-204; namely 
an additional glycosylation site (also found in a second 17DD vaccine (Post 
et al., 1992)). The importance or otherwise of glycosylation of the E protein 
of flaviviruses is not well understood.
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One major conclusion to be drawn from the sequence of the structural 
protein genes of the ITDD-Senegal vaccine virus, and also from the sequence 
data obtained in this and other studies for different isolates of the 17D vaccine 
strains is the overall genetic stability of this vaccine. Despite the difference in 
glycosylation of the E proteins, 17DD and 17D-204 vaccine strains exhibit a 
very high degree of homology over the structural protein genes (99.5 % at both 
the nucleotide and amino acid level). Since the 17D-204 and 17DD substrains 
diverged at passage 195 from the wild-type parent Asibi virus, and have since 
received 40 (17D-204) or 92 (17DD) further independent passages, the very 
low level of divergence seen between them is surprising.
In addition, the E protein of another 17D-204 strain did not differ at 
all from the two which had previously been studied, whilst the NS2a gene 
sequence of the 17D-204 virus manufactured in the United Kingdom was 
shown to differ by only one nucleotide (a silent change) from those of the two 
which had been previously published (Rice et a l,  1985; Dupuy et a l ,  1989). 
This suggests a very high degree of homology and stability for 17D-204 
vaccine viruses, since each country uses its' own method of producing vaccine 
lots. These may differ only to a small degree; however given the different 
sources of eggs for vaccine production, the time of infection and harvest 
(Barrett, 1987) and the natural variation seen in RNA viruses, the almost total 
lack of variation between 17D vaccine viruses at the molecular level is 
somewhat surprising. This may, in part, contribute to the success of live YF 
vaccines in preventing the disease. Furthermore, the lack of amino acid
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divergence in wild-type strains would support this proposal. Such data 
reinforces the view of the 17D YF vaccine viruses as a very safe and stable 
vaccine virus, probably the safest viral vaccine currently in use.
The presence of a shared vaccine epitope found on the E proteins of 
not only the 17D vaccine viruses, but also on another vaccine virus, FNV, 
was one of the reasons for investigating the latter virus. FNV was attenuated 
by a very different process to the 17D vaccine (passage in mouse brain as 
opposed to chicken embryo tissue with the nervous tissue removed). Despite 
this, the presence of a shared epitope, which had also been shown to be 
associated with YF viruses attenuated by less conventional methods (passage 
in HeLa cells and MAb neutralization resistant escape mutants) suggested that 
such an epitope was an important marker of attenuation, if not actually 
associated with the process of attenuation itself. Thus the sequence of the 
structural protein genes of the attenuated FNV virus and its' parent, F W , 
were elucidated. Comparison with one another, and also with the structural 
protein genes of 17D vaccines and the wild-type Asibi virus did not reveal a 
common substitution in the E protein shared by the vaccine viruses which 
could be responsible for the presence of the vaccine epitope shared by these 
viruses. In fact the E proteins of 17D and FNV vaccine viruses proved to be 
relatively dissimilar. However a cluster of changes observed around amino 
acids 52-56 in the E protein is worthy of further study. A common change 
was, however, located in the M proteins of the different vaccine viruses, at 
amino acid 35. Although it proved to be a conservative substitution, the fact
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that two very different attenuation processes have given rise to a common 
substitution in their attenuated derivatives is one of the important discoveries 
made in this study. The M protein is known to play a part in interaction of the 
virus with host cells in the related dengue virus (Brinton, 1986; Roehrig et 
al. , 1992), and such a common change must therefore be examined in greater 
detail in the future. Data from five wild-type YF viruses confirmed that all 
contained a leucine at M35.
A factor seen in some attenuated strains of YF virus is the appearance 
of a neurovirulent phenotype, in comparison to the viscerotropism commonly 
found in wild-type YF viruses. Why reversion to virulence should follow such 
a route, rather than a return to viscerotropism is unknown. The FNV vaccine 
virus exhibits such a neurotropic potential in both monkeys and mice. The 
molecular studies reported have not been able to identify a specific amino acid 
change which may be responsible for this (assuming that the main determinant 
is due to a change in receptor affinity as a result of E protein mutations). 
However, a number of residues in the FNV E protein, particularly those at 84 
and 249, should be examined to determine whether they have any effect on the 
neurotropic phenotype. Studies on the receptor binding of wild-type, 
attenuated and neurovirulent YF viruses are planned in the future (Barrett, 
personal communication). A reliable methodology will enable an examination 
of the molecular basis of neurovirulence, perhaps using site-directed 
mutagenesis of a YF virus infectious clone such as that constructed by Rice 
et al. (1989), to be interpreted with regard to the effect in vivo and in such
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receptor binding experiments of substitutions within the E protein of YF virus.
Neurotropism is seldom seen with the 17D vaccine viruses; however 
one well-documented fatal case of vaccine-associated encephalitis has been 
recorded (Anonymous, 1966). A YF virus isolated at post-mortem was 
included in these studies, and proved to differ from the non-neurovirulent 
17D-204 USA vaccine batch (6145) from which it originated at only two 
amino acids throughout the E protein (positions 155 and 303). Although 
neurotropism and virulence are multi-faceted, and may not be due to single 
amino acid substitutions in the E protein, these two changes, especially when 
compared to the almost complete uniformity of 17D-204 vaccine viruses at the 
molecular level discussed above, are surely worthy of further study. One in 
particular, that at amino acid 303 is located in a cluster of changes which 
occur in the attenuation of Asibi virus to 17D vaccine (amino acids 299 and 
305), and these changes significantly alter the hydrophilicity of the E protein 
in this region.
The results obtained from the study of the African wild-type virus, Y5, 
are interesting in that this virus shows a very large degree of divergence from 
the other African wild-type strains (Asibi and F W ) at the nucleotide level 
over the structural protein genes. At the amino acid level, the three viruses are 
much more similar; however the number of differences (particularly in the E 
protein) is comparable to the number seen in the passage of wild-type YF 
virus over 200 times to produce attenuated variants. Previous results (m vivo
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and antigenic studies) suggested that Y5 was an atypical wild-type virus 
(Fitzgeorge & Bradish, 1980; Sil et ah, 1992), and the molecular studies 
confirmed this. Although 26 years separated its’ isolation from those of Asibi 
and F W  viruses, time alone cannot account for the variation seen. 
Unpublished studies on a portion of the genome of a fourth African wild-type, 
Dakl279, which was also isolated in Senegal (as were Y5 and F W  viruses), 
but in 1965 (12 years after Y5 and 38 years after F W ) showed its sequence 
to be identical to F W  and Asibi viruses over a portion of the structural 
proteins coding for the C-terminal region of the M protein and the N-terminal 
region of the E protein (Venn, personal communication). In this same region 
(653 nucleotides in length), Y5 virus differed from Asibi virus by 65 
nucleotides, although no amino acid differences were seen. This and the 
atypical nature of Y5, in that it exhibits both "vaccine" and "wild-type" E 
protein epitopes which are otherwise mutually exclusive, and its’ relative 
virulence in vivo in mice as compared to other wild-type YF viruses suggest 
that some unique event or events occurred in Africa to give rise to such a 
strain. The time span separating isolation alone cannot account for the 
differences between it and Asibi and F W  viruses, as Dakl279 virus, in both 
molecular and antigenic studies, appears closer to Asibi and F W  viruses (Sil, 
1991), despite its longer chronological separation from them. Ti 
oligonucleotide mapping of wild-type YF viruses by Deubel et al. (1987) has 
suggested that there are three different topotypes or ’groups’ of wild-type YF 
virus populations in Africa, and it seems possible that Y5, although isolated 
in Senegal, in fact belongs to another of these groups. However no sequence
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data is available for other wild-type African YF viruses to confirm or deny 
this speculation. As to the virulence of the strain in vivo, this may be a 
characteristic of a group of African YF viruses, or may be due to some event 
or events that have occurred to force this particular virus to appear different 
to the others. The sequence data obtained from Y5 suggests a number of 
changes in the E protein which may play a role in the vaccine epitope, 
particularly that at amino acid 416.
Another feature to emerge from studies on the wild-type viruses was 
the high homology at the amino acid level of the prM/M proteins. Despite 
high levels of nucleotide divergence between prM and M protein genes of Y5 
and the other African wild-type viruses, and between the African viruses and 
a South American wild-type virus, B4.1, the prM and M proteins exhibit a 
high degree of homology, suggesting that these proteins are either subject to 
less pressure as regards mutation, or that their structures are of primary 
importance for the viability of the virus. The sequence data obtained in these 
studies reinforced the fact that the E protein appears to be the most variable 
of the structural proteins of YF at the amino acid level, presumably as this 
protein is continually exposed to the selection process of maintaining the 
mosquito-monkey transmission cycle.
Hahn et ah (1987) showed that the greatest divergence at both the 
nucleotide and amino acid level between Asibi and 17D-204 viruses was 
observed in the NS2a protein gene. Thus, studies were extended to analyze
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this gene at the molecular level in a number of other YF viruses. The results 
confirmed that such high variation at the amino acid level had not occurred 
during the attenuation of F W  virus to produce the attenuated FNV virus. The 
wild-type African virus, Y5, as in the structural protein genes, again showed 
a relatively high divergence from the other African wild-types at the 
nucleotide level. However, this resulted in few amino acid differences. It 
therefore appears that the attenuation process resulting in the 17D-204 vaccine 
strain has for some reason given rise to an unusually large degree of amino 
acid variation in the NS2a protein, as this pattern was not observed in the 
other YF viruses examined. The reason for, or significance of this fact 
remains unclear.
In total, this study has added approximately 15 kilobases of sequence 
data to that which previously existed for YF virus. The sequences of the 
structural protein genes of neurovirulent vaccine strains, additional African 
wild-type viruses and a 17DD vaccine strain have been determined for the first 
time. Such data is vital in furthering our understanding of the molecular 
biology of YF virus, as related to the type of disease it causes, and to 
attenuation and virulence. The nature of this study meant that, rather than 
providing definitive answers to these question, it enables the number of 
possibilities to be reduced, and concentrates on laying the foundations for 
future work. A number of exciting directions are available for further study. 
An infectious clone exists for YF virus (Rice et al., 1989), and, in 
conjunction with expression work (based on CV-1 cells), this could be used
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to elucidate some of the theories presented here. For example, the infectious 
clone of YF virus could be mutated to include the substitution at amino acid 
35 in the M protein seen in all vaccine viruses so far studied to discover 
whether this change has any significance in relation to virulence and 
attenuation. Two clusters in the E protein, amino acids 52-56 and 299-305 are 
also worthy of further examination in such a manner. Experiments could be 
devised to include some or all, of the changes seen in these regions. In 
addition, the basis of neurovirulence may be associated with amino acids 155, 
249 and 303 in the E protein. Unfortunately, a number of questions remain 
shrouded in mystery; the basis of mosquito competence of YF viruses, and the 
nature of the "wild-type" epitope amongst others. Expression of the E protein 
in CV-1 cells could be used to identify epitopes recognised by non-neutralizing 
MAbs. Specifically the E protein gene could be manipulated by site-directed 
mutagenesis and the expressed protein examined in infected cells by the panel 
of MAbs available at the University of Surrey.
In conclusion, this study has increased our knowledge of the molecular 
biology of YF virus, both vaccines and wild-type viruses, and has allowed a 
number of issues to be examined at the molecular level and compared with 
data previously obtained during biological and antigenic analysis of the virus. 
Clearly, the sequences of the complete genomes of F W , FNV and P-16065 
viruses need to be determined and analyzed. The use of a YF infectious clone, 
receptor studies and expression work in conjunction with the results from 
sequence data may allow definitive answers to some of these problems to be
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obtained in the near future.
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APPENDIX 1
Alignment of the nucleotide sequences of the structural protein
genes of wild-type yellow fever viruses
A s i b i
F W
Y5
B 4 .1
A s i b i
F W
Y5
B 4 .1
A s i b i
F W
Y5
B 4 .1
1 4 5
TCGTTGAGCGATTAGCAGAGAACTGACCAGAACATGTCTGGTCGTAAAGCTCAGGGAAAA 
.  .................................................................................................................... C ....................................... G
,TA,
2 0 5
ACCCTGGGCGTCAATATGGTACGACGAGGAGTTCGCTCCTTGTCAAACAAAATAAAACAA
,T ..............
,T  A.
2 6 5
AAAACAAAACAAATTGGAAACAGACCTGGACCTTCAAGAGGTGTTCAAGGATTTATCTTT 
.......................................................................... A .........................................................................................
A s i b i
F W
Y5
B 4 . 1
A s i b i
F W
Y5
B 4 . 1
A s i b i
F W
Y5
B 4 . 1
A s i b i
F W
Y5
B 4 . 1
A s i b i
F W
Y5
B 4 . 1
3 2 5
TTCTTTTTGTTCAACATTTTGACTGGAAAAAAGATCACGGCCCACCTAAAGAGGTTGTGG
 C.
T G . . C . ,GG T . . T . . T . . T . . G . . . . A . C ,
3 8 5
AAAATGCTGGACCCAAGACAAGGCTTGGCTGTTCTAAGGAAAGTTAAGAGAGTGGTGGCC
, G . . A .
G ..................... C.
G . A . . . G . . C ,
4 4 5
AGTTTGATGAGAGGATTGTCCTCAAGGAAACGCCGTTCCCATGATGTTCTGACTGTGCAA
. . CC.
, C  C ....................
.A.  . . T  A.  . CT,
5 0 5
TTCCTAATTTTGGGAATGCTGTTGATGACGGGTGGAGTGACCTTGGTGCGGAAAAACAGA
. . T . . G . . C C . . . . .................C.  . . , . . G ................. .. . . A .........................................................
5 6 5
TGGTTGCTCCTAAATGTGACATCTGAGGACCTCGGGAAAACATTCTCTGTGGGCACAGGC
, T T . G  C.
A s i b i
F W
Y5
B 4 . 1
A s i b i
F W
Y5
B 4 . 1
6 2 5
AACTGCACAACAAACATTTTGGAAGCCAAGTACTGGTGCCCAGACTCAATGGAATACAAC
..................T ....................................................... ... . .T . T . . . . T . . .
6 8 5
TGTCCCAATCTCAGTCCAAGAGAGGAGCCAGATGACATTGATTGCTGGTGCTATGGGGTG
............T . . C ................. .................................... G ...............
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A s i b i
F W
Y5
B 4 . 1
A s i b i
F W
Y5
B 4 . 1
A s i b i
F W
Y5
B 4 . 1
A s i b i
F W
Y5
B 4 . 1
A s i b i
F W
Y5
B 4 . 1
A s i b i
F W
Y5
B 4 . 1
A s i b i
F W
Y5
B 4 . 1
A s i b i
F W
Y5
B 4 . 1
A s i b i
F W
Y5
B 4 . 1
A s i b i
F W
Y5
B 4 . 1
A s i b i
F W
Y5
B 4 . 1
7 4 5
GAAAÀCGTTAGAGTCGCATATGGTAAGTGTGACTCAGCAGGCAGGTCTAGGAGGTCAAGA
 T . . C  T . .G  C ................................................................ A . .A ........................
 T  G . . T . . T  C .....................T ...................... T .............A .  . A .............T . . .
8 0 5
AGGGCCATTGACTTGCCTACGCATGAAAACCATGGTTTGAAGACCCGGCAAGAAAAATGG
. .A .  . T ............................. C ................................................CC .................. T ..........................................
.............................. T .  .A .  .C .  .A ................................................................ T ............................... G . . .
8 6 5
ATGACTGGAAGAATGGGTGAAAGGCAACTCCAAAAGATTGAGAGATGGCTCGTGAGGAAC
............................................... G . .G ................................................................................. T .......................T
............................................... C . .G .  .A .  . . T . G .  . G .  . A  A .....................A ........................
9 2 5
CCCTTTTTTGCAGTGACAGCTCTGACCATTGCCTACCTTGTGGGAAGCAACATGACGCAA
• • • • • C • • • • • • • »  • • • • • C T • • • • • • • C C • • • • • C • • • • • • • • • • • • • • •
............................. G .......................CT.  . G . T .............T .  . T T . A ............. G ..........................................
9 8 5
CGAGTCGTGATTGCCCTACTGGTCTTGGCTGTTGGTCCGGCCTACTCAGCTCACTGCATT
.............................................. G .............T ................................................T ..................... C .........................
 T ......................T T . G .  . A . .. T ............................... C.  . A .  . T .  . T .  . G .............................. A
1 0 4 5
GGAATTACTGACAGGGATTTCATTGAGGGGGTGCATGGAGGAACTTGGGTTTCAGCTACC
 C  T ....................................................  C .........C ............................... C . . .
 A  T ...........................................................................................................C  C . .T
1 1 0 5
CTGGAGCAAGACAAGTGTGTCACTGTTATGGCCCCTGACAAGCCTTCATTGGACATCTCA
T .A ................................................................C ........................................................... C ..............................
T .  . . .A .  .G ..............................T .............G ................................................C ............................... A . . .
1 1 6 5
CTAGAGACAGTAGCCATTGATGGACCTGCTGAGGCGAGGAAAGTGTGTTACAATGCAGTT
............................. G ...................... C ...............................................A . .G .................................................C
. .G .  .A  T ........................................................A . .A .............................................G .................C
1 2 2 5
CTCACTCATGTGAAGATTAATGACAAGTGCCCCAGCACTGGAGAGGCCCACCTAGCTGAA
.............................................. C .......................................T ...........................................................................G
T . G . . C ............................. C .............T ............. T ...................... C . . T . . A .............T T . G .  . C .  . .
1 2 8 5
GAGAACGAAGGGGACAATGCGTGCAAGCGCACTTATTCTGATAGAGGCTGGGGCAATGGC
. •  . • T . • G . . . . . T . . . . . . . . T . . . . . . . . . . . . . . G . . . . . . . . . . . . . .  . . C . . .
. . A  G.  . A .  . T C . C .  . C .  . T .  . A .  . A  C  C ...............................G.  . C .  . T
1 3 4 5
TGTGGCCTATTTGGGAAAGGGAGCATTGTGGCATGCGCCAAATTCACTTGTGCCAAATCC
..................... G . . C ......................A ............ C ................................................T ......................  . . A . .
......................G . . . .  .A ............ A ....................................... T .............................. C ............. T .  .G .  . .
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A s i b i
F W
Y5
B 4 . 1
1 4 0 5
ATGAGTTTGTTTGAGGTTGATCAGACCAAAATTCAGTATGTCATCAGAGCACAATTGCAT
C.  , 
CC,
c  A.  . G .  . c  C  C .........................C. A.
C ..............................C ............................... T .  . G .............GC.  . .
A s i b i
F W
Y5
B 4 . 1
1 4 6 5
GTAGGGGCCAAGCAGGAAAATTGGAATACCGACATTAAGACTCTCAAGTTTGATGCCCTG
,T  A.
, T . . A . . . ,
 ........................C .......................C.  . A.
. G . . C . . . . . . G . T . . T .................
A s i b i
F W
Y5
B 4 . 1
1 5 2 5
TCAGGCTCCCAGGAAGCCGAGTTCACTGGGTATGGAAAAGCTACACTGGAATGCCAGGTG
,T . . T  G . .T .
 .........................................T ......................T ................
,A . .C .  .G .  .G .  . C .....................G .............A . .A
A s i b i
F W
Y5
B 4 . 1
1 5 8 5
CAAACTGCGGTGGACTTTGGTAACAGTTACATCGCTGAGATGGAAAAAGAGAGCTGGATA
 ................A . .A .
• G . . C . . A ____
. . . C  C ..........................
, A . C  C  T .  .A.
A s i b i
F W
Y5
B 4 . 1
1 6 4 5
GTGGACAGACAGTGGGCCCAGGACTTGACCCTGCCATGGCAGAGTGGAAGTGGCGGGGTG
 G . .A  T  T .  .A ..........................
,T ..............................T . .A .  . T .......................A . .T .
C . .C .
A s i b i
F W
Y5
B 4 . 1
1 7 0 5
TGGAGAGAGATGCATCATCTTGTCGAATTTGAACCTCCGCATGCCGCCACTATCAGAGTA
..................G ...................................................................................................................................................
 G . .A  C .....................T ....................................... T ...................... A . .X .  . T .............G
......................................C ..................... G ............. C . .G ............. A .............T . . A ...................A . . . G
A s i b i
F W
Y5
B 4 . 1
1 7 6 5
CTGGCCCTGGGAAACCAGGAAGGCTCCTTGAAAACAGCTCTTACCGGCGCAATGAGGGTT
, T . . A ____
T C  . G.
C   A.  . T ,
 C . . T . . T . C  C
A s i b i
F W
Y5
B 4 . 1
A s i b i
F W
Y5
B 4 . 1
A s i b i
F W
Y5
B 4 . 1
1 8 2 5
ACAAAGGACACAAATGACAACAACCTTTACAAACTACATGGTGGACATGTTTCCTGCAGA
.............................G ..............................T .  .G .  . . .
1 8 8 5
GTGAAATTGTCAGCTTTGACACTCAAGGGGACATCCTACAAAATGTGCACTGACAAAATG
. .A ............ .........................A .................................... . T . . .
.................................................................................A . G . T .  . .
1 9 4 5
TCTTTTGTCAAGAACCCAACTGACACTGGCCATGGCACTGTTGTGATGCAGGTGAAAGTG
,T. CC.
A s i b i
F W
Y5
B 4 . 1
2 0 0 5
CCAAAAGGAGCCCCCTGCAAGATTCCAGTGATAGTAGCTGATGATCTTACAGCGGCAATC
....................................................G .................................................................................................................
............................. T .............................. C ......................................................................................................
 G . . . C ......................G .......................................C .................T . .G . .
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A s i b i
F W
Y5
B 4 . 1
A s i b i
F W
Y5
B 4 . 1
A s i b i
F W
Y5
B 4 . 1
A s i b i
F W
Y5
B 4 . 1
A s i b i
F W
Y5
B 4 . 1
A s i b i
F W
Y5
B 4 . 1
A s i b i
F W
Y5
B 4 . 1
A s i b i
F W
Y5
B 4 . 1
2 0 6 5
AATAAAGGCATTTTGGTTACAGTTAACCCCATCGCCTCAACCAATGATGATGAAGTGCTG
................................................................................................................................................................ T . .
. . C .............................A . . C .............C . . T . . A . . A .............C . . T ............. G ............. G ___ T . .
2 1 2 5
ATTGAGGTGAACCCACCTTTTGGAGACAGCTACATTATCGTTGGGACAGGAGATTCACGT
....................................................................... T .............................................................................................
, .C .  .A  T  C ..................... T .  . T .....................A ..........................................................
.................................... C . . C . . C . . G . . T ..............T . . C . . A ...............................G . . C . . T . . C
2 1 8 5
CTCACTTACCAGTGGCCCAAAGAGGGAAGCTCAATAGGAAAGTTGTTCACTCAGACCATG
........................................... A .........................................................................................................................
 C . . T . . A . . . . A ................................ T ................................ C ................... C .............T . . .
. . G .  . C ...........................A.  . . G .............C .............................. G ...........................................................
2 2 4 5
AAAGGCGTGGAACGCCTGGCCGTCATGGGAGACGCCGCCTGGGATTTCAGCTCCGCTGGA
.................................................................................................................................................... T ................
.G .  . . .C A . . .G .....................T ...................................... T ............................................... T ................
. . G . . . . C . . . G . . . T ..................T .............G . . T . . T . . T .............C ...................... T ................
2 3 0 5
GGGTTCTTCACTTCGGTTGGGAAAGGAATTCATACGGTGTTTGGCTCTGCCTTTCAGGGG
............................ C . .... ...............................................................................................................................
........................................ A .............................................C ............................................A ......................... A
. .A .  . T  A . .A .  .C .  .A .  .G  A . . C . T ................................................................... A
2 3 6 5
CTATTTGGCGGCTTGAACTGGATAACAAAGGTCATCATGGGGGCGGTACTCATATGGGTT
. . T  T ..................G ........................ G ...................................... C .............C . . T ....................... C
. .G  T  C  GT........................................................................ A . .C .  . T .........................
2 4 2 5
GGCATCAACACAAGAAACATGACAATGTCCATGAGCATGATCTTGGTAGGAGTGATCATG
..................................... G ........................................................................... C .A ..........................................
...........................TG. .G .......................................T  C . . . . T ............. C ................
2 4 5 2
ATGTTTTTGTCTCTAGGAGTTGGGGCG
 C .................... G .................................
............... C _____C ..................... G ................
X = Clonal variation seen at this point in Y5 virus (either C or T)
Numbering refers to the published 17D-204 ATCC sequence (Rice et a l ,  1985).
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APPENDIX 2
Molecular weight markers fragment sizes
Fragment Lam da/Hindin 0X /H aem
1 23,130 1,353
2 9,416 1,078
3 6,557 872
4 4,361 603
5 2,322 310
6 2,027 281
7 564 271
8 125 234
9 194
10 118
11 72
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APPENDIX 3
Structure of amino acids
Nonpolar (hydrophobic)  R groups:  
O X H  OXH
CH, H —  C—  CH'
CH,
CH,
A lan in e  Iso leucine Leucine
OOOH
1
COOH
11
0 — H
1
I
H2N —  0  —  1
1
OH2
!
0H2
0 —  O I3 0H2
OH3
1
s
I
CH3
MethI  on I ne
COOH COCH COOH
HgN —  C —  H HN —  C —  H HnN —  C —  H
CH2 HgC^^/CHg
CH,
Phenyla lan ine  Pro I i  ne
P o la r ,  uncharged R groups: 
COOH COOH
I I
HnN —  0 —  H HnN —  0 —  H
CH,
0 =  0
m .
OH,
SH
OH,
I  ^
0
I
OH
H2N
Asparagine Cysteine
OOOH
I
0 — H
I
OH2
CH2 
C = =  0
I
KH2 
G I utami ne
OOOH
H2N —  0 —  H 
H —  C —  OH,
OH,
Tryptophan Va I i ne
OOOH 
H2N —  0 —  H 
H
G l y c i n e
2 75
OOOH
1
OOOH
11
H2N —  0 —  H
1
H2N —  0  —  H
1
H — 0 —OH
1
1
H —  C —  OH
1
H
1
CH3,
Ser i ne Threon i ne
P o s i t i v e l y  charged R groups
OOOH
1
OOOH
11
H2N —  0 — H
1
H2N —  0  — ' H
1
OH2
1
CHg
OH2 0 = » 0H
1 11
OH2
. 1 1 
0
H
I
0 =  MH2^
1
NH2
Arg i n i ne Hi st id i ne
N e g a t iv e ly  charged R groups
COOH
1
COOH
11
H2N —  0 —  H
1
H2N —— 0 —* H
1
CH2
1
CH2
0 = 0
1
CH2
1
O'
1
0==0
COOH
H2N — C —  H
CH,
OH 
Tyros ine
OOOH
H2N — ■ 0 —  H 
CHo
OH,
OH,
OH,
Lys i ne
0
A s p a r t ic  ac id  Glutamic  ac id
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APPENDIX 4
LOG OOPS m J R l X  OF CAYHOFF. 1978
(Used  in CLUSTAL c o m p u t e r  p r o g r a m . )
The t a b l e  i n d i c a t e s  t h e  f r e q u e n c y  w i t h  w h i c h  v a r i o u s  
a mi n o  a c i d s  a r e  r e p l a c e d  by  e a c h  o t h e r .  Low v a l u e s  
i n d i c a t e  u n l i k e l y  s u b s t i t u t i o n s .
c 20*
s 8 10
T 6 9 11
P 5 9 8 14
A 6 9 9 9 10
G 5 9 8 7 9 13
N 4 9 8 7 8 8 10
D 3 8 8 7 8 9 10 12
E 3 8 8 7 8 8 9 11 12
Q 3 7 7 8 8 7 9 10 10 12
H 5 7 7 8 7 6 10 9 9 11 14
R 4 8 7 8 6 5 8 7 7 9 10 14
K 3 8 8 7 7 6 9 8 8 9 8 11 13
M 3 6 7 6 7 5 6 5 6 7 6 8 8 14
1 6 7 8 6 7 5 6 6 6 6 6 6 6 10 13
L 2 5 6 5 6 4 5 4 5 6 6 5 5 12 10 14
V 6 7 8 7 8 7 6 6 6 6 6 6 6 10 12 10 12
F 4 5 5 3 4 3 4 2 3 3 6 4 3 8 9 10 7 17*
Y 8 5 5 3 5 3 6 4 4 4 8 4 4 6 7 7 6 15 18 '
W 0 6 3 2 2 1 4 1 1 3 5 10 5 4 3 6 2 8 8 25*
C S T P A G N 0 E Q H R K M 1 L V F Y W
Match Scor e
Twd di f fe rent  
Two d i f fe rent
Two
Two
i dent i caI  
i dent i caI
res i dues wi th 
res idues wi th
a value less than the c u t - o f f  0
a value equal to or
g rea te r  than the c u t - o f f .  1
residues (except  C, F, Y or W) . 2
C, F, Y or W (marked * in the t a b l e ) .  3
277
References
278
Ackerman, R., Kruger, K., Roggendorf, M., Rehse-Kupper, M., Schneider, 
M & Vukadinovic, I. (1986). Spread of early-summer meningoencephalitis in 
the Federal Republic of Germany. Deutsche Medicalische Wochenschrieber 
111: 927-933
Aitken, T.H.G., Downs, W.G. & Shope, R.E. (1977). Aedes aegypti strain 
fitness for yellow fever transmission. American Journal o f Tropical Medicine 
and Hygiene 26: 985-995.
Anonymous. (1966). Fatal viral encephalitis following 17D yellow fever 
vaccine inoculation. Journal o f the American Medical Association 198: 671- 
672.
Badman, R.T., Campbell, J. & Aldred, J. (1984). Arbovirus infection in 
horses - Victoria 1984. Communicable Disease Intelligence 84/17: 5-7.
Ballinger-Crabtree, M.E. & Miller, B.R. (1990). Partial nucleotide sequence 
of South American yellow fever virus strain 1899/81: structural proteins and 
NSl. Journal o f General Virology 71: 2115-2121.
Bannatyne, C.C., Wilson, R.L., Reid, H.W., Buxton, D. & Pow, I. (1980). 
Louping ill infection in pigs. Veterinary Record 106: 13-20.
Barme, M. & Bronnert, C. (1984). Thermostabilisation du vaccin anati-amaril 
17D lyopphilise: Essai de substances protectrices. Journal o f Biological 
Standardization 12: 435-442.
Barnard, B.J., Buys, S.B., Du-Preez, J.H., Greyling, S.P. & Venter, H.J. 
(1980). Turkey meningoencephalitis in South Africa. Onderstepoort Journal 
o f Veterinary Research 47: 89-94.
279
Barrett, A.D.T. & Gould, E.A. (1986). Comparison of neurovirulence of 
different strains of yellow fever virus in mice. Journal o f General Virology 
67: 631-637.
Barrett, A.D.T. (1987). Yellow fever vaccines. Bulletin de Vlnstitut Pasteur 
85: 103-124.
Barrett, A.D.T, Pryde, A., Medlen, A.R., Ledger, T.N., Whitby, I.E ., 
Gibson, C.A., DeSilva, M., Groves, D.J., Langley, D.J. & Minor, P.D.
(1989). Examination of the envelope glycoprotein of yellow fever vaccine 
viruses with monoclonal antibodies. Vaccine 7: 333-336.
Barrett, A.D.T., Monath, T.P, Cropp, C.B., Adkins, J.D., Ledger, T.N., 
Gould, E.A., Schlesinger, J.J., Kinney, R.M. & Trent, D.W. (1990). 
Attenuation of wild-type yellow fever virus by passage in HeLa cells. Journal 
o f General Virology 71: 2301-2306.
Bazan, J.F. & Fletterick, R.J. (1989). Detection of a trypsin-like serine 
protease domain in flaviviruses and pestiviruses. Virology 171: 637-639.
Beatty, B.J., Tesh, R.B. & Aitken, T.H.G. (1980). Transovarial transmission 
of YF virus in Stegomia mosquitoes. American Journal o f Tropical Medicine 
and Hygiene 29: 125-136.
Beaucage, S.L. & Carruthers, M.H. (1981). Deoxynucleotide 
phosphoramidites - a new class of key intermediates for deoxypolynucleotide 
synthesis. Tetrahedron Letters 22: 1859-1862.
Berge, T.O. (1975). International Catalogue of Arboviruses, 2“* Edition. 
DHEW Publication number (CDC) 75-8301. United States Department of 
Health, Education and Welfare, Public Health Service, Washington, D.C.
280
Beuscher, EX . & Scherer, W.F. (1959). Ecologie studies of Japanese 
encephalitis virus in Japan. IX. Epidemiologic correlations and conclusions. 
American Journal o f Tropical Medicine and Hygiene 8: 719-738.
Bimboim, H.C. & Doly, J. (1979). A rapid alkaline extraction procedure for 
screening recombinant plasmid DNA. Nucleic Acids Research 7: 1513-1523.
Blackburn, N.K. & Swanpoel, R. (1980). An investigation of flavivirus 
infection of cattle in Zimbabwe, Rhodesia, with particular reference to 
Wesselsbron virus. Journal o f Hygiene 85: 1-33.
Blake, J.B. (1968). Yellow fever in eighteenth century America. Bulletin o f 
the New York Academy o f Science 44: 673-686.
Blaskovic, D. Pucekova, G. & Kubinyi, L. (1967). An epidemiological study 
of tick-borne encephalitis in the Tribec region: 1956-63. Bulletin o f the World 
Health Organisation 36: 89-94.
Bolivar, F., Rodriguez, R.L., Greene, P.J., Betlach, M.C., Heynecker, L. 
& Boyer, W.H. (1977). Construction and characterization of new cloning 
vehicles. H: A multipurpose cloning system. Gene 2: 95-113.
Boulton, R.W. & Westaway, E.G. (1972). Comparison of Togaviruses: 
Sindbis virus (group A) and Kunjin virus (group B). Virology 49: 283-289.
Brinton, M.A. (1986). Replication of flaviviruses. In The Togaviridae and 
Flaviviridae. (Editors: S.Schlesinger and M.J. Schlesinger) Plenum Press, 
pp327-374.
Brinton, M.A., Fernandez, A.V., & Amato, J. (1986). The 3’-nucleotides of 
flavivirus genomic RNA forms a conserved secondary structure. Virology 153: 
113-121.
281
Brinton, M.A. & Dispoto, J.H. (1988). Sequence and secondary structure 
analysis of flavivirus genome RNA. Virology 162: 290-299.
Bu’Lock, F.A. (1986). Japanese B virus encephalitis in India - a growing 
problem. Quarterly Journal o f Medicine 60: 825-836.
Burgher, J.C. (1951). The pathology of yellow fever. In Yellow Fever (Editor: 
G.K. Strode). McGraw-Hill, New York. ppl37-163.
Burke, D.S., Nisalak, A., Johnson, D.E. & Scott, R.M. (1988). A 
prospective study of dengue infections in Bangkok. American Journal o f 
Tropical Medicine and Hygiene 38: 172-180.
Calisher C.H., Karabatsos, N., Dalrymple, J.M., Shope, R.E., Porterfield, 
J.S., Westaway, E.G. & Brandt, W.E. (1989). Antigenic relationships 
between flaviviruses as determined by cross-neutralization tests between 
flaviviruses with polyclonal antisera. Journal o f General Virology 70: 37-43.
Camissa-Parks, H., Cisar, L.A., Kane, A. & Stollar, V. (1992). The 
complete nucleotide sequence of cell fusing agent (CFA): homology between 
the non-structural proteins encoded by CFA and the non-structural proteins 
encoded by arthropod-borne flaviviruses. Virology 189: 511-524.
Cane, P.A. & Gould, E.A. (1989). Immunoblotting reveals differences in the 
accumulation of envelope protein by wild-type and vaccine strains of yellow 
fever virus. Journal o f General Virology 70: 557-564.
Casals, J. & Brown, L.V. (1954). Haemagglutination with arthropod-borne 
viruses. Journal o f Experimental Medicine 99: 429-449.
Casals, J. (1957). Viruses: the versatile parasites. 7. The arthropod-borne 
group of animal viruses. Transactions o f the New York Academy o f Sciences
282
(Series 2) 19; 219-235.
Castle, E., Nowak, T., Leidner, U., Wengler, G & Wengler, G. (1985). 
Sequence analysis of the viral core protein and the membrane associated 
proteins VI and NV2 of the flavivirus West Nile virus and of the genome 
sequenced for those proteins. Virology 145: 227-236.
Castle, E., Leidner, U ., Nowak, T., Wengler, G. & Wengler, G. (1986). 
Primary structure of the West Nile flavivirus genome region coding for all 
non-structural proteins. Virology 149: 10-26.
Cecilia, D. & Gould, E.A. (1991). Nucleotide changes responsible for loss of 
neuroinvasiveness in Japanese encephalitis virus neutralization resistant 
mutants. Virology 181: 70-77.
Chambers, T.J & Rice, C.M. (1987). Molecular biology of the flaviviruses. 
Microbiological Sciences 4: 219-223.
Chambers, T.J., Hahn, C.S., Galler, R. & Rice, C.M. (1990). Flavivirus 
genome organization, expression, and replication.
Annual Reviews in Microbiology 44: 649-688.
Chambers, T.J., Grakoui, A. & Rice, C.M. (1991). Processing of the yellow 
fever virus nonstructural polyprotein: a catalytically active NS3 proteinase 
domain and NS2B are required for cleavages at dibasic sites. Journal o f 
Virology 65: 6042-6050.
Chen, E.Y. & Seeburg, P.H. (1985). Supercoil sequencing: a fast and simple 
method for sequencing plasmid DNA. DNA 4: 219-233.
Chu, P.W.G & Westaway, E. G. (1985). Replication strategy of Kunjin virus: 
evidence for recycling role of replicative form RNA as template in semi-
283
conservative and asymmetric replication. Virology 140: 68-79.
Chu, P.W.G & Westaway, E. G. (1987). Characterization of Kunjin virus 
RNA-dependant RNA polymerase: reinitiation of synthesis in vitro. Virology 
157: 330-337.
Clarke, D.H. (1960). Antigenic analysis of certain group B arthropod-borne 
viruses by antibody absorption. Journal o f Experimental Medicine 111: 21-32.
Cleaves, G.R. & Dubin, D.T. (1979). Méthylation status of intracellular 
dengue-2 40S RNA. Virology 96: 159-165.
Cleaves, G.R., Ryan, T.E. & Schlesinger, R.W. (1981). Identification and 
characterization of type 2 dengue virus replicative intermediate and replicative 
form RNAs. Virology 111: 73-80.
DeMadrid, A.T. & Porterfield, J.S. (1974). The flaviviruses (Group B 
arboviruses): a cross-protection study. Journal o f General Virology 23:91-96.
Deubel, V., Camicas, J.L., Pandare, D., Robert, V., Digoutte, J-P. & 
Germain, M. (1981). Développement de souches sauvages et vaccinales du 
virus de la fièvre jaune dans le cellules de Aedes aegypti et transmission au 
souriceau. Annals Virology (institute Pasteur) 132E: 41-50.
Deubel, V., Crouset, J., Benichou, D., Digoutte, J-P., Bouloy, M. & Girard, 
M. (1983). Preliminary characterization of the ribonucleic acid of yellow fever 
virus. Annals o f the Institut Pasteur 134E: 581-585.
Deubel, V., Schlesinger, J.J., Digoutte, J-P. & Girard, M. (1987). 
Comparative immunochemical and biological analysis of African and South 
American yellow fever viruses. Archives o f Virology 94:
331-338.
284
Dimmock, N.J. & Primrose, S.B. (1987). Introduction to Modem Virology. 
Third edition, Blackwell Scientific Publications, p238.
Downs, W.B. (1989). Arboviruses. In Viral Infections o f Humans: 
Epidemiology and control. (Edited: A.S. Evans Chapter 5 ppl05-132. Plenum 
Medical Books.
Duarty, B.E. & Le Duc, J.W. (1981). Transovarial transmission of yellow 
fever virus by a sylvatic vector, Haemagogus equinus. Transactions o f the 
Royal Society o f Tropical Medicine and Hygiene 75: 128-133.
Dunster, L.M. (1990). Studies on the attenuation of flaviviruses following 
passage in HeLa cells. Ph.D. thesis. University of Surrey.
Dunster, L.M., Gibson, C.A., Stephenson, J.R., Minor, P.D. & Barrett, 
A.D.T. (1990). Attenuation and virulence of flaviviruses following passage 
in HeLa cells. Journal o f General Virology 71: 601-607.
Dupuy, A., Despres, P., Cahour, A., Girard, M. & Bouloy, M. (1989) 
Nucleotide sequence comparison of the genome of two 17D-204 yellow fever 
vaccines. Nucleic Acids Research 17: 3989
Evans V.J., Bryant, J.L., Kerr, H.A. & Schilling, E.H. (1964). Chemically 
defined media for the cultivation of long-term cell strains from four different 
mammalian species. Experimental Cell Research 36: 439-474.
Falgout, B., Chamock, R & Lai, C-J. (1989). Proper processing of dengue 
virus nonstructural glycoprotein NSl requires the N-terminal hydrophobic 
signal sequence and the downstream nonstructural protein, NS2a. Journal o f 
Virology 63: 1852-1860.
Falgout, B., Pethel, M., Zhang, Y-M. & Lai, C-J. (1991). Both nonstructural
285
proteins NS2B and NS3 are required for the proteolytic processing of dengue 
virus nonstructural proteins. Journal o f Virology 65: 2467-2475.
Fedorcsak, I. & Ehrenberg, L. (1966). Effects of diethyl pyrocarbonate and 
methyl methanesulfonate on nucleic acids and nucleases. Acta Chemica 
Scandinavica 20: 107-112.
Findlay, G.M. & Clarke, C.P. (1934). The susceptibility of the hedgehog to 
yellow fever. Transactions o f the Royal Society fo r  Tropical Medicine and 
Hygiene 28: 335-345.
Fitzgeorge, R. & Bradish, C.J. (1980). The in vivo differentiation of strains 
of yellow fever virus in mice. Journal o f General Virology 46: 1-13.
Forbes, J.A. (1975). Murray Valley encephalitis. Australian Medical 
Publishing 1976.
Fox, J.P., Lennette, E.H., Monso, C. & Souza Aguir, J.R. (1942). 
Encephalitis in man following vaccination with 17D yellow fever virus. 
American Journal o f Hygiene 36: 117-141.
Freeman, R., Codd, A.A. & Selkon, J.B. (1982). Effect of beta- 
propriolactone in blood on routine haematological, biochemical and serological 
investigations. The Lancet i: 1048-1049.
Freestone, D.S., Ferris, R.D., Weinberg, A.L. & Kelly, A. (1977). 
Stabilized 17D yellow fever vaccine: dose response studies, clinical reactions 
and hepatic function. Journal o f Biological Standards 5: 181-200.
Freestone, D.S. (1988). Yellow fever vaccines. In Vaccines (Edited by S,A. 
Plotkin & E.A. Mortimer). Chapter 18 pp387-419. W.B. Saunders Company, 
Philadelphia.
286
Frey, T.K., Marr, L.D., Sanchez, A. & Simmons, R.B. (1989). Identification 
of the 5’-end of the rubella virus subgenomic RNA. Virology 168: 191-194.
Georges, A.I., Tible, F., Meunier, D.M.Y., Gonzalez, J.P., Beraud, A.M., 
Sissoko-Dybdahl, N.R., Abdul-Wahid, S., Fritzell, B., Girard, M. & 
Georges-Lourbot, M.C. (1985). Thermostability and efficacy in the field of 
a new, stabilized yellow fever vaccine virus. Vaccine 3: 313-315.
Germain, M., Saluzzo, J.F., Comet, J.P., Herv, J.P., Sureau, P., Camacas, 
J.L., Robin, Y., Salaur, J.J. & Heme, G. (1979). Isolement du virus en le 
fievre jaune partir de la ponte et de larves d’une tique Amblyoma variegatum. 
C.R. Acadamie Sciences (Paris) (Ser. D) 289: 235-237.
Germain, M., Cornet, J.P., Mouchet, J., Monath, T.P., Herv, J.P., Salaur, 
J.J., Cordellier, R., Saluzzo, J.F., Camacas, J.L., Hervy, J.P., Robert, V., 
Deubel, V., Gonzalez, J.P., Digoutte, J.P. & Darwish, D.O. (1982). Recent 
advances in research regarding sylvatic yellow fever in West and Central 
Africa. Bulletin o f the Institute Pasteur 80: 315-327.
Gey, G.O., Coffman, W.D. & Kubicek, M.T. (1952). Tissue culture studies 
of the proliferative capacity of cervical carcinoma and normal epithelium. 
Cancer Research 12: 264-265.
Gibson, C.A., Schlesinger, J.J. & Barrett, A.D.T. (1988). Prospect for a 
virus non-structural protein as a subunit vaccine. Vaccine 6: 7-9.
Gibson, C.A., Dunster, L.M., Bouloy, M., Minor, P.D., Sanders, P.G. & 
Barrett, A.D.T. (1990). Primer extension dideoxy chain termination nucleotide 
sequencing of partially purified RNA virus genomes: a technique for 
investigating low titre viruses with extensive genome secondary stmcture. 
Journal o f Virological Methods 29: 167-176.
287
Gorbalenya, A.E., Donchenko, A.P., Koonin, E.V. & Blinov, V.M. (1989a). 
N-terminal domains of putative helicases of flavi- and pestiviruses may be 
serine proteases. Nucleic Acids Research 17; 3889-3897.
Gorbalenya, A.E., Koonin, E.V., Donchenko, A.P. & Blinov, V.M. (1989b). 
Two related superfamilies of putative helicases involved in replication, 
recombination, repair and expression of DNA and RNA genomes. Nucleic 
Acids Research 17: 4713-4729.
Gould, E.A., Buckley, A., Cammack, N., Barrett, A.D.T., Clegg, J.C.S., 
Ishak, R. & Varma, M.G.R. (1985) Examination of the immunological 
relationships between flaviviruses using yellow fever monoclonal antibodies. 
Journal o f General Virology 66: 1369-1382
Grange, T., Bouloy, M. & Girard, M. (1985). Stable secondary structures at 
the 3’-end of the genome of yellow fever virus (17D vaccine strain). FEBS 
Letters 188: 159-162.
Gratz, N.G. (1991). Emergency control of Aedes aegypti as a disease vector 
in urban areas. Journal o f the American Mosquito Control Association 7: 353- 
365.
Grun, J.B. & Brinton, M.A.. (1986). Characterization of West Nile virus 
RNA-dependant RNA polymerase and cellular terminal adenylyl and uridylyl 
transferase in cell-free extracts. Journal o f Virology 61: 1113-1124.
Grunwedel, D.W.,& Davidson, N. (1966). Complexing and dénaturation of 
DNA by methylmercuric hydroxide. Journal o f Molecular Biology 21: 129- 
144.
Guillon, J.C., Oudar, J. & Joubert, L. (1968). Lesions histologiques due 
systemé nerveux dans l ’infection a virus West Nile chez le cheval. Annals o f
288
the Institut Pasteur 114: 539-550.
Guirakhoo, F., Heinz, F.X. & Kunz, C. (1989). Epitope model of tick-bome 
encephalitis virus envelope glycoprotein E: analysis of structural properties, 
role of carbohydrate side-chain, and conformational changes occurring at 
acidic pH. Virology 169: 90-99.
Guirakhoo, F ., Bolin, R.A. & Roehrig, J.T. (1992). The Murray Valley 
encephalitis prM protein confers acid resistance to virus particles and alters 
the expression of epitopes within the R2 domain of E-glycoprotein. Virology 
191: 921-931.
Habu, A., Murakanu, Y., Ogasa, A. & Fujisaki, Y. (1977). Disorders of 
spermatogenesis and viral discharge into semen in boars infected with 
Japanese encephalitis. Virus 27: 21-26.
Haddow, A.J., Smithbum, K.C., Drak, G., Kitchen, S.F. & Lumsden, 
W.H.R. (1967). Implication of the mosquito Aedes (Stegomyia) africanus 
Theobald in the forest cycle of yellow fever in Uganda. Annals o f Tropical 
Medicine 42: 218-223.
Hahn, C.S., Dalrymple, J.M., Strauss, J.H. & Rice, C.M. (1987). 
Comparison of the virulent Asibi strain of yellow fever virus with the 17D 
vaccine derived from it. Proceedings o f the National Academy o f Sciences , 
USA 84: 2019-2023.
Hahn, C.S., Galler, R., Hunkapiller, T., Dalrymple, J.M., Strauss, J.H. & 
Strauss, E.G. (1988).Nucleotide sequence of dengue 2 RNA and comparison 
of the encoded proteins with those of other flaviviruses. Virology 162: 167- 
180.
Halstead, S.B. (1980). Immunopathological parameters of togavirus disease
289
syndromes. In The Togaviruses: Biology, Structure, Replication (Ed. R.W. 
Schlesinger). Academic Press, New York. pl07-174
Halstead, S.B. (1988). Pathogenesis of dengue: challenges to molecular 
biology. Science 239; 476-481.
Hardy, P.M. (1963a). The growth of Asibi strain yellow fever virus in tissue 
culture. I. Sensitivity and capacity of tissue cultures. Journal o f Infectious 
Diseases 113: 1-8.
Hardy, P.M. (1963b). The growth of Asibi strain yellow fever virus in tissue 
culture, n . Modification of virus and cells. Journal o f Infectious Diseases 113: 
9-14.
Hartman, F.W., Lo Grippo, G. & Kelly, A.R. (1954). Preparation and 
sterilisation of blood plasma. American Journal o f Clinical Pathology 24:339- 
348.
Hashimoto, H., Nomoto, K., Watanabe, K., Mori, T., Takezawa, T., 
Aizawa, C., Takegami, T. & Hiramatsu, K. (1988). Molecular cloning and 
complete nucleotide sequence of the genome of Japanese encephalitis virus 
Beijing-1 strain. Virus Genes 1: 305-317.
Hawley, W.A. (1988). The biology of Aedes albopticus. Journal o f the 
American Mosquito Control Association Supplement 1: 1-40.
Hearn, H.J.Jr., Soper, W.T., & Miller, W.S. (1965). Loss in virulence of 
yellow fever virus serially passaged in HeLa cells. Proceedings o f the Society 
fo r Experimental Biology and Medicine 119: 319-322.
Hearn, H.J.Jr., Chapell, W.A., Demchak, P. & Dominik, J.W. (1966). 
Attenuation of aerosolised yellow fever virus after passage in cell culture.
290
Bacteriological Reviews 30: 615-623.
Heinz, F.X. (1986). Epitope mapping of flavivirus glycoproteins. Advances 
in Virus Research 31: 103-168.
Heinz, F.X., Mandl, C., Holzman, H., Guirakhoo, F., Tuma, W. & Kunz, 
C. (1990). In The Second International Symposium on Positive Strand 
Viruses, Vienna. (Editors: M.A. Brinton & F,X. Heinz). American Society 
of Microbiology, Washington D.C.
Heinz, F.X., Mandl, C.W., Holzmann, H., Kunz, C., Harris, B.A., Rey, F. 
& Harrison, S.C. (1991). The flavivirus envelope protein E: Isolation of a 
soluble form from tick-bome encephalitis vims and its crystallization. Journal 
o f Virology 65: 5579-5583.
Henchal, E,A., Henchal, L.S. & Thaisomboonsuk, B.K. (1987). Topological 
mapping of unique epitopes of the dengue-2 NSl protein using monoclonal 
antibodies. Journal o f General Virology 68: 845-851.
Henderson, B.E., Cheshire, P.P., Kirya, A.B. & Lule, M. (1970). 
Immunologic studies with yellow fever and selected African group B 
arbovimses in rhesus and vervet monkeys. American Journal o f Tropical 
Medicine and Hygiene 19: 110-118.
Hewlett, M.J., Petterson, R.F. & Baltimore, D. (1977). Circular forms of 
Uukuniemi virion RNA: an electron microscopic study. Journal o f Virology 
21: 1085-1093.
Higgins, D.G. & Sharp, P.M. (1988). CLUSTAL: a package for performing 
multiple sequence alignments on a microcomputer. Gene 73: 237-244.
Holtzmann, H., Mandl, C.W., Guirakhoo, F, Heinz, F.X. & Kunz, C.
291
(1989). Characterization of antigenic variants of tick-bome encephalitis vims 
selected with neutralizing monoclonal antibodies. Journal o f General Virology 
70; 219-222.
Horzinek, M.C. & Mussgay, M. (1969). Studies on the nucleocapsid stmcture 
of a Group A arbovims. Journal o f Virology 4: 514-520.
Hsu, M.T., Kung, H.J. & Davidson, N. (1973). An electron microscope 
study of Sindbis vims RNA. Cold spring Harbor Symposium o f Quaternary 
Biology 38: 943-950.
Igarashi, A., Harrap, K.A., Casals, J. & Stollar, V. (1976). Morphological, 
biochemical and serological studies on a viral agent (CFA) which replicates 
in and causes fusion of Aedes albopticus (Singh) cells. Virology 74: 174-187
Ish-Horowicz, D. & Burke, J.F. (1981). Rapid and efficient cosmid cloning. 
Nucleic Acids Research 9: 2989-2998.
Jones, T.A., Martins A. & McCoy, C.E. (1971). Re-examination and re- 
evaluation of the human carcinoma cell line HeLa. Obstetrics and 
Gynaecology 38: 945-949.
Kaarianen, L. & Soderlund, H. (1978). Stmcture and replication of 
alphavimses. Current Topics in Microbiology and Immunology 82 15-69.
Kamer, G & Argos, P. (1984). Primary stmctural comparison of RNA- 
dependant polymerases form plant, animal and bacterial vimses. Nucleic Acids 
Research 12: 7269-7282.
Karabatsos, N. (Editor). (1985). Intemational Catalogue of Arbovimses 
including certain other vimses of vertebrates, 3rd edition. The Sub-committee 
on Information Exchange of the American Committee on Arthropod-bome
292
viruses. American Society of Tropical Medicine and Hygiene, San Antonio, 
Texas, USA.
Kerr, J.A. (1951). The clinical aspects and diagnosis of yellow fever. In 
Yellow Fever (Editor: G.K. Strode). McGraw-Hill, New York, USA. pp385- 
425.
Klotz, O. & Belt T.H. (1930). Pathology of spleen in yellow fever. American 
Journal o f Pathology 6: 655-662.
Kokemot, R.H., Hayes, J., Will, R.L., Tempelis, C.H., Chan, D.H.M. & 
Radojevich, B. (1969). St. Louis encephalitis in the U.S.A. American Journal 
o f Tropical Medicine and Hygiene 18: 750-771.
Komarov, A. & Kalmar, E. (1960). Veterinary Record 72: 257-266.
Ledger, T.N. (1990). Study of yellow fever vaccine viruses with monoclonal 
antibodies. Ph.D thesis. University of Surrey.
Ledger, T.N., Sil, B.K., Wills, M.R., Lewis, G., Kinney, R.M., Jennings, 
A.D., Stephenson J.R. & Barrett, A.D.T. (1992). Variation in the biological 
functions of envelope protein epitopes of yellow fever vaccine viruses detected 
with monoclonal antibodies. Biologicals 20: 117-128.
Lee, C. & Schloemer, R.H. (1981). Identification of the antiviral factor in 
culture medium of mosquito cells persistently infected with Banzai virus. 
Virology 110: 445-451.
Lee, J.M., Crooks, A.J. & Stephenson, J.R. (1989). The synthesis and 
maturation of a non-structural extracellular antigen from tick-bome 
encephalitis vims and its relationship to the intracellular NSl protein. Journal 
o f General Virology 70: 335-343.
293
Lee, E., Femon, C., Simposon, R., Wier, R.C., Rice, C.M. & Dalgamo, L.
(1990). Sequence of the 3’ half of the Murray Valley encephalitis virus 
genome and mapping of the nonstructural proteins, NSl, NS3 and NS5. Virus 
Genes 4: 197-213.
Leibowitz, A., McCombs, W.B., Johnston, D., McCoy, C.E. & Stinson, J.C. 
(1973). New human cancer cell lines. I: SW13 small cell carcinoma of the 
adrenal cortex. Journal o f the National Cancer Institute 51: 691-697.
Lenette, E.H. & Schmidt, R.T. (Editors) (1969). Diagnostic procedures for 
viral and Rickettsial infections. Fourth edition. American Public Health 
Association, New York, USA.
Leon, M. Gravell, O., Gutenson, R., Hamilton, R. & London, W. (1982). 
Classification of simian haemorrhagic fever virus. In Fifth Intemational 
Congress o f Virology (Eds. L. Hirth & F.A. Murphy), Institute de Biologie 
Moléculaire et Cellulaire, Strasbourg, Abstracts, p385.
Lewis, J.G., Chang, G-J., Lanciotii, R.S. & Trent, D.W. (1992) Direct 
sequencing of large flavivirus PCR products for analysis of genome variation 
and molecular epidemiological investigations. Journal o f Virological Methods 
38: 11-24.
Liprandi, F. (1981). Isolation of plaque variants differing in virulence from 
the 17D strain of yellow fever virus. Journal o f General Virology 56: 363- 
370.
Lloyd, J.S. (1977). Improving the cold-chain for vaccines. World Health 
Organization Chronicle 31: 13-36.
Lobigs, M., Dalgamo, L., Schlesinger, J.J. & Wier, R.E. (1987). Location 
of a neutralization determinant in the E protein of yellow fever vims (17D
294
vaccine strain). Virology 161: 474-478.
Lobigs, M., Usha, R., Nestorowicz, A., Marshall, I.D ., Wier, R.C. & 
Dalgamo, L. (1990). Host cell selection of Murray Valley encephalitis vims 
variants altered at an RGD sequence in the envelope protein and in mouse 
virulence. Virology 176: 597-595.
Mackow, E., Makino, Y., Zhao, B., Zhang, Y-M., Markoff, L., Buckler- 
White, A., Guiler, M., Chanock, R. & Lai, C-J. (1987). The nucleotide 
sequence of dengue type 4 vims: analysis of genes coding for nonstmctural 
proteins. Virology 159: 217-228.
MacNamara, F.N. (1953). Reactions following neurotropic yellow fever 
vaccine given by scarification in Nigeria. Transactions o f the Royal Society fo r  
Tropical Medicine and Hygiene 47: 199-208.
Mandl, C.W., Heinz, F.X. & Kunz, C. (1988). Sequence of the stmctural 
proteins of tick-bome encephalitis (Westem sub-type) and comparative 
analysis with other flavivimses. Virology 166: 197-205.
Mandl, C.W., Heinz, F.X., Stockl, E. & Kunz, C. (1989a). Genome 
sequence of tick-bome encephalitis vims (Westem subtype) and comparative 
analysis with other flavivimses. Virology 173: 291-301.
Mandl, C.W., Guiarakhoo, F., Holzman, H., Heinz, F.X. & Kunz, C. 
(1989b). Antigenic stmcture of the flavivims envelope protein E at the 
molecular level, using tick-bome encephalitis as a model Journal o f Virology 
63: 564-571.
Mandl, C.W., Kunz, C. & Heinz, F.X. (1991). Presence of poly(A) in a 
flavivims: significant differences between the 3’ noncoding regions of the 
genomic RNAs of tick-bome encephalitis strains. Journal o f Virology 65:
295
4070-4077
Maniatis, T., Fiitsch, E.F. & Sambrook, J. (1982). Molecular cloning: a 
laboratory manual. Cold Spring Harbor Laboratory Press, Cold Spring 
Harbor, New York, USA.
Mason, P.W., McAda, P.C., Dalrymple, J.M., Fournier, M.J. & Mason, 
T.L. (1987). Expression of Japanese encephalitis virus antigens in Escherichia 
coli. Virology 158: 361-372.
Mason, P.W. (1989). Maturation of Japanese encephalitis virus glycoproteins 
produced by infected mammalian and mosquito cells. Virology 169: 354-364.
Mason, P.W., Dalrymple, J.M., Gentry, M.K., McCown, J.M., Hoke, C.H., 
Burke, D.S., Fournier, M.J. & Mason, T.L. (1989). Molecular 
characterization of a neutralizing domain of the Japanese encephalitis 
structural glycoprotein. Journal o f General Virology 70: 2037-2049.
Mathis, C., Sellards, A.W. & Laigret, J. (1928). Sensibilitié du Macac rhesus 
au virus de la fievre jaune. Compté rendu hebdomadaire des seances de 
L*Acadamie des Sciences 186: 604-606.
Matrhukrishnan, S., Both, G.W., Furuichi, Y. & Shatkin, A.J. (1975). 5’- 
terminal 7-methylguanosine in eukaryotic MRNA is required for translation. 
Nature 255: 33-37.
Matrhukrishnan, S., Morgan, M., Banneijee, A.K. & Shatkin, A.J. (1976). 
Influence of 5’-terminal m^G and 2’-0-methylated residues on message 
ribonucleic acid binding to ribosomes. Biochemistry 15: 5761-5768.
McIntosh, B.M., Jupp, P.G., Dos Santos, I. & Meeneham, G.M. (1976). 
Epidemics of West Nile and Sindbis viruses in South Africa with Culex
296
univittatus Theobald as vector. South African Journal o f Science 72; 295-306.
Meers, P.D. (1959). Adaptation of the 17D yellow fever virus to mouse brain 
by serial passage. Transactions o f the Royal Society o f Tropical Medicine and 
Hygiene 53: 445-457.
Mendez, M.R., Calisher, C.H., Kruger, H ., Sipan, P., Sanchez, S. & 
Lazuick, J.S. (1984). A continuing focus of yellow fever in the Apurimac 
River valley, Ayacucho, Peru, and the first isolation of yellow fever virus in 
that country. Bulletin o f the Pan American Health Organization 18: 172-179.
Miller, B.R. & Adkins, D. (1988). Biological characterization of plaque-size 
variants of yellow fever virus in mosquitoes and mice. Acta Virologica 32: 
227-234.
Messing, J., Gronenbom, B., Muller-Hill, B. & Hofschnieder, P.H. (1977). 
Filamentous coliphage M13 as a cloning vehicle: insertion of a HindUI 
fragment of the lac regulatory region in M13 replicative form in vitro. 
Proceeding o f the Academy o f Sciences, USA 74: 3642-3646.
Messing, J. & Vieira, J. (1982). A new pair of M13 vectors for selecting 
either DNA strand of double-digest restriction fragments. Gene 19: 269-276.
Miller, B.R. & Ballinger, M.E. (1988). Aedes albopticus mosquitoes 
introduced into Brazil: vector competence for yellow fever and dengue 
viruses. Transactions o f the Royal Society fo r Tropical Medicine and Hygiene 
82: 476-477.
Monath, T.P., Brinker, K.R., Chandler, F.W ., Kemp, G.E. & Cropp, C.B. 
(1981). Pathophysiological correlations in a rhesus monkey model of yellow 
fever, with special observations on acute necrosis of B-cell areas of lymphoid 
tissues. American Journal o f Tropical Medicine and Hygiene 30: 431-433.
297
Monath, T.P. (1984). Impact of arthropod-bome vims diseases in Africa and 
the Middle East. In Applied Virology (Eds: E. Kurstak, W. Al-Nakib & C. 
Kurstak). Academic Press pp377-379.
Monath, T.P., Schlesinger, J.J., Brandriss, M.W., Cropp, C.B. & Prange, 
W.C. (1984). Yellow fever monoclonal antibodies: type specific and cross­
reactive determinants identified by immunofluoresence. American Journal o f 
Tropical Medicine and Hygiene 33: 695-698.
Monath, T.P. (1986). Pathology of the flavivimses. In The Togaviridae and 
Flaviviradae (Eds. S. Schlesinger & M.J. Schlesinger), Plenum Press, p375.
Monath, T.P. (1987). Yellow fever: A medically neglected disease. Report on 
a Seminar. Reviews o f Infectious disease 9: 165-175.
Monath, T.P. (1989). Yellow fever. Chapter 59, in: The Arboviruses: 
Epidemiology and Ecology, Volume V (Ed. T.P. Monath). CRC Press, 
Florida. pl42-218.
Moss-Blundell, A.J.,Bemstein, S., Shepherd, W.M.,Longford, D.T., Ferris, 
R. & Kelly, S. (1981). A clinical study of stabilized 17D live attenuated 
yellow fever vaccine. Journal o f Biological Standards 9i 445-466.
Murphy, L.C., Hubbel, E.S. & Yager, R. (1955a). Propagation of 
Venezuelan equine encephalitis vims in cultures of human malignant epithelial 
cells strain HeLa. American Journal o f Veterinary Research 16: 304-307.
Murphy, L.C., Blackford, V.L. & Gleiser, G.A. (1955b). Study of the 
properties of the vims of Venezuelan equine encephalomyelitis modified by 
in vitro cultivation in HeLa cells. American Journal o f Veterinary Research 
16: 521-524.
298
Muiphy, F.A. (1980). Togavirus morphology and morphogenesis. In The 
Togaviruses (Editor: R.W. Schlesinger. Academic Press, New York. pp241- 
316.
Noguchi, H. (1919). Etiology of yellow fever. Journal o f Experimental 
Medicine 29: 565-584.
Norrander, J., Kempe, T. & Messing, J. (1983). Construction of improved 
M13 vectors using oligonucleotide-directed mutagenesis. Gene 26: 101-106.
Nowak, T. & Wengler, G. (1987). Analysis of di-sulphides present in the 
membrane proteins of the West Nile flavivirus. Virology 156: 127-137.
Nowak, T., Farber, P.M., Wengler, G & Wengler, G. (1989). Analyses of 
the terminal sequences of West Nile virus structural proteins and of the in vivo 
translation of these proteins allow the proposal of a complete scheme of the 
proteolytic cleavages involved in their synthesis. Virology 169: 365-376.
Osatomi, K. & Sumiyoshi, H. (1990). Complete nucleotide sequence of 
dengue 3 virus genome RNA. Virology 176: 643-647.
Pletnev, A.G., Yamshchikov, V.F. & Bilinov, V. (1990). Nucleotide 
sequence of the genome and complete amino acid sequence of the polyprotein 
of tick-bome encephalitis vims. Virology 174: 250-263.
Pogodina, V.V. (1958). The resistance of tick-bome encephalitis vims to the 
effects of gastric juice. Vopr, Virusol 3: 295-299.
Poland, J.D., Calisher, C.H., Monath, T.P., Downs, W.G. & Murphy, K. 
(1981). Persistence of neutralization antibody 30-35 years after immunization 
with 17D yellow fever vaccine. Bulletin o f the World Health Organization 59: 
895-900.
299
Porterfield, J.S., Casals, J., Chumakov, M.P., Gaidamovich, S., Y., 
Hannoun, C., Holmes, I.H., Horzinek, M.C., Mussgay, M., Okerblom, N., 
Russell, P.K. & Trent, D.W. (1978). Togaviruses. Intervirology 9: 129-148.
Porterfield, J.S. (1989a). Flaviviridae. '[n Andrewes* Viruses o f Vertebrates 
Chapter 7, p62-75. Baliere Tindall Press.
Porterfield, J.S. (1989b). Yellow fever in Africa: a retrospective glance. 
British Medical Journal 229: 1555-1557.
Post, P.R., Carvalho, R. & Galler, R. (1990). Glycosylation and secretion of 
yellow fever virus nonstructural protein NSl. Virus Research 18: 291-302.
Post, P.R., Santos, C.N.D., Carvalho, R., Cruz, A.C.R., Rice, C.M. & 
Galler, R. (1992) Heterogeneity in envelope protein sequences and N-linked 
glycosylation among yellow fever vaccine strains. Virology 188: 160-167
Promega Corporation. (1991). Protocols and application guide (Editor: D.E. 
Titus).
Queen, C. & Korn, L.J. (1984). A comprehensive sequence analysis program 
for the IBM personal computer. Nucleic Acids Research 12: 581-599
Reed, W. (1902) Recent researches concerning the etiology, propagation and 
prevention of yellow fever, by the United States Army Commission. Journal 
o f Hygiene 2: 101-119.
Reed, W. & Carroll, J. (1902). Etiology of yellow fever: supplemental note. 
American Medicine 3: 301-315.
Reid, H.W., Buxton, D., Pow, I. & Finlayson, J. (1982). Experimental 
louping ill virus infection in two species of British deer. Veterinary Record
300
I l l :  61-62.
Rice, C.M., Lenches, E.M., Eddy, S.R., Shi, S.J., Sheets, R.L. & Strauss, 
J.H. (1985). Nucleotide sequence of yellow fever virus: implications for 
flavivirus gene expression and evolution. Science 229: 726-733.
Rice, C.M., Strauss, E,.G. & Strauss, J.H. (1986). Structure of the flavivirus 
genome. In The Togaviridae and Flaviviridae (Editors: S.Schlesinger & M.J. 
Schlesinger). Plenum Press. pp279-326.
Rice, C.M., Grakoui, A., Galler, R. & Chambers, T.J. (1989). Transcription 
of infectious yellow fever virus RNA from full-length cDNA templates 
produced by in vitro ligation. New Biologist 1: 285-296.
Rice, C.M. (1990). Overview of flavivirus molecular biology and future 
vaccine development via recombinant DNA. Southeast Asian Journal o f 
Tropical Medicine and Public Health 21: 670-677.
Roehrig, J.T., Hunt, A.R., Johnson, A.J. & Hawkes, R.A. (1989). Synthetic 
peptides derived from deduced amino acid sequence of the E glycoprotein of 
Murray Valley encephalitis virus elicit antiviral antibody. Virology 171: 49- 
60.
Rosen, L. (1986). The natural history of Japanese encephalitis. Annual 
Reviews in Microbiology 40: 395-414.
Rosen, L. (1987). Sexual transmission of dengue virus by Aedes albopticus. 
American Journal o f Tropical Medicine and Hygiene 37: 398-402.
Russell, P.K., Brandt, W.E. & Dalrymple, J. M. (1980). Chemical and 
antigenic structure of flaviviruses. In The Togaviruses (Editor: R.W. 
Schlesinger), Academic Press, pp503-529.
301
Saiki, R.K., Scharf, S., Faloona, F., Mullis, K.B., Horn, G.T., Erlich, H.A. 
& Amheim, N. (1985). Enzymatic amplification of B-globin genomic 
sequences and restriction site analysis for diagnosis of sickle-cell anaemia. 
Science 230: 1350-1354.
Saluzzo, J.F. (1980). Isolements du virus de la fievre jaune a partir du 
mosquitoes du groupe (Stegomyia) afticanus (Theobald) en Republique 
Centrafricaine au cours de Tanee 1978. Annals de Virologie 131E: 313-321.
Sambrook, J., Fritsch, E.F. & Maniatis, T. (1989) Molecular cloning: a 
laboratory manual (2nd edition) Cold Spring Harbor Laboratory Press
Sanger, F., Nickien, S. & Coulson, A.R. (1977) DNA sequencing with chain- 
terminating inhibitors. Proceedings o f the National Academy o f Sciences, USA 
74: 5463-5476
Sangkawibha, N., Rohanasuphot, S., Ahandrik, S., Viriyapangse, S., 
Jutansen, S., Salitul, V., Panthumachinda, B. & Halstead, S.B. (1984). Risk 
functions in dengue shock syndrome: A prospective epidemiological study in 
Rayong, Thailand. I. The 1980 outbreak. American Journal o f Epidemiology 
120: 653-669.
Savage, H.M., Ezike, V.I., Nwanko, A.C., Spiegel, R & Miller, B.R. 
(1992). First record of breeding populations of Aedes albopticus in continental 
Africa: implications for arboviral transmission. Journal o f the American 
Mosquito Control Association 8: 101-103.
Schlesinger, R.W. (1980). Introduction. In The Togaviruses: Biology, 
Structure, Replication (Ed. R.W. Schlesinger). Academic Press, New York.
Schlesinger, J.J., Brandriss, M.W. & Monath, T.P. (1983). Monoclonal 
antibodies that distinguish between wild-type and vaccine strains of yellow
302
fever virus by neutralization, haemagglutination inhibition, and immune 
precipitation of the virus envelope protein. Virology 125: 8-17.
Schlesinger, J.J, Brandriss, M.W. & Walsh, E.A. (1985). Protection against 
17D yellow fever encephalitis in mice by passive transfer of monoclonal 
antibodies to the nonstructural glycoprotein gp48 and by active immunization 
with gp48. Journal o f Immunology 135: 2805-2809.
Schlesinger, J.J, Brandriss, M.W. Cropp, C.B & Monath, T.P. (1986). 
Protection against YF in monkeys by immunization with yellow fever virus 
nonstructural protein NSl. Journal o f Virology 60: 1153-1155.
Schlesinger, J.J, Brandriss, M.W. & Walsh, E.A. (1987). Protection of mice 
against dengue-2 encephalitis by immunization with the dengue-2 virus 
nonstructural glycoprotein NSl Journal o f General Virology 68: 853-857.
Schoub, B.D., Dommann, C.J., Johnson, S., Downie, C. & Patel, P.L.
(1990). Encephalitis in a 13-year old boy following 17D yellow fever vaccine. 
Journal o f Infection 21: 105-106.
Seeburg, P.H., Shine, J., Martial, J.A., Baxter, J.D. & Goodman, H.N. 
(1977). Nucleotide sequence and amplification in bacteria of a structural gene 
for rat growth hormone. Nature 270: 486-494.
Sérié, C., Lindrec, A., Poirier, A., Andrei, L. & Neri, P. (1968). Etudés sur 
la fievré jaune en Ethiopie Bw/Zerin o f the World Health Organisation 38: 879- 
884.
Shatzameyer, H.G., Nogueira, R.M.R & Travassos deRosa, A.P.A. (1986). 
An outbreak of dengue virus at Rio de Janiero, 1986. Memoirs o f the Institut 
de Oswaldo Cruz, Rio de Janiero 81: 245-246.
303
Shope, R. E. (1980). Medical significance of Togaviruses: An overview of 
disease in man and in domestic and wild animals. In The Togaviruses: 
Biology, Structure, Replication (Ed. R.W. Schlesinger). Academic Press, New 
York. p47-77.
Sil, B.K. (1991). Studies on the envelope protein epitopes of yellow fever and 
Japanese encephalitis viruses with monoclonal antibodies. Ph.D Thesis, 
University of Surrey.
Sil, B.K., Dunster, L.M., Ledger, T.N., Wills, M.R., Minor, P.D. & 
Barrett, A.D.T. (1992) Identification of envelope protein epitopes that are 
important in the attenuation process of wild-type yellow fever virus. Journal 
o f Virology 66: 4265-4270
Silber L.A. & Soloviev, V.D. (1946). In: American Review of Soviet 
Medicine pl-50. Special Supplement o f the American-Soviet Medical Society. 
New York.
Simpson, R.B. (1963). Association constants of methylmercuric and mercuric 
ions with nucleosides. Journal o f the American Chemical Society 86: 2059- 
2065.
Smith, T.J., Brandt, W.E., Swanson, J.L., McCown, J.M. & Buescher, E.L. 
(1970). Physical and biological properties of dengue-2 virus associated 
antigens. Journal o f Virology 5: 524-532.
Smith, G.W & Wright, P.J. (1985). Synthesis of proteins and glycoproteins 
in dengue type 2 virus-infected Vero and Aedes albopticus cells. Journal o f 
General Virology 66: 559-571.
Smith, C.E. & Gibson, M.E. (1986). Yellow fever in South Wales, 1865. 
Medical History 30: 322-340.
304
Sprigland, I., Jansinka-Klingberg, W., Hofsbi, E. & Goldblum, N. (1958). 
Clinical and laboratory observations in an outbreak of West Nile fever in 
Israel. Harejmh (Jerusalem) 63: 275-280.
Sreenivisan, M.A., Bhat, H.R. & Naik, S.V. (1979). Experimental 
transmission of Kyasanur Forest disease virus by Dermacentor auratus Supino 
ticks. Indian Journal o f Medical Research 27: 701-707.
Stephenson, J.R., Crooks, A.J. & Lee, J.M. (1987). The synthesis of 
immunogenic polypeptides encoded by tick-borne encephalitis virus. Journal 
o f General Virology 68: 1307-1316.
Stokes, A., Bauer, J.H. & Hudson, N.P. (1928). Experimental transmission 
of yellow fever to laboratory animals. American Journal o f Tropical Medicine 
8: 103-164.
Sumiyoshi, H., Mori, C., Puke, I., Morita, K., Kuhara, S., Kondou, J., 
Kikuchi, Y., Nagamatu, H. & Igarashi, A. (1987). Complete nucleotide 
sequence of the Japanese encephalitis virus genome RNA. Virology 161:497- 
510.
Susilowati, S. Okuno, Y., Fukunaga, T., Tadano, M., Juang, R.F. & Fukai, 
K. (1981). Neutralization antibody responses induced by Japanese encephalitis 
virus vaccine. Biken Journal 24: 137-143.
Sutcliffe, J.G. (1978). Nucleotide sequence of the ampicillin resistance gene 
of Escherichia coli plasmid pBR322. Proceedings o f the National Academy o f 
Sciences, USA 84: 4767-4771.
Swanpoel, R. (1988). Wesselsbron virus. In: The Arboviruses: Epidemiology 
and Ecology, Volume V (Ed. T.P. Monath). CRC Press, Florida. p87-115.
305
Tabor, S. & Richardson, C.C. (1987). DNA sequence analysis with a 
modified bacteriophage T7 DNA polymerase. Proceedings o f the National 
Academy o f Sciences, U.S. A. 84: 4767-4771.
Taylor, R.M. (1951). Epidemiology. In Yellow Fever (Editor: G.K. Strode) 
McGraw-Hill, New York. pp529-533.
Theiler, M. (1930). Studies on the action of yellow fever virus in mice. 
Annals o f Tropical Medicine 24: 249-272.
Theiler, M. (1933). The susceptibility of guinea pigs to the virus of yellow 
fever. American Journal o f Tropical Medicine 13: 399-414.
Theiler, M. & Smith, H.H. (1937a). Effects of prolonged cultivation in vitro 
upon the pathogenicity of yellow fever virus. Journal o f Experimental 
Medicine 65: 767-786.
Theiler, M. & Smith, H.H. (1937b). Use of yellow fever virus modified by 
in vitro cultivation for human immunization. Journal o f Experimental Medicine 
65: 787-800.
Theiler, M. (1951). The virus. In Yellow Fever (Ed. G.K. Strode) pp43-146. 
McGraw-Hill, New York.
Theiler, M. & Downs, W.G. (1973). "The Arthropod-borne Viruses of 
Vertebrates". Yale University Press, New Haven.
Trent, D.W. & Neave, C.W. (1980). Biochemistry and replication. IN St. 
Louis Encephalitis (Editor: T.P. Monath), American Public Health 
Association, Washington D.C. ppl59-199.
Trent, D.W., Kinney, R.M., Johnson, B.J.B., Vomdam, A.V., Grant, J.A.,
306
Deubel, V., Rice, C.M. & Hahn, C. (1987). Partial nucleotide sequence of 
St. Louis encephalitis virus RNA: structural proteins, NSl, NS2a and NS2b. 
Virology 156; 293-304.
Ullrich, A., Shine, J., Chirgwin, Pictet, R., Tischer, E., Rutter, W.J. & 
Goodman, H.M. (1977) Rat insulin genes: construction of plasmids containing 
the coding sequences. Science 196; 313-318.
Umenai, T., Kryskov, R., Bektrimirov, T.A. & Assas, F.A. (1985). Japanese 
encephalitis: current world-wide status. Bulletin o f the World Health 
Organization 63: 625-631.
Vieira, J. & Messing, J. (1982). The pUC plasmids, an M13mp7-derived 
system for insertion mutagenesis and sequencing with synthetic universal 
primers. Gene 19: 259-268.
von Heijne, G. (1984). How signal sequences maintain cleavage specificity. 
Journal o f Molecular Biology 173: 243-251.
Waters, T.D., Anderson, P.S., Beebe, G.W. & Miller, R.W. (1972) Yellow 
fever vaccination, avian leucosis virus, and cancer risk in man. Science 177: 
76-77.
Warren, A.J. (1951). Landmarks in the conquest of yellow fever. In Yellow 
Fever (Ed. G.K. Strode), pl-39, McGraw-Hill.
Weekly Epidemiological Record - World Health Organization. (1989a). 64 
(4): 22-28.
Weekly Epidemiological Record - World Health Organization. (1989b). 64 
(6): 37-44.
307
Wengler, G., Wengler, G. & Gross, H.J. (1978). Studies on virus-specified 
nucleic acids synthesised in vertebrate and mosquito cells infected with 
flaviviruses. Virology 96; 516-529.
Wengler, G. & Wengler, G. (1981). Terminal sequences of the genome and 
replication from RNA of the flavivirus West Nile virus: absence of poly(A) 
and possible role in RNA replication. Virology 113: 544-549.
Wengler, G., Castle, E., Leidner, U., Nowak, T., & Wengler, G. (1985). 
Sequence analysis of the membrane protein V3 of the flavivirus West Nile 
virus and its’ gene. Virology 147: 264-274.
Westaway, E.G. (1973) Proteins specified by Group B Togaviruses in 
mammalian cells during proliferative infections. Virology 51: 454-465.
Westaway, E.G. (1975). The proteins of Murray Valley encephalitis virus. 
Journal o f General Virology 27: 283-292.
Westaway, E.G. & Shew, M. (1977). Proteins and glycoproteins specified by 
the flavivirus Kunjin. Virology 80: 309-319.
Westaway, E.G. (1980). Replication of flaviviruses. In The Togaviruses 
(Editor: R.W. Schlesinger. Academic Press, New York. pp531-581.
Westaway, E.G., Brinton, M.A., Gaidamovich, S.Y., Horzinek, M.C., 
Igarashi, A., Kaarianen, L., Lvov, D.K., Porterfield, J.S., Russell, P.K. & 
Trent, D.W. (1985a). Togaviridae. Intervirology 24: 125-139.
Westaway, E.G., Brinton, M.A., Gaidamovich, S.Y., Horzinek, M.C., 
Igarashi, A., Kaarianen, L., Lvov, D.K., Porterfield, J.S., Russell, P.K. & 
Trent, D.W. (1985b). Flaviviradae. Intervirology 24: 183-192.
308
Whitby, J.E. (1992). Comparison of the structural protein genes of members 
of the tick-borne encephalitis complex of the Flaviviridae. Ph.D Thesis, 
University of Surrey.
Whitby, I.E., Jennings, A.D. and Barrett, A.D.T. (1992). Improved reverse 
transcription and amplification of flaviviral RNA following low level methyl 
mercury hydroxide dénaturation. Methods in Molecular and Cellular Biology 
In press.
Whitman, 1. (1951). in Yellow Fever (Edited G.K. Strode). p237. McGraw- 
Hill, New York.
Winkler,G., Heinz, F.X. & Kunz, C. (1987). Studies on the glycosylation of 
flavivirus E proteins and the role of carbohydrate in antigenic structure. 
Virology 159: 237-243.
Work, T.H. (1958). Russian spring summer virus in India. Kyasanur Forest 
disease. Progress in Medical Virology 1: 248-260.
World Health Organisation (1967). Arboviruses and human disease. Report 
of a World Health Organisation Scientific Group. World Health Organisation 
Technical Report Series 369: 84pp.
World Health Organisation Technical Report N°479. (1971). Third Report of 
the Expert Committee on Yellow Fever.
World Health Organisation Technical Report N°594 (1976). Requirements for 
yellow fever vaccine. pp23-49.
World Health Organisation Technical Report N°658. (1981). WHO Committee 
on Biological Standardization.
309
World Health Organisation Technical Report N°771. (1988). Requirements for 
yellow fever vaccine. pp208-210.
Yamshchikov, V.F. & Compans, R.W. (1993). Regulation of the late events 
in flavivirus protein processing and maturation. Virology 192: 38-51.
Yasmura, Y. & Kawakita, Y. (1963). Investigations of SV40 virus in tissue 
culture. Nippon Rinsho 21: 1201-1219.
Zhang, H., Scholl, R., Browse, J. & Somerville, C. (1988). Double stranded 
DNA sequencing as a choice for DNA sequencing. Nucleic Acids Research 
16: 1220.
310
